0001356090-18-000006.txt : 20180510 0001356090-18-000006.hdr.sgml : 20180510 20180510164937 ACCESSION NUMBER: 0001356090-18-000006 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180510 DATE AS OF CHANGE: 20180510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTREXON CORP CENTRAL INDEX KEY: 0001356090 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36042 FILM NUMBER: 18823673 BUSINESS ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 BUSINESS PHONE: 301-556-9809 MAIL ADDRESS: STREET 1: 1750 KRAFT DRIVE STREET 2: SUITE 1400 CITY: BLACKSBURG STATE: VA ZIP: 24060 10-Q 1 xon-20180331x10q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 10-Q
x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission File Number: 001-36042
 INTREXON CORPORATION
(Exact name of registrant as specified in its charter)
Virginia
 
26-0084895
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
20374 Seneca Meadows Parkway
Germantown, Maryland
 
20876
(Address of principal executive offices)
 
(Zip Code)
(301) 556-9900
(Registrant's telephone number, including area code) 
(Former name, former address and former fiscal year, if changed since last report date) 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
x
 
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨  (Do not check if a smaller reporting company)
 
Smaller reporting company
 
¨
 
 
 
 
Emerging growth company
 
¨
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
As of April 30, 2018, 129,294,079 shares of common stock, no par value per share, were outstanding.



INTREXON CORPORATION
FORM 10-Q
TABLE OF CONTENTS
 
Item No.
 
Page
1.
 
 
 
 
 
 
2.
3.
4.
 
1.
1A.
2.
6.
 
Intrexon®, Trans Ova Genetics®, Oxitec®, ViaGen®, ActoBiotics®, and AquAdvantage® are our and/or our affiliates' registered trademarks in the United States and AquaBounty™, GenVec™, EnviroFlight™, Okanagan Specialty Fruits™, Precigen™, ActoBio Therapeutics™, Progentus™ and AdenoVerse™ are our and/or our affiliates' common law trademarks in the United States. This quarterly report and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this quarterly report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies' trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names and service marks appearing in this quarterly report are the property of their respective owners.



2



Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q regarding our strategy, future events, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:
 
our strategy and overall approach to our business model;
our ability to successfully enter new markets or develop additional products, whether with our collaborators or independently;
our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future;
competition from existing technologies and products or new technologies and products that may emerge;
actual or anticipated variations in our operating results;
our current and future joint ventures, or JVs, exclusive channel collaborations, or ECCs, license agreements and other collaborations;
developments concerning our collaborators and licensees;
actual or anticipated fluctuations in our competitors' or our collaborators' and licensees' operating results or changes in their respective growth rates;
our cash position;
market conditions in our industry;
our ability to protect our intellectual property and other proprietary rights and technologies;
our ability to adapt to changes in laws or regulations and policies;
the ability of our collaborators and licensees to adapt to changes in laws or regulations and policies and to secure any necessary regulatory approvals to commercialize any products developed under the ECCs, license agreements and JVs
the ability of our collaborators and licensees to protect our intellectual property and other proprietary rights and technologies;
the ability of our collaborators and licensees to develop and successfully commercialize products enabled by our technologies;
the rate and degree of market acceptance of any products developed by our subsidiaries, a collaborator under an ECC, or through a JV or license under a license agreement;
our ability to retain and recruit key personnel;
the result of litigation proceedings that we face currently or may face in the future;
our expectations related to the use of proceeds from our public offerings and other financing efforts;

3


our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
the impact of the Tax Cuts and Jobs Act of 2017 on our current and future operating results.
Forward-looking statements may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.
You should read this Quarterly Report on Form 10-Q, the documents that we reference in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2017 and the documents that we have filed as exhibits to our filings with the Securities and Exchange Commission completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


4


PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Intrexon Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)
March 31,
2018
 
December 31,
2017
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
119,930

 
$
68,111

Restricted cash
6,987

 
6,987

Short-term investments
275

 
6,273

Equity securities
3,298

 
5,285

Receivables
 
 
 
Trade, net
17,697

 
19,775

Related parties, net
10,585

 
17,913

Other
2,437

 
2,153

Inventory
20,271

 
20,493

Prepaid expenses and other
6,065

 
7,057

Total current assets
187,545

 
154,047

Equity securities, noncurrent
10,745

 
9,815

Investments in preferred stock
166,069

 
161,225

Property, plant and equipment, net
119,244

 
112,674

Intangible assets, net
231,883

 
232,877

Goodwill
154,748

 
153,289

Investments in affiliates
21,406

 
18,870

Other assets
4,026

 
4,054

Total assets
$
895,666

 
$
846,851

The accompanying notes are an integral part of these consolidated financial statements.

5


Intrexon Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)
March 31,
2018
 
December 31,
2017
Liabilities and Total Equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
7,842

 
$
8,701

Accrued compensation and benefits
11,356

 
6,474

Other accrued liabilities
18,041

 
21,080

Deferred revenue, including $28,684 and $29,155 from related parties as of March 31, 2018 and December 31, 2017, respectively
48,646

 
42,870

Lines of credit
321

 
233

Current portion of long term debt
501

 
502

Related party payables
147

 
313

Total current liabilities
86,854

 
80,173

Long term debt, net of current portion
7,425

 
7,535

Deferred revenue, net of current portion, including $147,708 and $157,628 from related parties as of March 31, 2018 and December 31, 2017, respectively
214,744

 
193,527

Deferred tax liabilities, net
11,631

 
15,620

Other long term liabilities
3,586

 
3,451

Total liabilities
324,240

 
300,306

Commitments and contingencies (Note 16)

 

Total equity
 
 
 
Common stock, no par value, 200,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 129,239,376 and 122,087,040 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively

 

Additional paid-in capital
1,492,916

 
1,397,005

Accumulated deficit
(930,220
)
 
(847,820
)
Accumulated other comprehensive loss
(9,587
)
 
(15,554
)
Total Intrexon shareholders' equity
553,109

 
533,631

Noncontrolling interests
18,317

 
12,914

Total equity
571,426

 
546,545

Total liabilities and total equity
$
895,666

 
$
846,851

The accompanying notes are an integral part of these consolidated financial statements.

6


Intrexon Corporation and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
 
(Amounts in thousands, except share and per share data)
Three Months Ended 
 March 31,
2018
 
2017
Revenues
 
 
 
Collaboration and licensing revenues, including $19,815 and $28,887 from related parties during the three months ended March 31, 2018 and 2017, respectively
$
24,025

 
$
33,065

Product revenues
7,152

 
8,130

Service revenues
12,247

 
12,031

Other revenues
419

 
521

Total revenues
43,843

 
53,747

Operating Expenses
 
 
 
Cost of products
8,530

 
9,006

Cost of services
6,783

 
6,804

Research and development
37,267

 
34,180

Selling, general and administrative
39,737

 
35,138

Total operating expenses
92,317

 
85,128

Operating loss
(48,474
)
 
(31,381
)
Other Income, Net
 
 
 
Unrealized depreciation in fair value of equity securities and preferred stock, net
(1,096
)
 
(1,622
)
Interest expense
(99
)
 
(179
)
Interest and dividend income
5,470

 
4,624

Other income (expense), net
(659
)
 
595

Total other income, net
3,616

 
3,418

Equity in net loss of affiliates
(2,460
)
 
(4,947
)
Loss before income taxes
(47,318
)
 
(32,910
)
Income tax benefit
4,086

 
533

Net loss
$
(43,232
)
 
$
(32,377
)
Net loss attributable to the noncontrolling interests
1,244

 
978

Net loss attributable to Intrexon
$
(41,988
)
 
$
(31,399
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.33
)
 
$
(0.26
)
Weighted average shares outstanding, basic and diluted
127,693,336

 
118,956,780

The accompanying notes are an integral part of these consolidated financial statements.


7


Intrexon Corporation and Subsidiaries
Consolidated Statements of Comprehensive Loss
(Unaudited)
 
 
Three Months Ended 
 March 31,
(Amounts in thousands)
2018
 
2017
Net loss
$
(43,232
)
 
$
(32,377
)
Other comprehensive income (loss):
 
 
 
Unrealized gain (loss) on investments
2

 
(20
)
Gain on foreign currency translation adjustments
5,906

 
3,252

Comprehensive loss
(37,324
)
 
(29,145
)
Comprehensive loss attributable to the noncontrolling interests
1,303

 
981

Comprehensive loss attributable to Intrexon
$
(36,021
)
 
$
(28,164
)
The accompanying notes are an integral part of these consolidated financial statements.


8


Intrexon Corporation and Subsidiaries
Consolidated Statements of Shareholders' and Total Equity
(Unaudited)
 
(Amounts in thousands, except share data)
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated
Deficit
 
Total
Intrexon
Shareholders'
Equity
 
Noncontrolling
Interests
 
Total
Equity
Shares
 
Amount
 
 
 
 
 
 
Balances at December 31, 2017
122,087,040

 
$

 
$
1,397,005

 
$
(15,554
)
 
$
(847,820
)
 
$
533,631

 
$
12,914

 
$
546,545

Cumulative effect of adoption of ASC 606

 

 

 

 
(40,412
)
 
(40,412
)
 

 
(40,412
)
Stock-based compensation expense

 

 
11,340

 

 

 
11,340

 
22

 
11,362

Exercises of stock options and warrants
21,722

 

 
74

 

 

 
74

 
250

 
324

Shares issued as payment for services
230,614

 

 
2,941

 

 

 
2,941

 

 
2,941

Shares and warrants issued in public offerings, net of issuance costs
6,900,000

 

 
82,374

 

 

 
82,374

 
5,616

 
87,990

Adjustments for noncontrolling interests

 

 
(818
)
 

 

 
(818
)
 
818

 

Net loss

 

 

 

 
(41,988
)
 
(41,988
)
 
(1,244
)
 
(43,232
)
Other comprehensive income (loss)

 

 

 
5,967

 

 
5,967

 
(59
)
 
5,908

Balances at March 31, 2018
129,239,376

 
$

 
$
1,492,916

 
$
(9,587
)
 
$
(930,220
)
 
$
553,109

 
$
18,317

 
$
571,426

The accompanying notes are an integral part of these consolidated financial statements


9


Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
 
 
Three Months Ended 
 March 31,
(Amounts in thousands)
2018
 
2017
Cash flows from operating activities
 
 
 
Net loss
$
(43,232
)
 
$
(32,377
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
8,382

 
7,400

Loss on disposal of long-lived assets
316

 
566

Unrealized depreciation on equity securities and preferred stock, net
1,096

 
1,622

Noncash dividend income
(4,883
)
 
(3,926
)
Amortization of premiums on investments

 
198

Equity in net loss of affiliates
2,460

 
4,947

Stock-based compensation expense
11,362

 
7,894

Shares issued as payment for services
2,941

 
2,915

Provision for bad debts
218

 
9

Deferred income taxes
(4,074
)
 
(638
)
Other noncash items
127

 
(146
)
Changes in operating assets and liabilities:
 
 
 
Receivables:
 
 
 
Trade
1,856

 
1,931

Related parties
4,729

 
(4,994
)
Other
(215
)
 
859

Inventory
231

 
2,058

Prepaid expenses and other
1,062

 
210

Other assets
(47
)
 
(526
)
Accounts payable
(764
)
 
(990
)
Accrued compensation and benefits
4,851

 
924

Other accrued liabilities
(2,473
)
 
69

Deferred revenue
(13,800
)
 
(13,011
)
Related party payables
(165
)
 
161

Other long term liabilities
134

 
156

Net cash used in operating activities
(29,888
)
 
(24,689
)
Cash flows from investing activities
 
 
 
Maturities of investments
6,000

 
45,000

Purchases of preferred stock and warrants

 
(1,161
)
Investments in affiliates
(5,510
)
 
(4,579
)
Return of investment upon dissolution of affiliate
2,598

 

Purchases of property, plant and equipment
(10,774
)
 
(6,343
)
Proceeds from sale of property, plant and equipment
230

 
137

Proceeds from repayment of notes receivable

 
1,500

Net cash provided by (used in) investing activities
(7,456
)
 
34,554

The accompanying notes are an integral part of these consolidated financial statements.

10


Intrexon Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)

 
Three Months Ended 
 March 31,
(Amounts in thousands)
2018
 
2017
Cash flows from financing activities
 
 
 
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs
87,990

 

Acquisitions of noncontrolling interests

 
(913
)
Advances from lines of credit
1,239

 
1,678

Repayments of advances from lines of credit
(1,151
)
 
(2,088
)
Proceeds from long term debt

 
126

Payments of long term debt
(140
)
 
(123
)
Payments of deferred consideration for acquisitions

 
(1,991
)
Proceeds from stock option and warrant exercises
324

 
175

Payment of stock issuance costs

 
(10
)
Net cash provided by (used in) financing activities
88,262

 
(3,146
)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
914

 
526

Net increase in cash, cash equivalents, and restricted cash
51,832

 
7,245

Cash, cash equivalents, and restricted cash
 
 
 
Beginning of period
75,545

 
69,594

End of period
$
127,377

 
$
76,839

Supplemental disclosure of cash flow information
 
 
 
Cash paid during the period for interest
$
82

 
$
70

Cash paid during the period for income taxes
20

 

Significant noncash financing and investing activities
 
 
 
Stock issued to acquire noncontrolling interest
$

 
$
5,082

Noncash dividend to shareholders

 
22,385

Purchases of equipment included in accounts payable and other accrued liabilities
2,016

 
1,132

Purchases of equipment financed through debt
76

 

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of March 31, 2018 and December 31, 2017 as shown above:
 
March 31,
2018
 
December 31,
2017
Cash and cash equivalents
$
119,930

 
$
68,111

Restricted cash
6,987

 
6,987

Restricted cash included in other assets
460

 
447

Cash, cash equivalents, and restricted cash
$
127,377

 
$
75,545

The accompanying notes are an integral part of these consolidated financial statements.

11


Intrexon Corporation and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
(Amounts in thousands, except share and per share data)
1. Organization
Intrexon Corporation ("Intrexon"), a Virginia corporation, including through its wholly owned subsidiaries Precigen, Inc. ("Precigen") and ActoBio Therapeutics, Inc. ("ActoBio"), uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.
Trans Ova Genetics, L.C. ("Trans Ova"), and Progentus, L.C. ("Progentus"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in Iowa, Maryland, Missouri, New York, Oklahoma, and Texas.
Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil.
Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.
ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively.
In January 2018, AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, completed an underwritten public offering which resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased $5,000 of additional AquaBounty common stock, reducing its ownership stake from approximately 58% to approximately 53%.
Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2018 and results of operations and cash flows for the interim periods ended March 31, 2018 and 2017. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2018, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

12


Revenue Recognition
Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.
The Company's revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Collaboration and licensing revenues
The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.
The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.
At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.
The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

13


Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.
Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. The Company typically determines that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.
Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.
As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.
From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
Product and service revenues
The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered. Payment terms are typically due within 30 days.
Equity Method Investments
The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 17) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.
The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators, using the fair value option. The fair value of the Company's investment in Oragenics was $2,334 and $3,085 as of March 31, 2018 and December 31, 2017, respectively, and is included as equity securities in the accompanying consolidated balance sheets. The Company's ownership of Oragenics was 27.9% and 29.4% as of March 31, 2018 and December 31, 2017, respectively. Unrealized depreciation in the fair value of these securities was $751 and $1,341 for the three months ended March 31, 2018 and 2017, respectively. See Note 7 for additional discussion regarding Oragenics.

14


Summarized financial data as of March 31, 2018 and December 31, 2017 and for the three months ended March 31, 2018 and 2017, for the Company's equity method investments are shown in the following tables.
 
March 31,
2018
 
December 31,
2017
Current assets
$
57,724

 
$
61,086

Non-current assets
15,553

 
13,598

Total assets
73,277

 
74,684

Current liabilities
7,946

 
6,213

Net assets
$
65,331

 
$
68,471


 
Three Months Ended 
 March 31,
 
2018
 
2017
Revenues
$
67

 
$
30

Operating expenses
8,610

 
13,343

Operating loss
(8,543
)
 
(13,313
)
Other, net
14

 
5

Net loss
$
(8,529
)
 
$
(13,308
)
Variable Interest Entities
As of March 31, 2018 and December 31, 2017, the Company determined that certain of its collaborators and joint ventures as well as Harvest were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of March 31, 2018 and December 31, 2017 were $191,731 and $185,261, respectively, which represents the Company's maximum risk of loss related to the identified VIEs.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law and significantly revised U.S. corporate income tax law by, among other things, reducing the corporate income tax rate to 21% effective January 1, 2018, eliminating the corporate alternative minimum tax and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings from foreign subsidiaries. The U.S. Securities and Exchange Commission ("SEC") Staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed, including computations, in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company recognized provisional tax impacts related to revaluation of most of the Company's domestic deferred tax assets, the impact of revaluation of those deferred tax assets on the Company's valuation allowance and elimination of the corporate alternative minimum tax, and included those amounts in the consolidated financial statements for the year ended December 31, 2017. The actual impact

15


of the Tax Act may differ from the Company's estimates due to, among other things, changes in interpretations and assumptions made, and guidance that may be issued as a result of the Tax Act.
In addition, the Tax Act implemented a new minimum tax on global intangible low-taxed income ("GILTI"). A company can elect an accounting policy to account for GILTI in either of the following ways:
As a period charge in the future period in which the tax arises; or
As part of deferred taxes related to the investment or subsidiary.
The Company has not made a policy decision regarding whether to record deferred taxes under the GILTI regime.
The accounting is expected to be completed within the one-year measurement period as allowed by SAB 118 for items impacted or introduced by the Tax Act. No further adjustments to these provisional amounts occurred in the three months ended March 31, 2018 and the amounts continue to be provisional.
Segment Information
While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment. As of March 31, 2018 and December 31, 2017, the Company had $23,019 and $21,837, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $4,431 and $3,714 for the three months ended March 31, 2018 and 2017, respectively.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements
The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. Under the previous revenue guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to another collaborator, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (see Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 for additional discussion of these collaborations). Because the Company controls the performance obligation, ASC 606 requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under ASC 606, the Company recorded $40,789 of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company reduced deferred revenue by $377 as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC would have been recognized immediately under ASC 606. The milestone payment was received by the Company in form of ZIOPHARM's common stock and under previous guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. As a result of these changes under ASC 606, the Company recognized a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of $40,412.

16


In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the three months ended March 31, 2018 and consolidated balance sheet as of March 31, 2018 was as follows:
 
Three Months Ended March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Statement of Operations
 
 
 
 
 
Collaboration and licensing revenues
$
24,025

 
$
22,444

 
$
1,581

Net loss
(43,232
)
 
(44,813
)
 
1,581

Net loss attributable to Intrexon
(41,988
)
 
(43,569
)
 
1,581

 
March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Balance Sheet
 
 
 
 
 
Liabilities
 
 
 
 
 
Deferred revenue, current
$
48,646

 
$
42,320

 
$
6,326

Deferred revenue, net of current portion
214,744

 
182,239

 
32,505

Total Equity
 
 
 
 
 
Accumulated deficit
(930,220
)
 
(891,389
)
 
(38,831
)
In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation-Stock Compensation (Topic 718) – Scope of Modification Accounting ("ASU 2017-09"). The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force) ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, the "Cash, cash equivalents, and restricted cash" beginning period balance increased by $7,434 for the three months ended March 31, 2018 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2018, and the beginning and ending period balances increased by $6,987 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2017 from what was previously reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2017.
In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement

17


of Cash Flows, and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.

18


3. Mergers and Acquisitions
GenVec Acquisition
In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired 100% of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of 684,240 shares of the Company's common stock and have the right to receive contingent consideration equal to 50% of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within three years after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:
Common shares
$
15,616

Warrants
1,381

Contingent consideration
585

 
$
17,582

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash and cash equivalents
$
2,054

Short term investments
542

Trade receivables
75

Other receivables
97

Prepaid expenses and other
227

Property and equipment
250

Intangible assets
14,000

Other noncurrent assets
58

Total assets acquired
17,303

Accounts payable
2,158

Accrued compensation and benefits
1,226

Other accrued expenses
856

Other long term liabilities
92

Deferred tax liabilities
239

Total liabilities assumed
4,571

Net assets acquired
12,732

Goodwill
4,850

Total consideration
$
17,582

The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of eleven years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology.

19


Acquisition-related costs totaling $238 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the three months ended March 31, 2017.
Condensed Pro Forma Financial Information
GenVec's results of operations subsequent to the acquisition are included in the consolidated statement of operations. The following condensed pro forma financial information for the three months ended March 31, 2017 is presented as if the acquisition had been consummated on January 1, 2016:
 
Three Months Ended 
 March 31,
 
2017
 
Pro forma
Revenues
$
53,861

Loss before income taxes
(36,765
)
Net loss
(36,232
)
Net loss attributable to the noncontrolling interests
978

Net loss attributable to Intrexon
(35,254
)
4. Investments in Joint Ventures
S & I Ophthalmic
In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governed the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leveraged experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic was governed by a board of managers which had four members, two each from the Company and Sun Pharmaceutical Subsidiary. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of $5,000.
In December 2017, both the Company and Sun Pharmaceutical Subsidiary agreed to dissolve S & I Ophthalmic and terminate the related ECC agreement. In January 2018, the Company received $2,598 upon the dissolution of S & I Ophthalmic which represented the Company's portion of S & I Ophthalmic's remaining cash after all liabilities were settled.
OvaXon
In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development, and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. Through March 31, 2018, both the Company and OvaScience have made subsequent capital contributions of $4,350.
In March 2018, the Company and OvaScience agreed to terminate the ECC agreement with OvaScience. The Company and OvaScience are in discussions regarding dissolving the OvaXon joint venture and terminating the related ECC agreement.
The Company's investment in OvaXon was $146 as of March 31, 2018 and December 31, 2017, and is included in investments in affiliates in the accompanying consolidated balance sheets.

20


Intrexon Energy Partners
In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of March 31, 2018, the Company's remaining commitment was $6,011. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.
The Company's investment in Intrexon Energy Partners was $(806) and $(444) as of March 31, 2018 and December 31, 2017, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
Intrexon Energy Partners II
In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.
The Company's investment in Intrexon Energy Partners II was $515 and $572 as of March 31, 2018 and December 31, 2017, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.
EnviroFlight
In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through March 31, 2018, both the Company and Darling have made subsequent capital contributions of $8,250.
The Company's investment in New EnviroFlight was $10,072 and $7,092 as of March 31, 2018 and December 31, 2017, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.

21


Intrexon T1D Partners
In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Intrexon has committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of March 31, 2018, the Company's remaining commitment was $1,250. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has five members. Two members of the Intrexon T1D Partners Board are designated by the Company and three members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board.
The Company's investment in Intrexon T1D Partners was $(67) and $(943) as of March 31, 2018 and December 31, 2017, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
5. Collaboration and Licensing Revenue
The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.
The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained under ASC 606. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement.
See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.
The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Amounts for periods subsequent to January 1, 2018 reflect revenue recognition under ASC 606.

22


The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2018 and 2017.
 
Three Months Ended 
 March 31,
 
2018
 
2017
ZIOPHARM Oncology, Inc.
$
6,879

 
$
10,985

Oragenics, Inc.
342

 
569

Fibrocell Science, Inc.
835

 
1,739

Genopaver, LLC
1,288

 
1,680

S & I Ophthalmic, LLC

 
303

OvaXon, LLC

 
824

Intrexon Energy Partners, LLC
1,252

 
5,086

Persea Bio, LLC
252

 
289

Ares Trading S.A.
3,368

 
3,315

Intrexon Energy Partners II, LLC
615

 
1,149

Intrexon T1D Partners, LLC
1,468

 
1,132

Harvest start-up entities (1)
3,354

 
3,363

Other
4,372

 
2,631

Total
$
24,025

 
$
33,065

(1)
For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
Other than the termination of the OvaScience ECC in March 2018 (Note 4), there have been no significant changes to arrangements with our collaborators and licensees in the three months ended March 31, 2018. See Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 for additional details of the Company's existing collaboration and licensing agreements.
Deferred Revenue
Deferred revenue primarily consists of consideration received for the Company's collaborations and licensing agreements and prepayments for product and service revenues. Deferred revenue consists of the following:
 
March 31,
2018
 
December 31,
2017
Collaboration and licensing agreements
$
258,174

 
$
231,583

Prepaid product and service revenues
5,138

 
4,681

Other
78

 
133

Total
$
263,390

 
$
236,397

Current portion of deferred revenue
$
48,646

 
$
42,870

Long-term portion of deferred revenue
214,744

 
193,527

Total
$
263,390

 
$
236,397


23


The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of March 31, 2018 and December 31, 2017, including the estimated remaining performance period as of March 31, 2018.
 
Average Remaining Performance Period (Years)
 
March 31,
2018
 
December 31,
2017
ZIOPHARM Oncology, Inc.
5.8
 
$
86,365

 
$
90,496

Oragenics, Inc.
6.2
 
6,456

 
6,719

Fibrocell Science, Inc.
6.6
 
16,002

 
16,607

Genopaver, LLC
6.0
 
1,635

 
1,704

Intrexon Energy Partners, LLC
6.0
 
15,000

 
15,625

Persea Bio, LLC
6.8
 
3,375

 
3,500

Ares Trading S.A.
6.1
 
78,384

 
40,789

Intrexon Energy Partners II, LLC
6.7
 
13,333

 
13,833

Intrexon T1D Partners, LLC
7.0
 
8,334

 
8,435

Harvest start-up entities (1)
7.1
 
17,918

 
18,400

Other
3.7
 
10,494

 
14,423

Total
 
 
$
257,296

 
$
230,531

(1)
As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
6. Short-term Investments
The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2018:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
Certificates of deposit
$
275

 
$

 
$

 
$
275

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2017:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
6,000

 
$

 
$
(2
)
 
$
5,998

Certificates of deposit
275

 

 

 
275

Total
$
6,275

 
$

 
$
(2
)
 
$
6,273

For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
As of March 31, 2018, all of the available-for-sale investments were due within one year based on their contractual maturities.
Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and there were none as of March 31, 2018.

24


As of March 31, 2018 and December 31, 2017, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.
7. Investments in Preferred Stock
Investment in ZIOPHARM Preferred Stock
In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM, a related party, with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements. A summary of the terms of the Preferred Shares follows.
Conversion. The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the twenty trading days ending on the Conversion Event Date or (ii) $1.00. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation").
Dividend Rights. The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from $12.00 to $24.00 per Preferred Share per month.
Voting Rights. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation.
Liquidation Rights. In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer, or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the twenty day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.
The investment in ZIOPHARM preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in ZIOPHARM preferred stock is estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model are (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. A significant change in unobservable inputs discussed above could result in a significant impact on the fair value of the Company's investment in ZIOPHARM preferred stock. The fair value of the Company's investment in ZIOPHARM preferred stock, including additional Preferred Shares received as dividends, was $165,703 and $160,832 as of March 31, 2018 and December 31, 2017, respectively. During the three months ended March 31, 2018 and 2017, the Company received 3,624 shares and 3,216 shares, respectively, of additional Preferred Shares and recognized $4,871 and $3,923, respectively, of dividend income in the accompanying consolidated statements of operations.

25


Investment in Fibrocell Preferred Stock
In March 2017, Fibrocell Science, Inc. ("Fibrocell"), one of the Company's collaborators and a related party, sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 498,843 shares of Fibrocell common stock. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of March 31, 2018 and December 31, 2017, the fair value of the Company's investment in Fibrocell preferred stock totaled $366 and $393, respectively. See Note 17 for additional discussion of the warrants.
Investment in Oragenics Preferred Stock
In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrues an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increases to 20%. Additionally, the Company and Oragenics amended certain future payment terms under its ECCs, as discussed in Note 5 of the Company's Annual Report on Form 10-K for the year ended December 31, 2017. As of March 31, 2018 and December 31, 2017, based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock.
Changes in the Fair Value of Investments in Preferred Stock
The following table summarizes the changes in the Level 3 investments in preferred stock during the three months ended March 31, 2018.
 
Three Months Ended 
 March 31, 2018
Beginning balance
$
161,225

Dividend income from investments in preferred stock
4,883

Net unrealized depreciation in the fair value of the investments in preferred stock
(39
)
Ending balance
$
166,069

8. Fair Value Measurements
The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.

26


The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at March 31, 2018:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
March 31,
2018
Assets
 
 
 
 
 
 
 
Equity securities
9,622

 
4,421

 

 
14,043

Preferred stock

 

 
166,069

 
166,069

Other

 
769

 

 
769

Total
$
9,622

 
$
5,190

 
$
166,069

 
$
180,881

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2017:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2017
Assets
 
 
 
 
 
 
 
U.S. government debt securities
$

 
$
5,998

 
$

 
$
5,998

Equity securities
10,537

 
4,563

 

 
15,100

Preferred stock

 

 
161,225

 
161,225

Other

 
850

 

 
850

Total
$
10,537

 
$
11,411

 
$
161,225

 
$
183,173

The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The methods used to estimate the fair value of the Level 3 assets are discussed in Note 7.
There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2018.
The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The Company's contingent consideration liabilities from previous acquisitions are measured on a recurring basis and were $585 at March 31, 2018 and December 31, 2017. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the three months ended March 31, 2018.

27



9. Inventory
Inventory consists of the following:
 
March 31,
2018
 
December 31,
2017
Supplies, embryos and other production materials
$
3,386

 
$
2,673

Work in process
4,422

 
4,767

Livestock
10,991

 
11,040

Feed
1,472

 
2,013

Total inventory
$
20,271

 
$
20,493

10. Property, Plant and Equipment, Net
Property, plant and equipment consist of the following:
 
March 31,
2018
 
December 31,
2017
Land and land improvements
$
11,815

 
$
11,767

Buildings and building improvements
18,160

 
18,183

Furniture and fixtures
2,516

 
2,515

Equipment
69,568

 
65,863

Leasehold improvements
27,811

 
25,277

Breeding stock
4,204

 
3,832

Computer hardware and software
10,442

 
10,128

Trees
7,996

 
6,642

Construction and other assets in progress
15,819

 
14,113

 
168,331

 
158,320

Less: Accumulated depreciation and amortization
(49,087
)
 
(45,646
)
Property, plant and equipment, net
$
119,244

 
$
112,674

Depreciation expense was $3,456 and $2,782 for the three months ended March 31, 2018 and 2017, respectively.
11. Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for the three months ended March 31, 2018 are as follows:
Balance at December 31, 2017
$
153,289

Foreign currency translation adjustments
1,459

Balance at March 31, 2018
$
154,748

The Company had $13,823 of accumulated impairment losses as of March 31, 2018 and December 31, 2017.

28


Intangible assets consist of the following as of March 31, 2018:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
266,579

 
$
(48,586
)
 
$
217,993

Customer relationships
10,700

 
(6,733
)
 
3,967

Trademarks
6,800

 
(2,760
)
 
4,040

In-process research and development
5,883

 

 
5,883

Total
$
289,962

 
$
(58,079
)
 
$
231,883

Intangible assets consist of the following as of December 31, 2017:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
263,615

 
$
(44,954
)
 
$
218,661

Customer relationships
10,700

 
(6,383
)
 
4,317

Trademarks
6,800

 
(2,567
)
 
4,233

In-process research and development
5,666

 

 
5,666

Total
$
286,781

 
$
(53,904
)
 
$
232,877

The balance of in-process research and development includes certain in-process research and development technology acquired
in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have
been obtained for the in-process programs.
Amortization expense was $4,926 and $4,618 for the three months ended March 31, 2018 and 2017, respectively.
12. Lines of Credit and Long Term Debt
Lines of Credit
Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha which matures on June 1, 2018. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and the actual rate was 4.62% as of March 31, 2018. As of March 31, 2018, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of March 31, 2018.
Exemplar has a $700 revolving line of credit with American State Bank which matures on October 30, 2018. The line of credit bears interest at 5.25% per annum. As of March 31, 2018, there was an outstanding balance of $321.

29



Long Term Debt
Long term debt consists of the following:
 
March 31,
2018
 
December 31,
2017
Notes payable
$
4,896

 
$
5,010

Royalty-based financing
2,108

 
2,132

Other
922

 
895

Long term debt
7,926

 
8,037

Less current portion
501

 
502

Long term debt, less current portion
$
7,425

 
$
7,535

Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $4,775 as of March 31, 2018. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.
AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency, a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,226, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the date of the acquisition by Intrexon in March 2013, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Subsequent to the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long term debt of $2,108 as of March 31, 2018.
Future maturities of long term debt are as follows:
2018
$
398

2019
411

2020
382

2021
830

2022
373

2023
386

Thereafter
3,038

Total
$
5,818

The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.
13. Income Taxes
Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three months ended March 31, 2018, the Company had U.S. taxable loss of approximately $35,100 and recorded $113 of current domestic income tax expense. For the three months ended March 31, 2018, the Company recognized $125 of current foreign income tax benefit. For the three months ended March 31, 2017, the Company had U.S. taxable income of approximately $11,800 and recorded $236 of current domestic income tax expense. For the three months ended March 31, 2017, the Company recognized $131 of current foreign income tax benefit. For the three months ended March 31, 2018, the Company recorded deferred tax benefit of $4,074. For the three months ended March 31, 2017, the Company recorded deferred tax benefit of $638. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $11,631, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm

30



recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
As of March 31, 2018, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $279,500 available to offset future taxable income, and federal and state research and development tax credits of approximately $7,800, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. These carryforwards will begin to expire in 2022. As of March 31, 2018, the Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $160,700, most of which do not expire.
In 2017, the Company recorded a net provisional income tax benefit upon enactment of the Tax Act. The Company has provisionally estimated its transition tax exposure to be zero, as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries. The provisional amounts recorded are subject to further refinement within the measurement period prescribed by SAB 118. As a result, the recorded amounts are subject to change, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company utilized to provisionally compute the transition impact. No adjustments to these provisional amounts were recorded during the three months ended March 31, 2018.
14. Shareholders' Equity
Issuances of Common Stock
In January 2018, Intrexon closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374, after deducting underwriting discounts of $3,688 and offering expenses of $188, all of which were capitalized.
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss are as follows:
 
March 31,
2018
 
December 31,
2017
Unrealized loss on investments
$

 
$
(2
)
Loss on foreign currency translation adjustments
(9,587
)
 
(15,552
)
Total accumulated other comprehensive loss
$
(9,587
)
 
$
(15,554
)
15. Share-Based Payments
The Company records the fair value of stock options and restricted stock units ("RSUs") issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Cost of products
$
25

 
$
26

Cost of services
77

 
78

Research and development
3,258

 
2,193

Selling, general and administrative
8,002

 
5,597

Total
$
11,362

 
$
7,894


31



Intrexon Stock Option Plans
In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of March 31, 2018, there were 431,649 stock options outstanding under the 2008 Plan.
Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of March 31, 2018, there were 18,000,000 shares authorized for issuance under the 2013 Plan, of which 11,114,785 stock options and 1,052,182 RSUs were outstanding and 3,279,291 shares were available for grant. In March 2018, Intrexon's board of directors approved, subject to shareholder approval at Intrexon's annual meeting in June 2018, an increase of 2,000,000 shares of common stock to be reserved for issuance under the 2013 Plan.
Stock option activity was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2017
11,382,747

 
$
28.99

 
7.32
Granted
656,339

 
14.84

 
 
Exercised
(21,722
)
 
(3.40
)
 
 
Forfeited
(186,811
)
 
(26.37
)
 
 
Expired
(284,119
)
 
(27.67
)
 
 
Balances at March 31, 2018
11,546,434

 
28.31

 
7.25
Exercisable at March 31, 2018
6,533,996

 
29.29

 
6.38
During the three months ended March 31, 2018, Intrexon granted 1,059,126 RSUs with a weighted average grant date fair value of $13.83 per share, of which 1,052,182 remain outstanding and unvested as of March 31, 2018.
Intrexon currently uses authorized and unissued shares to satisfy share award exercises.
In October 2015, the compensation committee and the independent members of Intrexon's board of directors approved a compensation arrangement whereby the Company's Chief Executive Officer ("CEO") would receive a monthly salary. Previously, the CEO did not receive compensation for his services as an employee of the Company other than through his participation in the Company's Annual Executive Incentive Plan which became effective January 1, 2015. Pursuant to the compensation agreement, the CEO receives a base salary of $200 per month payable in fully vested shares of Intrexon common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") which was executed between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement became effective in November 2015, and had an initial term of twelve months. The independent members of Intrexon's board of directors, with the recommendation of the compensation committee of the board of directors, subsequently approved extensions of the RSU Agreement through March 31, 2019, all of which are on the same terms as the original RSU Agreement. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled $486 and $471 for the three months ended March 31, 2018 and 2017, respectively.
AquaBounty Stock Option Plans
In March 2016, AquaBounty's board of directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan"). The AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, no new awards may be granted under the AquaBounty 2006 Plan.

32



As of March 31, 2018, there were 340,764 options outstanding under both AquaBounty plans, of which 207,390 were exercisable, at a weighted average exercise price of $7.09 per share.
16. Commitments and Contingencies
Operating Leases
The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At March 31, 2018, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2018
$
6,096

2019
9,441

2020
9,506

2021
8,601

2022
7,595

2023
6,558

Thereafter
23,923

Total
$
71,720

Rent expense, including other facility expenses, was $3,259 and $2,301 for the three months ended March 31, 2018 and 2017, respectively.
Purchase Commitments
As of March 31, 2018, the Company had outstanding contractual purchase commitments of $15,098, which primarily relate to amounts that will be paid in 2018, 2019, and 2020 upon delivery of commercial non-browning apple trees.
Contingencies
In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breached a 2004 licensing agreement and infringed on patents that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. In Colorado District Court, the matter proceeded to a jury trial in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with a compulsory license to XY's technology, subject to an ongoing royalty obligation. Both parties appealed the court's order, which appeal is pending before the Court of Appeals for the Federal Circuit. Since the inception of the 2004 agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the April 2016 court order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the court's April 2016 order, aggregate royalty and license payments were $3,170, of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded expense of $4,228 representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of March 31, 2018, this amount is included in restricted cash on the accompanying consolidated balance sheet. In December 2016, Trans Ova elected to void the outstanding checks discussed above, and these amounts have been reclassified to other accrued liabilities on the accompanying consolidated balance sheets as of March 31, 2018 and December 31, 2017. Depending on the outcome of an appeal decision, the damages awarded to either party could decrease, increase, or be eliminated. The appeal decision may also remand to the Colorado District Court all, or a portion, of the issues being appealed. In December 2016, XY filed a complaint for patent infringement and trade secret misappropriation against Trans Ova in the District Court of Waco, Texas. Since the claims in this 2016 complaint directly relate to the 2012 licensing dispute and patent issues, Trans Ova filed and was granted a motion for change of venue to Colorado District Court. Trans Ova also filed a motion to dismiss, from which the Court recently dismissed nine of the twelve counts of the complaint. Presently, three counts for patent infringement remain pending. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation, to modify the court-ordered license to XY's technologies, or to recover monetary damages stemming from Trans Ova's counterclaims for antitrust violations by XY and its parent company, Inguran.

33


In June and July 2016, two shareholders made separate demands under Virginia law demanding that the Company file suit against certain of its current officers and directors for alleged breaches of fiduciary duty and other claims. The demands were based upon and asserted the allegations contained in a report published in April 2016 on the Seeking Alpha financial blog. In July 2016, the Company's board of directors authorized its Special Litigation Committee ("SLC"), consisting of independent directors, to investigate the claims and allegations made in the two shareholder demands and to decide on behalf of the Company whether the claims and allegations should be pursued. In February 2017, the SLC completed its review and evaluation and unanimously determined that there was no basis for any of the allegations, that the Company's officers and directors did not breach their fiduciary duties or any other applicable law, and that prosecution of the asserted claims was not in the best interest of Intrexon or its shareholders.
Following the SLC's determination, in March 2017, a derivative complaint captioned Luger v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, alleging causes of action for breaches of fiduciary duty and unjust enrichment relating to the same allegations investigated by the SLC. On April 4, 2018, the plaintiff filed a motion to nonsuit, which the court granted without prejudice on April 13, 2018.
The Division of Enforcement of the SEC is conducting an investigation which the Company believes concerns certain issues raised by the foregoing and by the previously disclosed consolidated putative shareholder class action lawsuit, captioned Intrexon Corporation Securities Litigation, that was dismissed on November 1, 2017 and the previously disclosed shareholder derivative action captioned Basile v. Kirk et al. that was dismissed on January 25, 2018. The Company has met with the SEC staff and is voluntarily cooperating with their investigation. The Company's board of directors has authorized the SLC to monitor the Company's interaction with the SEC staff.
The Company may become subject to other claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2018 and December 31, 2017, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.
17. Related Party Transactions
Third Security and Affiliates
The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15). The Services Agreement had a term of one year, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2019. For the three months ended March 31, 2018 and 2017, the Company issued 160,626 shares and 103,930 shares, respectively, with values of $2,041 and $2,039, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement were $14 and $66 for the three months ended March 31, 2018 and 2017, respectively.
See also Note 15 regarding compensation arrangements between the Company and its CEO.
In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Facility, the Company may, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). Any issued Series A Preferred Stock is non-voting, accrues dividends of 8% per annum and, subject to limited exceptions, is senior to Intrexon's common stock with respect to the rights to the payment of

34


dividends and on parity with the common stock with respect to the distribution of assets in the event of any liquidation, dissolution or winding up or change of control of Intrexon. Any issued Series A Preferred Stock is convertible into common stock only following receipt of shareholder approval by the Company, including a majority of the shares voted by those shareholders unaffiliated with Mr. Kirk (the "Shareholder Approval"), subject to any necessary regulatory approvals. Following receipt of the Shareholder Approval and receipt of any necessary regulatory approvals, any issued Series A Preferred Stock is convertible into Intrexon common stock based on a conversion price using the 20-day volume-weighted average market price as of market closing on the fifth business day prior to the mailing of the proxy statement soliciting the Shareholder Approval, subject to adjustment for certain stock splits and similar events. The Company has agreed to take all reasonable steps necessary to seek Shareholder Approval on or before the date of its annual meeting of shareholders in 2019. Any issued Series A Preferred Stock is redeemable at the election of the Company at any time, or at the election of the Third Security Affiliate after December 31, 2020. The Preferred Stock Facility will expire on the earliest to occur of: (i) the date on which the Third Security Affiliate has purchased shares of Series A Preferred Stock in the aggregate amount of $100,000, (ii) April 30, 2019, (iii) the date of the Shareholder Approval, and (iv) the mutual agreement of the parties. To date, the Company has not utilized the Preferred Stock Facility.
The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $21 and $11 for the three months ended March 31, 2018 and 2017, respectively.
Transactions with ECC Parties
In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties.
The Company holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. As of March 31, 2018 and December 31, 2017, the value of the convertible note and warrants totaled $494 and $575, respectively, and is included in other assets on the accompanying consolidated balance sheets. See Note 7 for additional discussion of the Company's investments in Fibrocell.
Other Related Parties
In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $603 for the three months ended March 31, 2017. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities.
18. Net Loss per Share
The following table presents the computation of basic and diluted net loss per share:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Historical net loss per share:
 
 
 
Numerator:
 
 
 
Net loss attributable to Intrexon
$
(41,988
)
 
$
(31,399
)
Denominator:
 
 
 
Weighted average shares outstanding, basic and diluted
127,693,336

 
118,956,780

Net loss attributable to Intrexon per share, basic and diluted
$
(0.33
)
 
$
(0.26
)

35


The following potentially dilutive securities as of March 31, 2018 and 2017, have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive:
 
March 31,
 
2018
 
2017
Options
11,546,434

 
12,632,507

Restricted stock units
1,052,182

 

Warrants
133,264

 

Total
12,731,880

 
12,632,507

19. Subsequent Events
In May 2018, the Company commenced efforts to shift certain of the manufacturing and distribution operations of Oxitec's Brazilian subsidiary to a decentralized operation and as a result, the Company anticipates one-time charges of up to approximately $6,000 in the second quarter of 2018. These charges are comprised primarily of the costs to vacate its existing leased premises, the write-down of certain fixed assets previously used in production, and severance costs.

36


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K.
The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements and you are cautioned not to place undue reliance on forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in "Special Note Regarding Forward-Looking Statements" and "Risk Factors." The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof.
Overview
We believe we are a leader in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Synthetic biology involves the tightly controlled expression of natural and engineered genes (DNA segments) in a variety of animal, plant and microorganismal hosts. Our historical approach primarily involved an exclusive channel collaboration, or ECC, model in which we served principally as the technology engine for a partner experienced in a given commercial arena. As our experience has deepened, we have moved toward more joint ventures, or JVs, and the self-development of projects we view as particularly compelling and within our increasing areas of expertise.
Synthetic biology is a rapidly evolving discipline that applies engineering principles to biological systems to enable rational, design-based control of cellular function for a specific purpose. Using our suite of proprietary and complementary technologies, we design, build and regulate gene programs, which are DNA sequences that consist of key genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment. It is these genetically modified cell systems that can be used to produce biological effector molecules, or be employed directly to enable the development of new and improved products and manufacturing processes across a variety of end markets, including health, food, energy, environment, and consumer. Our synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
We believe our technologies are broadly applicable across many diverse end markets, including some end markets that have failed to recognize the applicability of synthetic biology or failed to efficiently utilize biologically-based processes to produce products. To enable us to maximize the number of these markets we could address, we devised a strategy that allowed us to focus on our core expertise in synthetic biology while developing many different commercial product candidates via collaborations in a broad range of industries or end markets. Historically, we built our business model primarily around the formation of ECCs. An ECC is an agreement with a collaborator to develop products based on technologies in a specifically defined field. We have sought collaborators with expertise within a specific industry sector and the commitment to provide resources for the commercialization of products within that industry sector. Through our ECCs, we provide expertise in the engineering of gene programs and cellular systems, and our collaborators are responsible for providing market and product development expertise, as well as sales and marketing capabilities. In addition, we have sometimes executed a research collaboration to develop an early-stage program pursuant to which we received reimbursement for our development costs but the exclusive commercial rights, and related access fees, were deferred until completion of an initial research program.
This ECC strategy has allowed us to leverage our capabilities and capital across numerous product development programs and a broader landscape of end markets than we would have been capable of addressing on our own. The strategy has also allowed us to participate in the potential upside from products that are enabled by our technologies across an extensive range of industries, without the need for us to invest considerable resources in bringing individual products to market. We presently are party to a number of these collaborations, which are in varying stages from research and development of product candidates to monitoring the progress of our collaborator in their further development and, we expect, commercialization of product candidates enabled through our collaborations.
Over time, our strategy has evolved away from ECC-type collaborations to relationships and structures that provide us with more control and ownership over the development process and commercialization path. In these new relationships and structures, we bear more of the responsibility to fund the projects and execute on product candidate development.

37


First, in certain strategic circumstances, we may enter into a JV with a third party collaborator whereby we may contribute access to our technology, cash or both into the JV which we will jointly control with our collaborator. Pursuant to a JV agreement, we may be required to contribute additional capital to the JV, and we may be able to receive a higher financial return than we would normally receive from an ECC to the extent that we and our collaborator are successful in developing one or more products. For a discussion of our JVs, see the "Notes to the Consolidated Financial Statements (Unaudited) - Note 4" appearing elsewhere in this Quarterly Report on Form 10-Q. Second, we are increasing the resources we are expending internally on early-stage proof of concept programs where we can leverage our competitive edge in gene program creation and host cell and genome expertise. We are also seeking to partner more mature programs and capabilities or later-stage assets. In this way, we endeavor to leverage our capital resources and ultimately hope to realize significant value from our mature assets.
As we consider the broad potential applications of our synthetic biology technologies, and consistent with the evolution of our business strategy, we have acquired a number of ventures that are already enabling products that benefit from the application of synthetic biology. Our strategy contemplates the continued acquisition of product-focused companies that we believe may leverage our technologies and expertise in order to expand their respective product applications. We believe that the acquisition of these types of companies allows us to develop and commercialize innovative products and create significant value.
Consistent with the ongoing evolution of our strategy, from principally utilizing ECCs to seeking a more diverse approach to leverage our technology assets, we routinely consider ways to organize our business and the grouping of our assets to facilitate strategic opportunities.
Our operating subsidiaries
To derive value from the broad potential applications of our synthetic biology technologies, and consistent with the evolution of our business strategy, we routinely consider ways to organize our business to facilitate strategic opportunities. For example, effective January 1, 2018, we transferred substantially all of our gene and cell therapy assets for human health under a newly-formed wholly owned subsidiary, Precigen, Inc., or Precigen, and we consolidated therapeutic applications of our proprietary ActoBiotics platform under ActoBio Therapeutics, Inc., or ActoBio. In addition, we have acquired a number of ventures that are already enabling products that benefit from the application of synthetic biology and that we now operate as subsidiaries. Our strategy contemplates the continued formation and acquisition of such operating subsidiaries. As these enterprises develop, we will determine whether to maintain full ownership, introduce investors via either private or public financing, or seek strategic options to partner or divest the businesses.
Primary wholly owned operating subsidiaries
Precigen, Inc.
Precigen is a fully-integrated gene and cell therapy company committed to delivering precision medicines through innovation that puts patients first. Utilizing platform technologies owned by Precigen or licensed from Intrexon for programming and engineering genetic code, Precigen is developing and investigating next-generation therapeutics to enable patient-focused, cost-effective treatments to address unmet medical needs in the areas of immuno-oncology, autoimmune conditions, and infectious diseases. Precigen is designing investigational therapies intended to be controllable and targeted, with a broad pipeline of internal and partnered programs, all of which are at the preclinical or clinical stages.
ActoBio Therapeutics, Inc.
ActoBio is pioneering a new class of microbe-based ActoBiotics biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The ActoBiotics platform produces biologics through oral or topical administration with treatment applications across many diseases including oral, gastrointestinal, and autoimmune/allergic disorders. We believe this cost-effective approach to development will provide safer and more efficacious treatments than injectable biologics. ActoBio, which is party to a number of our ECC agreements, has a strong research and development pipeline with the latest stage candidate in Phase 2b clinical trials and an extensive portfolio of candidates ready for clinical development across a number of potential indications.
Trans Ova Genetics, L.C.
Trans Ova Genetics, L.C., or Trans Ova, is internationally recognized as a provider of industry-leading bovine reproductive technologies. Intrexon and Trans Ova are building upon Trans Ova's original platform with a goal of achieving higher levels of delivered value to dairy and beef cattle producers. Progentus, L.C., or Progentus, a wholly owned subsidiary of Trans Ova, is a provider of bovine embryos. ViaGen, L.C., or ViaGen, a wholly owned subsidiary of Trans Ova, is a provider of cloning

38


technology for non-primate species. Exemplar Genetics, LLC, or Exemplar, a wholly owned subsidiary through the combined ownership of Trans Ova, ViaGen and us, is committed to enabling the study of life-threatening human diseases through the development of miniswine research models and services.
Okanagan Specialty Fruits, Inc.
Okanagan Specialty Fruits, Inc. and its affiliates, or Okanagan, is the pioneering agricultural company behind the world's first non-browning apple without the use of any flavor altering chemical or antioxidant additives. Okanagan is scaling up its commercial supplies of non-browning apples and developing new commercial tree fruit varieties intended to provide benefits to the entire supply chain, from growers to consumers.
Oxitec Limited
Oxitec Limited, or Oxitec, is a pioneering company in biological insect control solutions. Oxitec is developing products that use genetic engineering to control insect pests that spread disease and damage crops. Among the applications of its platform which uses advanced genetics and molecular biology, Oxitec has developed a new and innovative solution to controlling Aedes aegypti, a mosquito that is a known vector for the transmission of infectious disease including dengue fever, chikungunya, and Zika. This genetically engineered, self-limiting line of the Aedes aegypti mosquito, or OX513A, has been approved by Brazil's National Biosafety Committee for unrestricted releases throughout the country. Additionally, open field trials of these mosquitoes have been conducted in Brazil, the Cayman Islands, Panama, and Malaysia under relevant permits or approvals. Further approvals will be required for commercial production and use.
Primary majority-owned operating subsidiary
AquaBounty Technologies, Inc.
AquaBounty Technologies, Inc., or AquaBounty, of which we owned approximately 58 percent as of December 31, 2017, is focusing on improving productivity in commercial aquaculture, including the development of the AquAdvantage Salmon, an Atlantic salmon that has been genetically enhanced to reach market size in less time than conventionally farmed Atlantic salmon and approved by the Food and Drug Administration. In January 2018, AquaBounty raised $12.0 million through an underwritten public offering, in which we participated by investing $5 million. As a result of this transaction, our ownership decreased to approximately 53 percent. In the future, our ownership stake in AquaBounty may drop below 50 percent, which may result in us deconsolidating AquaBounty.
Mergers, acquisitions, and technology in-licensing
We may augment our suite of proprietary technologies through mergers or acquisitions of technologies which then become available to new or existing ventures, including operating subsidiaries, JVs, and collaborations. Among other things, we may pursue technologies that we believe will be generally complementary to our existing technologies and also meet our desired return on investment and other economic criteria. In certain cases, such technologies may already be applied in the production of products or services and in these cases we may seek to expand the breadth or efficacy of such products or services through the use of our technologies. There have been no mergers, acquisitions or significant technology in-licensing activities in 2018. For a discussion of our 2017 acquisition, see "Notes to the Consolidated Financial Statements (Unaudited) - Note 3" appearing elsewhere in this Quarterly Report on Form 10-Q.
Financial overview
We have incurred significant losses since our inception. We anticipate that we may continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. Outside of collaboration and license fee payments, which vary over time, we have not generated significant revenues, including revenues or royalties from product sales by us or our collaborators. Certain of our consolidated subsidiaries require regulatory approval and/or commercial scale-up before they may commence significant product sales and operating profits.
We expect our future capital requirements will be substantial, particularly as we continue to develop our business and expand our synthetic biology technology platform. In January 2018, we closed a public offering of 6,900,000 shares of our common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security, LLC, or Third Security, the net proceeds of which were $82.4 million, after deducting underwriting discounts and commissions and offering expenses paid by us. Additionally, we have a Preferred Stock Equity Facility, or Preferred Stock Facility, with an affiliate of Third Security, which will terminate no later than April 30, 2019. Our Chairman and Chief Executive Officer, or CEO, also serves as the Senior

39


Managing Director and CEO of Third Security and owns all of the outstanding equity interests of Third Security. Under the Preferred Stock Facility, we may, at our sole and exclusive option, issue and sell to the affiliate of Third Security, up to $100 million of newly issued Series A Redeemable Preferred Stock, or Series A Preferred Stock. We believe that our existing cash and cash equivalents, short-term investments, cash expected to be received from our current collaborators and for sales of products and services provided by our consolidated subsidiaries, cash received in our January 2018 offering, and any issuances of Series A Preferred Stock under the Preferred Stock Facility will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.
Sources of revenue
Historically, we have derived our collaboration and licensing revenues through agreements with counterparties for the development and commercialization of products enabled by our technologies. Generally, the terms of these collaborations provide that we receive some or all of the following: (i) technology access fees upon signing; (ii) reimbursements of costs incurred by us for our research and development and/or manufacturing efforts related to specific applications provided for in the collaboration; (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration.
Our technology access fees and milestone payments may be in the form of cash or securities of the collaborator. Our collaborations contain multiple arrangements and we typically defer revenues from the technology access fees and milestone payments received and recognize such revenues in the future over the anticipated performance period. We are also entitled to sublicensing revenues in those situations where our collaborators choose to license our technologies to other parties.
From time to time, we and certain collaborators may cancel the agreements, relieving us of any further performance obligations under the agreement. When no further performance obligations are required of us under an agreement, we may recognize any remaining deferred revenue.
We generate product and service revenues primarily through sales of products or services that are created from technologies developed or owned by us. Our primary current offerings include sales of advanced reproductive technologies, including our bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. We recognize revenue when the customer takes ownership of the promised product or when the promised service is completed.
In future periods, our revenues will depend in part on our ability to partner our more mature programs and capabilities, the number of collaborations to which we are party, the advancement and creation of programs within our collaborations and the extent to which our collaborators bring products enabled by our technologies to market. Our revenues will also depend upon our ability to maintain or improve the volume and pricing of our current product and service offerings and to develop and scale up production of new offerings from the various technologies of our subsidiaries. Our future revenues may also include additional revenue streams we may acquire through mergers and acquisitions. In light of our limited operating history and experience, there can be no assurance as to the timing, magnitude and predictability of revenues to which we might be entitled.
Cost of products and services
Cost of products and services includes primarily labor and related costs, drugs and supplies used primarily in the embryo transfer and in vitro fertilization processes, livestock and feed used in production, and facility charges, including rent and depreciation. Fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and no derivative financial instruments are used to mitigate the price risk.
Research and development expenses
We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
salaries and benefits, including stock-based compensation expense, for personnel in research and development functions;
fees paid to consultants and contract research organizations who perform research on our behalf and under our direction;

40


costs related to laboratory supplies used in our research and development efforts;
costs related to certain in-licensed technology rights;
depreciation of leasehold improvements and laboratory equipment;
amortization of patents and related technologies acquired in mergers and acquisitions; and
rent and utility costs for our research and development facilities.
We have no individually significant research and development projects and our research and development expenses primarily relate to either the costs incurred to expand or otherwise improve our multiple platform technologies, the costs incurred to develop a specific application of our technologies in support of current or prospective partners, or costs incurred to expand or otherwise improve our products and services. Research and development expenses, including costs for preclinical and clinical development, incurred for programs we support pursuant to an ECC agreement are typically reimbursed by the partner at cost and all other research and development programs may be terminated or otherwise deferred at our discretion. The amount of our research and development expenses may be impacted by, among other things, the number of ECCs and the number and size of programs we may support on behalf of an ECC.
The table below summarizes our research and development expenses incurred to expand or otherwise improve our multiple platform technologies, the costs incurred to develop a specific application of our technologies in support of current or prospective partners, or costs incurred to expand or otherwise improve our products and services for the three months ended March 31, 2018 and 2017. Other research and development expenses for these periods include indirect salaries and overhead expenses that are not allocated to either expanding or improving our multiple platform technologies, specific applications of our technologies in support of current or prospective partners, or expanding or improving our product and services offerings.
 
Three Months Ended 
 March 31,
 
2018
 
2017
 
(In thousands)
Expansion or improvement of our platform technologies
$
3,794

 
$
2,803

Specific applications of our technologies in support of current and prospective partners
18,314

 
19,173

Expansion or improvement of our product and service offerings
8,012

 
6,352

Other
7,147

 
5,852

Total research and development expenses
$
37,267

 
$
34,180

We expect that our research and development expenses will increase as we enter into new collaborations, develop our own proprietary programs, and expand our offerings. We believe these increases will likely include increased costs related to the hiring of additional personnel in research and development functions, increased costs paid to consultants and contract research organizations and increased costs related to laboratory supplies. Research and development expenses may also increase as a result of ongoing research and development operations which we might assume through mergers and acquisitions.
Selling, general and administrative expenses
Selling, general and administrative, or SG&A, expenses consist primarily of salaries and related costs, including stock-based compensation expense, for employees in executive, operational, finance, sales and marketing, information technology, legal and corporate communications functions. Other significant SG&A expenses include rent and utilities, insurance, accounting and legal services and expenses associated with obtaining and maintaining our intellectual property.
We expect that our SG&A expenses will continue to increase to support our expanding operations as we explore new partnering opportunities and continue to develop our proprietary programs. We believe that these increases will likely include costs related to the hiring of additional personnel and increased fees for business development functions, costs associated with defending the Company in litigation matters, the costs of outside consultants and other professional services. SG&A expenses may also increase as a result of ongoing operations which we might assume through mergers and acquisitions.

41


Other income (expense), net
We hold equity securities and preferred stock received and/or purchased from certain collaborators. Other than investments accounted for using the equity method discussed below, we elected the fair value option to account for our equity securities and preferred stock held in these collaborators. These equity securities and preferred stock are recorded at fair value at each reporting date. Unrealized appreciation (depreciation) resulting from fair value adjustments are reported as other income (expense) in the consolidated statement of operations. As such, we bear the risk that fluctuations in the securities' share prices may significantly impact our results of operations.
Interest income consists of interest earned on our cash and cash equivalents and short-term and long-term investments. Dividend income consists of the monthly preferred stock dividends received from our investments in preferred stock.
In September 2017, the commitment period for Harvest Intrexon Enterprise Fund I, LP, or Harvest, was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities. Through September 2017, as consideration for providing exclusive rights of first-look and first negotiation, we received a portion of the management fee collected by the fund sponsor of Harvest for our obligation to provide Harvest with investment proposals that were suitable for pursuit by a start-up. These fees are included in other income.
Equity in net income (loss) of affiliates
Equity in net income or loss of affiliates is our pro-rata share of our equity method investments' operating results, adjusted for accretion of basis difference. We account for investments in our JVs and start-up entities backed by Harvest using the equity method of accounting since we have the ability to exercise significant influence, but not control, over the operating activities of these entities.

42


Results of operations
Comparison of the three months ended March 31, 2018 and the three months ended March 31, 2017
The following table summarizes our results of operations for the three months ended March 31, 2018 and 2017, together with the changes in those items in dollars and as a percentage:
 
Three Months Ended 
 March 31,
 
Dollar
Change
 
Percent
Change
 
2018
 
2017
 
 
(In thousands)
 
 
Revenues
 
 
 
 
 
 
 
Collaboration and licensing revenues (1)
$
24,025

 
$
33,065

 
$
(9,040
)
 
(27.3
)%
Product revenues
7,152

 
8,130

 
(978
)
 
(12.0
)%
Service revenues
12,247

 
12,031

 
216

 
1.8
 %
Other revenues
419

 
521

 
(102
)
 
(19.6
)%
Total revenues
43,843

 
53,747

 
(9,904
)
 
(18.4
)%
Operating expenses
 
 
 
 
 
 


Cost of products
8,530

 
9,006

 
(476
)
 
(5.3
)%
Cost of services
6,783

 
6,804

 
(21
)
 
(0.3
)%
Research and development
37,267

 
34,180

 
3,087

 
9.0
 %
Selling, general and administrative
39,737

 
35,138

 
4,599

 
13.1
 %
Total operating expenses
92,317

 
85,128

 
7,189

 
8.4
 %
Operating loss
(48,474
)
 
(31,381
)
 
(17,093
)
 
54.5
 %
Total other income, net
3,616

 
3,418

 
198

 
5.8
 %
Equity in loss of affiliates
(2,460
)
 
(4,947
)
 
2,487

 
(50.3
)%
Loss before income taxes
(47,318
)
 
(32,910
)
 
(14,408
)
 
43.8
 %
Income tax benefit
4,086

 
533

 
3,553

 
>200%

Net loss
(43,232
)
 
(32,377
)
 
(10,855
)
 
33.5
 %
Net loss attributable to noncontrolling interests
1,244

 
978

 
266

 
27.2
 %
Net loss attributable to Intrexon
$
(41,988
)
 
$
(31,399
)
 
$
(10,589
)
 
33.7
 %
(1)
Including $19,815 and $28,887 from related parties for the three months ended March 31, 2018 and 2017, respectively.

43


Collaboration and licensing revenues
The following table shows the collaboration and licensing revenues recognized for the three months ended March 31, 2018 and 2017, together with the changes in those items.
 
Three Months Ended 
 March 31,
 
Dollar
Change
 
2018
 
2017
 
 
(In thousands)
ZIOPHARM Oncology, Inc.
$
6,879

 
$
10,985

 
$
(4,106
)
Oragenics, Inc.
342

 
569

 
(227
)
Fibrocell Science, Inc.
835

 
1,739

 
(904
)
Genopaver, LLC
1,288

 
1,680

 
(392
)
S & I Ophthalmic, LLC

 
303

 
(303
)
OvaXon, LLC

 
824

 
(824
)
Intrexon Energy Partners, LLC
1,252

 
5,086

 
(3,834
)
Persea Bio, LLC
252

 
289

 
(37
)
Ares Trading S.A.
3,368

 
3,315

 
53

Intrexon Energy Partners II, LLC
615

 
1,149

 
(534
)
Intrexon T1D Partners, LLC
1,468

 
1,132

 
336

Harvest Start-up Entities (1)
3,354

 
3,363

 
(9
)
Other
4,372

 
2,631

 
1,741

Total
$
24,025

 
$
33,065

 
$
(9,040
)
(1)
For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
Collaboration and licensing revenues decreased $9.0 million, or 27 percent, from the three months ended March 31, 2017 due to a decrease in research and development services for certain of our ECCs as we redeployed certain resources towards supporting prospective new platforms and partnering opportunities and began to focus more on the further development of relationships and structures that provide us with more control and ownership over the development process and commercialization path. This decrease was partially offset by the accelerated recognition of the remaining balance of previously deferred revenue related to our ECC with OvaScience, Inc., which was mutually terminated in March 2018.
Product revenues and gross margin
Product revenues decreased $1.0 million, or 12 percent, from the three months ended March 31, 2017. The decrease in product revenues was primarily due to lower customer demand for cows and live calves combined with lower sales prices on cows. Gross margin on products declined in the current period as a result of increased operating costs associated with new product offerings.
Service revenues and gross margin
Service revenues increased $0.2 million, or 2 percent, over the three months ended March 31, 2017. The increase in service revenues relates to an increase in the number of bovine in vitro fertilization cycles performed due to higher customer demand. Gross margin on these services were consistent period over period.
Research and development expenses
Research and development expenses increased $3.1 million, or 9 percent, over the three months ended March 31, 2017. The increase is due primarily to increases in (i) salaries, benefits and other personnel costs for research and development employees and (ii) depreciation and amortization. Salaries, benefits and other personnel costs increased $1.5 million due to an increase in research and development headcount necessary to invest in current or expanding platforms and increased compensation

44


expenses related to performance and retention incentives for research and development employees. Depreciation and amortization increased $1.2 million primarily as a result of (i) the amortization of developed technology acquired from GenVec, Inc., or GenVec, in June 2017, and (ii) additional research and development assets placed in service in 2017 at Oxitec.
Selling, general and administrative expenses
SG&A expenses increased $4.6 million, or 13 percent, over the three months ended March 31, 2017. Salaries, benefits and other personnel costs increased $6.2 million primarily due to (i) increased headcount to support our expanding operations, (ii) increased compensation expenses related to performance and retention incentives for SG&A employees, and (iii) higher stock-based compensation expense due to the inclusion in three months ended March 31, 2017 of the reversal of previously recognized stock-based compensation expense for stock options granted to our former President who resigned in March 2017 as well as incremental stock-based compensation expense associated with new equity grants issued in 2018. Legal and professional fees decreased $2.3 million primarily due to (i) decreased legal fees associated with ongoing litigation and (ii) decreased fees incurred for regulatory and other consultants.
Equity in net loss of affiliates
Equity in net loss of affiliates for the three months ended March 31, 2018 and 2017, includes our pro-rata share of the net losses of our investments we account for using the equity method of accounting. The $2.5 million, or 50 percent, decrease from the three months ended March 31, 2017 was directly related to the decrease in collaboration revenues from collaborators in which we own an equity-method interest.
Liquidity and capital resources
Sources of liquidity
We have incurred losses from operations since our inception and as of March 31, 2018, we had an accumulated deficit of $930.2 million. From our inception through March 31, 2018, we have funded our operations principally with proceeds received from private and public offerings, cash received from our collaborators and through product and service sales made directly to customers. As of March 31, 2018, we had cash and cash equivalents of $119.9 million, and we have the Preferred Stock Facility with an affiliate of Third Security, under which we may, at our sole and exclusive option, issue and sell up to $100 million of newly issued Series A Preferred Stock. Cash in excess of immediate requirements is typically invested primarily in money market funds and U.S. government debt securities in order to maintain liquidity and preserve capital.
We currently generate cash receipts primarily from technology access fees, reimbursement of research and development services performed by us and sales of products and services.
Cash flows
The following table sets forth the significant sources and uses of cash for the periods set forth below: 
 
Three Months Ended 
 March 31,
 
2018
 
2017
 
(In thousands)
Net cash provided by (used in):
 
 
 
Operating activities
$
(29,888
)
 
$
(24,689
)
Investing activities
(7,456
)
 
34,554

Financing activities
88,262

 
(3,146
)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
914

 
526

Net increase in cash, cash equivalents and restricted cash
$
51,832

 
$
7,245

Cash flows from operating activities:
During the three months ended March 31, 2018, our net loss was $43.2 million, which includes the following significant noncash expenses that total $26.3 million: (i) $11.4 million of stock-based compensation expense, (ii) $8.4 million of depreciation and amortization expense, (iii) $2.9 million of shares issued as payment for services, (iv) $2.5 million of equity in

45


net loss of affiliates, and (v) $1.1 million of noncash net unrealized losses on our equity securities and preferred stock, partially offset by $4.9 million of noncash dividend income. Additionally, we had a $4.6 million net increase in our operating assets and liabilities. During the three months ended March 31, 2017, our net loss was $32.4 million, which includes the following significant noncash expenses that total $24.7 million: (i) $7.9 million of stock-based compensation expense, (ii) $7.4 million of depreciation and amortization expense, (iii) $4.9 million of equity in net loss of affiliates, (iv) $2.9 million of shares issued as payment for services, and (v) $1.6 million of noncash unrealized losses on our equity securities and preferred stock, partially offset by $3.9 million of noncash dividend income. Additionally, we had a $13.2 million net increase in our operating assets and liabilities.
Cash flows from investing activities:
During the three months ended March 31, 2018, we received proceeds of $6.0 million from the maturity of short-term investments and $2.6 million from the return of the balance from an investment in an affiliate that was dissolved, and used $10.8 million for purchases of property, plant and equipment and $5.5 million for investments in our JVs. During the three months ended March 31, 2017, we received proceeds of $45.0 million from the maturity of short-term investments and used $6.3 million for purchases of property, plant and equipment and $4.6 million for investments in our JVs.
Cash flows from financing activities:
During the three months ended March 31, 2018, we received $88.0 net proceeds from public financings in January. During the three months ended March 31, 2017, we paid $2.0 million of deferred consideration to former shareholders of an acquired business and $0.9 million to acquire the remaining noncontrolling interest of one of our subsidiaries.
Future capital requirements
We established our strategy and business model of commercializing our technologies through collaborations with development expertise in 2010, and we consummated our first collaboration in January 2011. We believe that our efforts to partner our more mature programs and capabilities and to continue to consummate collaborations across our various industries will result in additional upfront, milestone and cost recovery payments in the future.
We believe that our existing cash and cash equivalents, cash expected to be received from our current collaborators and for sales of products and services provided by our consolidated subsidiaries, and proceeds received from any issuance of Series A Preferred Stock under the Preferred Stock Facility will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.
We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:
 
progress in our research and development programs, as well as the magnitude of these programs;
the timing, receipt and amount of any payments received in connection with strategic transactions;
the timing, receipt and amount of upfront, milestone and other payments, if any, from present and future collaborators, if any;
the timing, receipt and amount of sales and royalties, if any, from our potential products;
our ability to maintain or improve the volume and pricing of our current product and service offerings and to develop new offerings, including those which may incorporate new technologies;
the timing and capital requirements to scale up our various product and service offerings and customer acceptance thereof;
our ability to maintain and establish additional collaborative arrangements and/or new strategic initiatives;
the timing of regulatory approval of products of our collaborations and operations;

46


the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;
investments we may make in current and future collaborators, including JVs;
strategic mergers and acquisitions, including both the upfront acquisition cost as well as the cost to integrate, maintain, and expand the strategic target; and
the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes.
Until such time, if ever, as we can regularly generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, including issuances from the Preferred Stock Facility; debt financings; government or other third-party funding; strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other strategic transactions, collaborations, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
Contractual obligations and commitments
The following table summarizes our significant contractual obligations and commitments as of March 31, 2018 and the effects such obligations are expected to have on our liquidity and cash flows in future periods:
 
Total
 
Less Than 1 Year
 
1 - 3 Years
 
3 - 5 Years
 
More Than 5 Years
 
(In thousands)
Operating leases
$
71,720

 
$
8,458

 
$
18,913

 
$
15,595

 
$
28,754

Purchase commitments
15,098

 
10,320

 
4,778

 

 

Long term debt
5,818

 
501

 
784

 
1,204

 
3,329

Contingent consideration
585

 

 
585

 

 

Total
$
93,221

 
$
19,279

 
$
25,060

 
$
16,799

 
$
32,083

In addition to the obligations in the table above, as of March 31, 2018 we also have the following significant contractual obligations described below.
In conjunction with the formation of our JVs, we committed to making future capital contributions of at least $40.0 million to the JVs, subject to certain conditions and limitations. As of March 31, 2018, our remaining capital contribution commitments to our JVs were $17.3 million. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.
We are party to in-licensed research and development agreements with various academic and commercial institutions where we could be required to make future payments for annual maintenance fees as well as for milestones and royalties we might receive upon commercial sales of products which incorporate their technologies. These agreements are generally subject to termination by us and therefore no amounts are included in the tables above. At March 31, 2018, we also had research and development commitments with third parties totaling $11.1 million that had not yet been incurred.
In January 2015, we and ZIOPHARM Oncology, Inc., or ZIOPHARM, jointly entered into a license agreement with the University of Texas MD Anderson Cancer Center, or MD Anderson, whereby we received an exclusive license to certain technologies owned by MD Anderson. ZIOPHARM received access to these technologies pursuant to the terms of our ECC. We and ZIOPHARM are obligated to reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies. These reimbursements are not included in the table above due to the uncertainty of the timing and amounts of such reimbursements.

47


As part of our August 2014 acquisition of Trans Ova, we agreed to pay a portion of certain cash proceeds received from the litigation with XY, LLC. These amounts are not included in the table above due to the uncertainty of whether and when any amounts may be due.
In conjunction with a prior transaction associated with Trans Ova's subsidiary, ViaGen, in September 2012, we may be obligated to make certain future contingent payments to the former equity holders of ViaGen, up to a total of $3.0 million if certain revenue targets, as defined in the share purchase agreement, are met. This amount is not included in the table above due to the uncertainty of when we will make any of these future payments, if ever.
In January 2009, AquaBounty was awarded a grant to provide funding of a research and development project from the Atlantic Canada Opportunities Agency, a Canadian government agency. Amounts claimed by AquaBounty must be repaid in the form of a 10 percent royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. AquaBounty claimed all amounts available under the grant, resulting in total long term debt of $2.1 million on our consolidated financial statements as of March 31, 2018. This amount is not included in the table above due to the uncertainty of the timing of repayment.
Net operating losses
As of March 31, 2018, we had net operating loss carryforwards of approximately $279.5 million for U.S. federal income tax purposes available to offset future taxable income, and U.S. federal and state research and development tax credits of approximately $7.8 million, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended, or Section 382. These carryforwards begin to expire in 2022. Our direct foreign subsidiaries have foreign loss carryforwards of approximately $160.7 million, most of which do not expire. Excluding certain deferred tax liabilities totaling $11.6 million, our remaining net deferred tax assets, which primarily relate to these loss carryforwards, are offset by a valuation allowance due to our history of net losses.
As a result of our past issuances of stock, as well as due to prior mergers and acquisitions, certain of our net operating losses have been subject to limitations pursuant to Section 382. As of March 31, 2018, Intrexon has utilized all net operating losses subject to Section 382 limitations, other than those losses inherited via acquisitions. As of March 31, 2018, approximately $33.6 million of domestic net operating losses were inherited via acquisition, including approximately $13.4 million acquired in our acquisition of GenVec, and are limited based on the value of the target at the time of the transaction. Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.
The Tax Cuts and Jobs Act of 2017 introduces certain limitations on utilization of net operating losses that are generated after 2017, generally limiting utilization of those losses to 80 percent of future annual taxable income. However, losses generated after 2017 will generally have an indefinite carryforward period.
Off-balance sheet arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, other than operating leases and purchase commitments as mentioned above, as defined under Securities and Exchange Commission, or SEC, rules.
Critical accounting policies and estimates
Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2017, except as follows:

48


Revenue Recognition
Effective January 1, 2018, we apply Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or ASC 606. Under ASC 606, we recognize revenue when our customer obtains control of the promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.
Our revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.
Collaboration and licensing revenues
We generate collaboration and licensing revenues through the execution of agreements with collaborators, known as ECCs, and licensing agreements whereby the collaborators or the licensee obtain exclusive access to our proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that we receive some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by us for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of our collaborators retains a right to terminate the agreement upon providing us written notice a certain period of time prior to such termination, generally 90 days.
Our collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. We determine whether each of the promises is a distinct performance obligation. As the nature of the promises in our collaboration and licensing agreements are highly integrated and interrelated, we typically combine most of our promises into a single performance obligation. Because we are performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, we have determined that the technology license and research and development services are typically inseparable from each other during the performance period of our collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of our agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.
At contract inception, we determine the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by us for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. We determine the initial transaction price and exclude variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.
The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. We typically group the promises in our collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as we provide interrelated research and development services along with other obligations over an estimated period of performance. We utilize judgment to determine the most appropriate method to measure our progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. We evaluate our measure of progress to recognize revenue each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

49


Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to our efforts to provide services and the reimbursements are consistent with what we would typically charge other collaborators for similar services.
Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. We typically determine that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.
Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because we apply the sales- or usage-based royalties recognition exception provided for under ASC 606. We determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.
As we receive upfront payments in our collaboration and licensing agreements, we evaluate whether any significant financing components exist in our collaboration and licensing agreements. Based on the nature of our collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that we will complete our obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or us.
From time to time, we and certain collaborators may cancel our agreements, relieving us of any further performance obligations under the agreement. When no further performance obligations are required of us under an agreement, we recognize any remaining deferred revenue.
Product and service revenues
We generate product and service revenues primarily through sales of products and services which are created from technologies developed or owned by us. Our current offerings include sales of advanced reproductive technologies, including our bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, we recognize the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered. Payment terms are typically due within 30 days.
Recent accounting pronouncements
For information with respect to recent accounting pronouncements and the impact of these pronouncements on our consolidated financial statements, see "Notes to the Consolidated Financial Statements (Unaudited) - Note 2" appearing elsewhere in this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The following sections provide quantitative information on our exposure to interest rate risk, stock price risk, and foreign currency exchange risk. We make use of sensitivity analyses which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.
Interest rate risk
We had cash, cash equivalents and short-term investments of $120.2 million and $74.4 million at March 31, 2018 and December 31, 2017, respectively. Our cash and cash equivalents and short-term investments consist of cash, money market funds, U.S. government debt securities, and certificates of deposit. The primary objectives of our investment activities are to preserve principal, maintain liquidity and maximize income without significantly increasing risk. Our investments consist of U.S. government debt securities and certificates of deposit which may be subject to market risk due to changes in prevailing interest rates that may cause the fair values of our investments to fluctuate. We believe that a hypothetical 100 basis point increase in interest rates would not materially affect the fair value of our interest-sensitive financial instruments and any such losses would only be realized if we sold the investments prior to maturity.

50



Investments in publicly traded companies' common stock
We have common stock investments in several publicly traded companies that are subject to market price volatility. We have adopted the fair value method of accounting for these investments, except for our investment in AquaBounty as further described below, and therefore, have recorded them at fair value at the end of each reporting period with the unrealized gain or loss recorded as a separate component of other income, net for the period. As of March 31, 2018 and December 31, 2017, the original aggregate cost basis of these investments was $102.6 million, and the market value was $14.0 million and $15.1 million, respectively. The fair value of these investments is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these companies. The fair value of these investments as of March 31, 2018 would be approximately $15.4 million and $11.2 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments. The fair value of these investments as of December 31, 2017 would be approximately $16.6 million and $12.1 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments.
The common stock of AquaBounty is traded on the NASDAQ Stock Market. As of March 31, 2018, we owned 6,700,738 shares, or approximately 53 percent. The fair value of our investment in AquaBounty as of March 31, 2018 and December 31, 2017 was $19.8 million and $18.2 million, respectively, based on AquaBounty's quoted closing price on the NASDAQ Stock Market. The fair value of our investment in AquaBounty as of March 31, 2018 would be approximately $21.8 million and $15.8 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty. The fair value of our investment in AquaBounty as of December 31, 2017 would be approximately $20.0 million and $14.6 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the share price of AquaBounty.
Investments in publicly traded companies' preferred stock
We have preferred stock investments in several publicly traded companies, most of which may be converted to common stock in the future. We have adopted the fair value method of accounting for these investments whereby the value of preferred stock is adjusted to fair value as of each reporting date. As of March 31, 2018 and December 31, 2017, the original cost basis of these investments, including dividends, was $153.2 million and $148.3 million, respectively, and the fair value of these investments was $166.1 million and $161.2 million, respectively. The fair value of these investments is subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of the preferred stock into common stock, the volatility of each company's common stock, and changes in general economic and financial conditions of these companies. The fair value of these investments as of March 31, 2018 would be approximately $182.7 million and $132.9 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments. The fair value of these investments as of December 31, 2017 would be approximately $177.3 million and $129.0 million, respectively, based on a hypothetical 10 percent increase or 20 percent decrease in the value of the investments.
Foreign currency exchange risk
We have international subsidiaries in Belgium, Brazil, Canada, England, and Hungary. These subsidiaries' assets, liabilities, and current revenues and expenses are denominated in their respective foreign currency. We do not hedge our foreign currency exchange rate risk. The effect of a hypothetical 10 percent change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements.
Item 4. Controls and Procedures
Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation, under supervision and with the participation of our management, including our Chief Executive Officer ("CEO"), who is our principal executive officer, and our Chief Financial Officer ("CFO"), who is our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined under Rule 13a-15(e) and 15(d)-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, as of the end of the period covered by this report, our CEO and CFO concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.
There has been no change in our internal control over financial reporting during the three months ended March 31, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

51


PART II. OTHER INFORMATION 
Item 1. Legal Proceedings
We are involved in litigation or legal matters incidental to our business activities. While the outcome of these matters cannot be predicted with certainty, we do not currently expect that any of these matters will have a material adverse effect on our business or financial position. However, should one or more of these matters be resolved in a manner adverse to our current expectation, the effect on our results of operations for a particular fiscal reporting period could be material.
In June and July 2016, two shareholders made separate demands under Virginia law demanding that we file suit against certain of our current officers and directors for alleged breaches of fiduciary duty and other claims. The demands were based upon and asserted the allegations contained in a report published in April 2016 on the Seeking Alpha financial blog. In July 2016, our board of directors authorized our Special Litigation Committee, or the SLC, consisting of independent directors, to investigate the claims and allegations made in the two shareholder demands and to decide on our behalf whether the claims and allegations should be pursued. In February 2017, the SLC completed its review and evaluation and unanimously determined that there was no basis for any of the allegations, that our officers and directors did not breach their fiduciary duties or any other applicable law, and that prosecution of the asserted claims was not in our or our shareholders' best interest.
Following the SLC's determination, in March 2017, a derivative complaint captioned Luger v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, alleging causes of action for breaches of fiduciary duty and unjust enrichment relating to the same allegations investigated by the SLC. On April 4, 2018, the plaintiff filed a motion to nonsuit, which the court granted without prejudice on April 13, 2018.
The Division of Enforcement of the SEC is conducting an investigation which we believe concerns certain issues raised by the foregoing and by the previously disclosed consolidated putative shareholder class action lawsuit, captioned Intrexon Corporation Securities Litigation, that was dismissed on November 1, 2017 and the previously disclosed shareholder derivative action captioned Basile v. Kirk et al. that was dismissed on January 25, 2018. We have met with the SEC staff and are voluntarily cooperating with their investigation. Our board of directors has authorized the SLC to monitor our interaction with the SEC staff.
Item 1A. Risk Factors
As disclosed in "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2017, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There are no additional material updates or changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2017, except as follows:
If we experience a significant breach of data security or disruption in our information systems, our business could be adversely affected.
We rely on various information systems to manage our operations and to store information, including sensitive data such as confidential business information and personally identifiable information. These systems could be vulnerable to interruption or malfunction, including due to events beyond our control, and to unauthorized access, computer hackers, ransomware, viruses and other security problems. Failure of these systems or any significant breach of our data security could have an adverse effect on our business and may materially adversely affect our operating results and financial condition.
Data security breaches could result in loss or misuse of information, which could, in turn, result in potential regulatory actions or litigation, including material claims for damages, compelled compliance with breach notification laws, interruption to our operations, damage to our reputation or could otherwise have a material adverse effect on our business, financial condition and operating results. Companies throughout our industry have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access to networks or sensitive information. While we have implemented and continue to implement cybersecurity safeguards and procedures, we may be unable to implement adequate protective measures. As cyber threats continue to evolve, we may be required to expend additional resources to enhance our cybersecurity measures or to investigate or remediate any vulnerabilities or breaches.
In addition, our information systems are complex and include software that is internally developed, software licensed from third parties and hardware purchased from third parties. These products may contain internal errors or defects, particularly when first introduced or when new versions or enhancements are released.

52



Additionally, in evaluating our risks, readers also should carefully consider the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business, financial condition or operating results, in addition to the other information set forth in this report and in our other filings with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) Sales of Unregistered Securities
From January 1, 2018 through March 31, 2018, we consummated the following transactions involving the issuance of unregistered securities:
the issuance of 160,626 unregistered shares of our common stock in January, February, and March 2018, as payment under the Services Agreement entered into and effective as of November 1, 2015, as amended, by and between us and Third Security as previously discussed in our Current Report on Form 8-K filed on March 31, 2017. We issued these shares of common stock in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act.
(b) Use of Proceeds
None.
(c) Issuer Purchases of Equity Securities
None.

53



Item 6. Exhibits
Exhibit
No.
 
Description
10.1*
 
Third Amendment to Services Agreement, by and between Intrexon Corporation and Third Security, LLC, effective as of January 1, 2018 (incorporated by reference to Exhibit 10.1 to Intrexon Corporation's Current Report on Form 8-K filed on January 2, 2018 with the Securities and Exchange Commission).
 
 
10.2*†
 
Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of April 1, 2018 (incorporated by reference to Exhibit 10.1 to Intrexon Corporation's Current Report on Form 8-K filed on April 5, 2018 with the Securities and Exchange Commission).
 
 
10.2A*†
 
Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Form of Restricted Stock Unit Agreement for Officers (incorporated by reference to Exhibit 10.2K to Intrexon Corporation's Annual Report on Form 10-K filed on March 1, 2018 with the Securities and Exchange Commission).
 
 
10.2B*†
 
Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Form of Restricted Stock Unit Agreement for Directors (incorporated by reference to Exhibit 10.2L to Intrexon Corporation's Annual Report on Form 10-K filed on March 1, 2018 with the Securities and Exchange Commission).
 
 
31.1
 
 
 
31.2
 
 
 
32.1**
 
 
 
32.2**
 
 
 
101.0
 
Interactive Data File (Quarterly Report on Form 10-Q, for the quarterly period ended March 31, 2018, formatted in XBRL (eXtensible Business Reporting Language)).
 
Attached as Exhibit 101.0 to this Quarterly Report on Form 10-Q are the following documents formatted in XBRL: (i) the Consolidated Balance Sheets at March 31, 2018 and December 31, 2017, (ii) the Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017, (iii) the Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2018 and 2017, (iv) the Consolidated Statements of Shareholders' and Total Equity for the three months ended March 31, 2018, (v) the Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017, and (vi) the Notes to Consolidated Financial Statements.
*    Previously filed.
**
Furnished herewith.
Indicates management contract or compensatory plan.

54



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Intrexon Corporation
 
 
(Registrant)
 
 
 
Date: May 10, 2018
 
By:
 
/s/  Rick L. Sterling
 
 
 
 
Rick L. Sterling
 
 
 
 
Chief Financial Officer
 
 
 
 
(Principal Financial and Accounting Officer)


55
EX-31.1 2 xon-20180331xexx311.htm EX-31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Randal J. Kirk, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 10, 2018
 
/s/ RANDAL J. KIRK
Randal J. Kirk
Chairman and Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 xon-20180331xexx312.htm EX-31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Rick L. Sterling, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Intrexon Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 Date: May 10, 2018
 
/s/ RICK L. STERLING
Rick L. Sterling
Chief Financial Officer
(Principal Financial Officer)


EX-32.1 4 xon-20180331xexx321.htm EX-32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 10, 2018
 
/s/ RANDAL J. KIRK
Randal J. Kirk
Chairman and Chief Executive Officer
(Principal Executive Officer)
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



EX-32.2 5 xon-20180331xexx322.htm EX-32.2 Exhibit


Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Rick L. Sterling, Chief Financial Officer of Intrexon Corporation (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 10, 2018
 
/s/ RICK L. STERLING
Rick L. Sterling
Chief Financial Officer
(Principal Financial Officer)
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.



EX-101.INS 6 xon-20180331.xml XBRL INSTANCE DOCUMENT 0001356090 2018-01-01 2018-03-31 0001356090 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0001356090 xon:GenVecInc.Member 2018-01-01 2018-03-31 0001356090 2018-04-30 0001356090 2018-03-31 0001356090 2017-12-31 0001356090 xon:RelatedPartiesAggregatedMember 2018-03-31 0001356090 xon:RelatedPartiesAggregatedMember 2017-12-31 0001356090 2017-01-01 2017-03-31 0001356090 xon:RelatedPartiesAggregatedMember 2018-01-01 2018-03-31 0001356090 xon:RelatedPartiesAggregatedMember 2017-01-01 2017-03-31 0001356090 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001356090 us-gaap:CommonStockMember 2018-03-31 0001356090 us-gaap:CommonStockMember 2017-12-31 0001356090 us-gaap:ParentMember 2018-01-01 2018-03-31 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001356090 us-gaap:NoncontrollingInterestMember 2017-12-31 0001356090 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001356090 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001356090 us-gaap:NoncontrollingInterestMember 2018-03-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001356090 us-gaap:RetainedEarningsMember 2017-12-31 0001356090 us-gaap:RetainedEarningsMember 2018-03-31 0001356090 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001356090 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001356090 us-gaap:ParentMember 2017-12-31 0001356090 us-gaap:ParentMember 2018-03-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001356090 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001356090 2017-03-31 0001356090 2016-12-31 0001356090 xon:AquaBountyMember 2018-01-01 2018-01-31 0001356090 xon:AquaBountyMember 2017-12-31 0001356090 xon:AquaBountyMember 2018-03-31 0001356090 us-gaap:AccountingStandardsUpdate201409Member xon:ZiopharmMember 2018-01-01 0001356090 xon:CollaborationandlicensingagreementsMember 2018-01-01 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2018-03-31 0001356090 us-gaap:NonUsMember 2017-01-01 2017-03-31 0001356090 us-gaap:AccountingStandardsUpdate201618Member 2017-03-31 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2018-01-01 2018-03-31 0001356090 us-gaap:NonUsMember 2017-12-31 0001356090 xon:ProductsandServicesRevenuesMember 2018-01-01 2018-03-31 0001356090 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2017-01-01 2017-03-31 0001356090 us-gaap:AccountingStandardsUpdate201409Member xon:AresTradingS.A.Member 2018-01-01 0001356090 us-gaap:NonUsMember 2018-01-01 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember xon:OragenicsMember 2017-12-31 0001356090 xon:OragenicsMember 2018-03-31 0001356090 us-gaap:NonUsMember 2018-03-31 0001356090 us-gaap:AccountingStandardsUpdate201618Member 2017-12-31 0001356090 xon:OragenicsMember 2017-12-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2017-01-01 2017-03-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-03-31 0001356090 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0001356090 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-03-31 0001356090 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-03-31 0001356090 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-03-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2018-03-31 0001356090 us-gaap:EquityMethodInvestmentsMember 2017-12-31 0001356090 us-gaap:AccountingStandardsUpdate201618Member 2016-12-31 0001356090 xon:GenVecInc.Member 2017-06-01 2017-06-30 0001356090 xon:GenVecInc.Member 2017-06-30 0001356090 xon:GenVecInc.Member us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0001356090 xon:IntrexonEnergyPartnersMember 2018-03-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2018-03-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 xon:UpfrontMember xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonT1DPartnersLLCMember 2016-03-31 0001356090 xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-01 2014-03-31 0001356090 xon:OvaXonMember 2018-03-31 0001356090 xon:SIOphthalmicMember 2013-10-01 2013-10-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonT1DPartnersLLCMember 2017-12-31 0001356090 xon:OvaXonMember 2014-01-01 2014-01-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:OvaXonMember 2014-02-01 2018-03-31 0001356090 xon:SIOphthalmicMember 2013-10-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-31 0001356090 xon:OvaXonMember 2014-01-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonT1DPartnersLLCMember 2018-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:EnviroFlightLLCMember 2017-12-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersMember 2014-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2016-03-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2017-12-31 0001356090 xon:InvestmentsInAffiliatesMember xon:IntrexonEnergyPartnersIILLCMember 2017-12-31 0001356090 xon:AllInvestorsMember xon:IntrexonEnergyPartnersIILLCMember 2015-12-01 2015-12-31 0001356090 xon:InvestmentsInAffiliatesMember xon:OvaXonMember 2018-03-31 0001356090 xon:SIOphthalmicMember 2018-03-31 0001356090 xon:SIOphthalmicMember 2018-01-01 2018-01-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2018-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:IntrexonEnergyPartnersIILLCMember 2018-03-31 0001356090 us-gaap:InvestorMember xon:IntrexonT1DPartnersLLCMember 2016-03-01 2016-03-31 0001356090 xon:InvestmentsInAffiliatesMember xon:EnviroFlightLLCMember 2018-03-31 0001356090 xon:SIOphthalmicMember 2015-01-01 2015-12-31 0001356090 xon:OtherAccruedLiabilitiesMember xon:IntrexonEnergyPartnersMember 2018-03-31 0001356090 xon:EnviroFlightLLCMember 2016-03-01 2018-03-31 0001356090 us-gaap:InvestorMember xon:OvaXonMember 2014-02-01 2018-03-31 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2013-10-31 0001356090 us-gaap:InvestorMember xon:OvaXonMember 2014-01-01 2014-01-31 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2015-01-01 2015-12-31 0001356090 us-gaap:InvestorMember xon:SIOphthalmicMember 2013-10-01 2013-10-31 0001356090 xon:InvestmentsInAffiliatesMember xon:OvaXonMember 2017-12-31 0001356090 us-gaap:InvestorMember xon:EnviroFlightLLCMember 2016-03-01 2018-03-31 0001356090 us-gaap:InvestorMember xon:OvaXonMember 2014-01-31 0001356090 xon:OragenicsMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonT1DPartnersLLCMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:HarvestStartUpEntitiesAggregatedMember 2017-12-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2018-03-31 0001356090 xon:OtherCollaborationsMember 2018-01-01 2018-03-31 0001356090 xon:HarvestStartUpEntitiesAggregatedMember 2018-01-01 2018-03-31 0001356090 xon:AresTradingS.A.Member 2018-01-01 2018-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:HarvestStartUpEntitiesAggregatedMember 2018-03-31 0001356090 xon:PerseaBioLLCMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2017-12-31 0001356090 xon:GenopaverLLCMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OtherCollaborationsMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2017-12-31 0001356090 xon:ZiopharmMember 2018-01-01 2018-03-31 0001356090 xon:FibrocellMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:AresTradingS.A.Member 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:OragenicsMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2017-12-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:FibrocellMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:IntrexonEnergyPartnersIILLCMember 2017-12-31 0001356090 xon:IntrexonEnergyPartnersMember 2018-01-01 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:GenopaverLLCMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember xon:PerseaBioLLCMember 2018-03-31 0001356090 xon:UpfrontAndMilestonePaymentsMember 2017-12-31 0001356090 xon:DeferredRevenueOtherMember 2018-03-31 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2017-12-31 0001356090 xon:DeferredRevenueOtherMember 2017-12-31 0001356090 xon:CollaborationandlicensingagreementsMember 2018-03-31 0001356090 xon:CollaborationandlicensingagreementsMember 2017-12-31 0001356090 xon:PrepaidProductAndServiceRevenuesMember 2018-03-31 0001356090 xon:SIOpthalmicMember 2017-01-01 2017-03-31 0001356090 xon:OragenicsMember 2017-01-01 2017-03-31 0001356090 xon:PerseaBioLLCMember 2017-01-01 2017-03-31 0001356090 xon:IntrexonEnergyPartnersIILLCMember 2017-01-01 2017-03-31 0001356090 xon:OvaXonMember 2017-01-01 2017-03-31 0001356090 xon:ZiopharmMember 2017-01-01 2017-03-31 0001356090 xon:AresTradingS.A.Member 2017-01-01 2017-03-31 0001356090 xon:IntrexonT1DPartnersLLCMember 2017-01-01 2017-03-31 0001356090 xon:FibrocellMember 2017-01-01 2017-03-31 0001356090 xon:OvaXonMember 2018-01-01 2018-03-31 0001356090 xon:HarvestStartUpEntitiesAggregatedMember 2017-01-01 2017-03-31 0001356090 xon:IntrexonEnergyPartnersMember 2017-01-01 2017-03-31 0001356090 xon:GenopaverLLCMember 2017-01-01 2017-03-31 0001356090 xon:SIOpthalmicMember 2018-01-01 2018-03-31 0001356090 xon:OtherCollaborationsMember 2017-01-01 2017-03-31 0001356090 us-gaap:CertificatesOfDepositMember 2018-03-31 0001356090 us-gaap:CertificatesOfDepositMember 2017-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2017-12-31 0001356090 xon:FibrocellMember 2017-03-01 2017-03-31 0001356090 xon:ZiopharmMember 2018-01-01 2018-03-31 0001356090 xon:ZiopharmMember us-gaap:PreferredStockMember 2017-12-31 0001356090 xon:FibrocellMember 2017-03-31 0001356090 xon:OragenicsMember us-gaap:PreferredStockMember 2017-11-01 2017-11-30 0001356090 xon:OragenicsMember us-gaap:PreferredStockMember 2018-03-31 0001356090 xon:FibrocellMember 2018-01-01 2018-03-31 0001356090 xon:FibrocellMember us-gaap:PreferredStockMember 2018-03-31 0001356090 xon:OragenicsMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001356090 xon:ZiopharmMember 2017-01-01 2017-03-31 0001356090 xon:ZiopharmMember 2016-06-30 0001356090 xon:FibrocellMember us-gaap:PreferredStockMember 2017-12-31 0001356090 xon:FibrocellMember 2017-03-01 2017-03-31 0001356090 xon:OtherContractualPaymentsMember xon:UpfrontAndMilestonePaymentsMember xon:ZiopharmMember 2016-06-01 2016-06-30 0001356090 xon:ZiopharmMember 2018-01-01 2018-03-31 0001356090 xon:ZiopharmMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0001356090 xon:ZiopharmMember us-gaap:PreferredStockMember 2018-03-31 0001356090 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001356090 us-gaap:FairValueInputsLevel3Member 2018-01-01 2018-03-31 0001356090 us-gaap:FairValueInputsLevel3Member 2018-03-31 0001356090 xon:OragenicsMember us-gaap:PreferredStockMember 2017-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0001356090 us-gaap:FairValueInputsLevel1Member 2018-03-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember 2018-03-31 0001356090 us-gaap:FairValueInputsLevel2Member 2018-03-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0001356090 us-gaap:PreferredStockMember 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0001356090 xon:OtherFinancialAssetsMember 2018-03-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember 2017-12-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001356090 us-gaap:PreferredStockMember 2017-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001356090 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001356090 us-gaap:EquitySecuritiesMember 2017-12-31 0001356090 us-gaap:PreferredStockMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001356090 xon:OtherFinancialAssetsMember 2017-12-31 0001356090 xon:OtherFinancialAssetsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001356090 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001356090 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001356090 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001356090 xon:SuppliesEmbryosAndOtherProductionMaterialsMember 2017-12-31 0001356090 xon:LivestockMember 2017-12-31 0001356090 xon:LivestockMember 2018-03-31 0001356090 xon:SuppliesEmbryosAndOtherProductionMaterialsMember 2018-03-31 0001356090 xon:FeedMember 2017-12-31 0001356090 xon:FeedMember 2018-03-31 0001356090 xon:WorkInProcessMember 2018-03-31 0001356090 xon:WorkInProcessMember 2017-12-31 0001356090 us-gaap:IntellectualPropertyMember 2017-12-31 0001356090 us-gaap:TrademarksMember 2017-12-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 0001356090 us-gaap:CustomerRelationshipsMember 2017-12-31 0001356090 us-gaap:TrademarksMember 2018-03-31 0001356090 us-gaap:InProcessResearchAndDevelopmentMember 2018-03-31 0001356090 us-gaap:IntellectualPropertyMember 2018-03-31 0001356090 us-gaap:CustomerRelationshipsMember 2018-03-31 0001356090 xon:ExemplarGeneticsLLCMember us-gaap:RevolvingCreditFacilityMember xon:AmericanStateBankMember 2018-03-31 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember 2018-03-31 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2018-03-31 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2018-03-31 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2013-03-31 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:MinimumMember 2018-03-31 0001356090 xon:TransOvaGeneticsLcMember us-gaap:RevolvingCreditFacilityMember xon:FirstNationalBankofOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001356090 xon:AquaBountyMember xon:AtlanticCanadaOpportunitiesAgencyMember xon:RoyaltybasedFinancingMember 2018-01-01 2018-03-31 0001356090 xon:TransOvaGeneticsLcMember xon:AmericanStateBankMember us-gaap:NotesPayableToBanksMember 2018-01-01 2018-03-31 0001356090 xon:OtherLongTermDebtMember 2017-12-31 0001356090 xon:RoyaltybasedFinancingMember 2017-12-31 0001356090 us-gaap:NotesPayableOtherPayablesMember 2017-12-31 0001356090 xon:RoyaltybasedFinancingMember 2018-03-31 0001356090 us-gaap:NotesPayableOtherPayablesMember 2018-03-31 0001356090 xon:OtherLongTermDebtMember 2018-03-31 0001356090 us-gaap:DomesticCountryMember 2018-01-01 2018-03-31 0001356090 us-gaap:ForeignCountryMember 2018-01-01 2018-03-31 0001356090 us-gaap:DomesticCountryMember 2017-01-01 2017-03-31 0001356090 us-gaap:DomesticCountryMember 2018-03-31 0001356090 us-gaap:ForeignCountryMember 2018-03-31 0001356090 us-gaap:ForeignCountryMember 2017-01-01 2017-03-31 0001356090 2017-01-01 2017-12-31 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0001356090 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-03-31 0001356090 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001356090 2018-01-01 2018-01-31 0001356090 xon:AffiliatesOfThirdSecurityMember 2018-01-01 2018-01-31 0001356090 xon:IntrexonStockOptionPlanMember 2018-01-01 2018-03-31 0001356090 xon:IntrexonStockOptionPlanMember 2018-03-31 0001356090 xon:IntrexonStockOptionPlanMember 2017-01-01 2017-12-31 0001356090 xon:IntrexonStockOptionPlanMember 2017-12-31 0001356090 xon:CostOfServicesMember 2017-01-01 2017-03-31 0001356090 xon:CostOfProductsMember 2017-01-01 2017-03-31 0001356090 xon:CostOfServicesMember 2018-01-01 2018-03-31 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001356090 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001356090 xon:CostOfProductsMember 2018-01-01 2018-03-31 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2018-03-31 0001356090 xon:AquaBountyStockOptionPlansMember 2018-03-31 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2018-03-01 2018-03-31 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2018-03-31 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ChiefExecutiveOfficerMember 2018-01-01 2018-03-31 0001356090 xon:IntrexonStockOptionPlan2013PlanMember 2018-01-01 2018-03-31 0001356090 xon:AquaBounty2006StockOptionPlanMember 2016-04-30 0001356090 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-03-31 0001356090 us-gaap:ChiefExecutiveOfficerMember 2015-11-01 2015-11-30 0001356090 xon:IntrexonStockOptionPlan2008PlanMember 2013-08-31 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-01-01 2016-12-31 0001356090 xon:LicensingAndPatentInfringementSuitMember 2012-03-01 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2018-01-01 2018-03-31 0001356090 xon:ShareholderDemandSeekingAlphaFinancialBlogAllegationsMember 2016-06-01 2016-07-31 0001356090 xon:XYLLCMember xon:LicensingAndPatentInfringementSuitMember 2018-03-31 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-04-30 0001356090 xon:LicensingAndPatentInfringementSuitMember 2016-04-01 2016-04-30 0001356090 xon:ThirdSecurityMember 2018-01-01 2018-03-31 0001356090 xon:ThirdSecurityMember 2017-01-01 2017-03-31 0001356090 us-gaap:OtherNoncurrentAssetsMember xon:ConvertibleNoteandWarrantsMember xon:FibrocellMember 2018-03-31 0001356090 xon:ThirdSecurityMember us-gaap:ChiefExecutiveOfficerMember 2018-03-31 0001356090 xon:AffiliatesOfThirdSecurityMember xon:SeriesAPreferredSharesMember 2017-10-31 0001356090 xon:ThirdSecurityMember us-gaap:CommonStockMember 2015-11-01 2015-11-30 0001356090 xon:HarvestIntrexonEnterpriseFundILPMember 2017-01-01 2017-03-31 0001356090 xon:ThirdSecurityMember 2015-11-01 2015-11-30 0001356090 xon:SeriesAPreferredSharesMember 2017-10-01 2017-10-31 0001356090 xon:AffiliatesOfThirdSecurityMember xon:SeriesAPreferredSharesMember 2017-10-01 2017-10-31 0001356090 us-gaap:OtherNoncurrentAssetsMember xon:ConvertibleNoteandWarrantsMember xon:FibrocellMember 2017-12-31 0001356090 us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-01-01 2017-03-31 0001356090 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-03-31 0001356090 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001356090 us-gaap:StockOptionMember 2018-01-01 2018-03-31 0001356090 us-gaap:StockOptionMember 2017-01-01 2017-03-31 0001356090 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001356090 us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2018-04-01 2018-06-30 xbrli:shares iso4217:USD xon:segment xon:board_seat iso4217:USD xbrli:shares xbrli:pure xon:claim false --12-31 Q1 2018 2018-03-31 10-Q 0001356090 129294079 Large Accelerated Filer INTREXON CORP XON 2153000 2437000 8701000 7842000 19775000 17697000 -198000 0 45646000 49087000 -15554000 -9587000 1397005000 1492916000 11362000 11340000 22000 11340000 188000 7894000 2193000 5597000 26000 78000 3258000 8002000 25000 77000 11362000 4618000 4926000 12632507 0 12632507 0 12731880 1052182 11546434 133264 846851000 895666000 154047000 187545000 183173000 393000 0 160832000 575000 15100000 10537000 4563000 0 3085000 161225000 0 0 161225000 5998000 0 5998000 0 850000 0 850000 0 10537000 11411000 161225000 180881000 366000 0 165703000 494000 14043000 9622000 4421000 0 2334000 166069000 0 0 166069000 769000 0 769000 0 9622000 5190000 166069000 0 0 0 0 2000 0 2000 0 0 6275000 275000 6000000 275000 6273000 275000 5998000 275000 18183000 18160000 684240 1 -35254000 53861000 238000 17582000 15616000 17303000 2054000 542000 227000 75000 2158000 856000 239000 14000000 4571000 12732000 1107000 92000 58000 250000 17582000 1132000 2016000 68111000 119930000 69594000 6987000 76839000 6987000 75545000 7434000 127377000 7245000 51832000 200000000 200000000 122087040 129239376 122087040 122087040 129239376 129239376 0 0 -28164000 -36021000 -981000 -1303000 -29145000 -37324000 5000000 14113000 15819000 9006000 8530000 6804000 6783000 -40412000 -40789000 377000 236000 -131000 113000 -125000 0.0295 0.0525 0.03 0.0395 39000 -638000 -4074000 236397000 231583000 133000 4681000 230531000 40789000 16607000 1704000 18400000 13833000 15625000 8435000 6719000 14423000 3500000 90496000 263390000 258174000 78000 5138000 257296000 78384000 16002000 1635000 17918000 13333000 15000000 8334000 6456000 10494000 3375000 86365000 42870000 29155000 48646000 42320000 6326000 28684000 193527000 157628000 214744000 182239000 32505000 147708000 7800000 11631000 15620000 11631000 2782000 3456000 7400000 8382000 17913000 10585000 313000 147000 -0.26 -0.33 526000 914000 6474000 11356000 0.5 0.5 0.5 0.5 0.5 0.5 0.294 0.279 0.5 0.5 0.5 0.5 74684000 73277000 61086000 57724000 6213000 7946000 -13308000 -8529000 13598000 15553000 30000 67000 18870000 7092000 572000 146000 -444000 -943000 21406000 10072000 515000 146000 -806000 -67000 3688000 -39000 161225000 166069000 0 P11Y 53904000 6383000 0 44954000 2567000 58079000 6733000 0 48586000 2760000 286781000 10700000 5666000 263615000 6800000 289962000 10700000 5883000 266579000 6800000 232877000 4317000 5666000 218661000 4233000 231883000 3967000 5883000 217993000 4040000 2515000 2516000 -566000 -316000 4850000 153289000 154748000 1459000 13823000 13823000 -32910000 -47318000 -4947000 -2460000 -533000 -4086000 0 20000 -990000 -764000 -1931000 -1856000 -13011000 -13800000 4994000 -4729000 161000 -165000 924000 4851000 -2058000 -231000 69000 -2473000 156000 134000 526000 47000 -859000 215000 -210000 -1062000 232877000 231883000 179000 99000 70000 82000 20493000 2013000 11040000 2673000 4767000 20271000 1472000 10991000 3386000 4422000 4624000 5470000 11767000 11815000 2301000 3259000 25277000 27811000 300306000 324240000 846851000 895666000 0 76000 80173000 86854000 585000 585000 321000 0 0.0462 700000 5000000 233000 321000 528000 6066000 4228000 8037000 5010000 895000 2132000 7926000 2108000 4775000 4896000 922000 2108000 502000 501000 373000 830000 382000 411000 398000 7535000 7425000 9 2 3 65863000 69568000 12914000 18317000 0.58 0.53 -3146000 88262000 34554000 -7456000 -24689000 -29888000 -31399000 -43569000 1581000 -41988000 -978000 -1244000 3418000 5000 14000 3616000 1 85128000 13343000 8610000 92317000 -31381000 -13313000 -8543000 -48474000 71720000 7595000 8601000 9506000 9441000 23923000 6096000 11000 21000 279500000 160700000 21080000 18041000 4054000 4026000 -20000 2000 3252000 5906000 5908000 5967000 -59000 5967000 3451000 3586000 5285000 3298000 9815000 10745000 146000 -127000 595000 603000 -659000 6000000 521000 419000 3170000 10000 0 913000 0 5000000 5000000 1500000 1500000 25000000 18000000 4000000 10000000 4350000 4350000 8250000 8250000 5000000 5000000 4579000 5510000 1161000 1161000 0 6343000 10774000 12.00 0.08 0.04 3216 3624 1200 7057000 6065000 1500000 0 2598000 0 2598000 82374000 10616000 126000 0 1678000 1239000 45000000 6000000 137000 230000 800000 66000 14000 -32377000 -44813000 1581000 -43232000 -1244000 -41988000 -41988000 158320000 168331000 112674000 21837000 119244000 23019000 9000 218000 2088000 1151000 123000 140000 34180000 37267000 6987000 6987000 447000 460000 -847820000 -930220000 -891389000 -38831000 30 days 53747000 3714000 4431000 43843000 8130000 7152000 12031000 12247000 35138000 39737000 7894000 11362000 1059126 13.83 1052182 18000000 3279291 0 0 207390 6533996 29.29 284119 186811 656339 11382747 340764 431649 11114785 11546434 28.99 7.09 28.31 3.40 27.67 26.37 14.84 P6Y4M18D P7Y3M24D P7Y3M0D 6273000 275000 103930 160626 230614 6900000 1000000 6900000 21722 2039000 2041000 2941000 2941000 0 2941000 87990000 82374000 5616000 82374000 533631000 -2000 -15554000 -15552000 553109000 0 -9587000 -9587000 546545000 -15554000 1397005000 0 12914000 533631000 -847820000 571426000 -9587000 1492916000 0 18317000 553109000 -930220000 -1341000 -751000 185261000 191731000 118956780 127693336 845000 2000000 0 -818000 818000 -818000 2226000 1952000 3385000 3832000 4204000 -36765000 -978000 -36232000 1381000 585000 P3Y 1226000 97000 P90D 33065000 28887000 3315000 1739000 1680000 3363000 1149000 5086000 1132000 569000 2631000 824000 289000 303000 10985000 22444000 1581000 19815000 0 0 24025000 3368000 835000 1288000 3354000 615000 1252000 1468000 342000 4372000 252000 6879000 0.5 100000 25000000 18000000 10000000 P12M 200000 10128000 10442000 P20D 1161 100000000 P20D -40412000 0 0 0 -40412000 -40412000 68471000 65331000 -1622000 -1096000 P5Y 161225000 166069000 25000000 25000000 10000000 10000000 5000000 5000000 6011000 1250000 P3Y 3038000 386000 5818000 15098000 12 3926000 3923000 4871000 4883000 4883000 22385000 0 5 5 5 4 4 4 3 3 2 2 1 2 2 2 2 6558000 1991000 0 1.00 24.00 0.12 0.2 0 87990000 175000 324000 0.1 1 P6Y1M6D P6Y7M6D P6Y P7Y1M6D P6Y8M12D P6Y P7Y P6Y2M12D P3Y8M12D P6Y9M18D P5Y9M18D 2759000 P1Y 2915000 471000 486000 2941000 21722 5082000 0 324000 74000 250000 74000 0 11800000 -35100000 6642000 7996000 498843 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and results of operations and cash flows for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisition had been consummated on January&#160;1, 2016:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and Licensing Revenue</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained under ASC 606. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Amounts for periods subsequent to January 1, 2018 reflect revenue recognition under ASC 606.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harvest start-up entities (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than the termination of the OvaScience ECC in March 2018 (Note </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">), there have been no significant changes to arrangements with our collaborators and licensees in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">. See Note 5 in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> for additional details of the Company's existing collaboration and licensing agreements. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue primarily consists of consideration received for the Company's collaborations and licensing agreements and prepayments for product and service revenues. Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and licensing agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193,527</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, including the estimated remaining performance period as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Remaining Performance Period (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harvest start-up entities (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,558</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense, including other facility expenses, was </font><font style="font-family:inherit;font-size:10pt;">$3,259</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,301</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding contractual purchase commitments of </font><font style="font-family:inherit;font-size:10pt;">$15,098</font><font style="font-family:inherit;font-size:10pt;">, which primarily relate to amounts that will be paid in 2018, 2019, and 2020 upon delivery of commercial non-browning apple trees.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breached a 2004 licensing agreement and infringed on patents that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. In Colorado District Court, the matter proceeded to a jury trial in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents.&#160;In April 2016, the court issued its post-trial order, awarding </font><font style="font-family:inherit;font-size:10pt;">$528</font><font style="font-family:inherit;font-size:10pt;"> in damages to Trans Ova and </font><font style="font-family:inherit;font-size:10pt;">$6,066</font><font style="font-family:inherit;font-size:10pt;"> in damages to XY. The order also provided Trans Ova with a compulsory license to XY's technology, subject to an ongoing royalty obligation. Both parties appealed the court's order, which appeal is pending before the Court of Appeals for the Federal Circuit. Since the inception of the 2004 agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the April 2016 court order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods.&#160;For the period from inception of the 2004 agreement through the court's April 2016 order, aggregate royalty and license payments were </font><font style="font-family:inherit;font-size:10pt;">$3,170</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$2,759</font><font style="font-family:inherit;font-size:10pt;"> had not yet been deposited by XY.&#160;In 2016, the Company recorded expense of </font><font style="font-family:inherit;font-size:10pt;">$4,228</font><font style="font-family:inherit;font-size:10pt;"> representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, this amount is included in restricted cash on the accompanying consolidated balance sheet. In December 2016, Trans Ova elected to void the outstanding checks discussed above, and these amounts have been reclassified to other accrued liabilities on the accompanying consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Depending on the outcome of an appeal decision, the damages awarded to either party could decrease, increase, or be eliminated. The appeal decision may also remand to the Colorado District Court all, or a portion, of the issues being appealed. In December 2016, XY filed a complaint for patent infringement and trade secret misappropriation against Trans Ova in the District Court of Waco, Texas. Since the claims in this 2016 complaint directly relate to the 2012 licensing dispute and patent issues, Trans Ova filed and was granted a motion for change of venue to Colorado District Court. Trans Ova also filed a motion to dismiss, from which the Court recently dismissed </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;"> counts of the complaint. Presently, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> counts for patent infringement remain pending. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation, to modify the court-ordered license to XY's technologies, or to recover monetary damages stemming from Trans Ova's counterclaims for antitrust violations by XY and its parent company, Inguran.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June and July 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> shareholders made separate demands under Virginia law demanding that the Company file suit against certain of its current officers and directors for alleged breaches of fiduciary duty and other claims. The demands were based upon and asserted the allegations contained in a report published in April 2016 on the Seeking Alpha financial blog. In July 2016, the Company's board of directors authorized its Special Litigation Committee ("SLC"), consisting of independent directors, to investigate the claims and allegations made in the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> shareholder demands and to decide on behalf of the Company whether the claims and allegations should be pursued. In February 2017, the SLC completed its review and evaluation and unanimously determined that there was no basis for any of the allegations, that the Company's officers and directors did not breach their fiduciary duties or any other applicable law, and that prosecution of the asserted claims was not in the best interest of Intrexon or its shareholders.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the SLC's determination, in March 2017, a derivative complaint captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Luger v. Kirk et al.</font><font style="font-family:inherit;font-size:10pt;"> was filed in the Circuit Court of Fairfax County, Virginia, alleging causes of action for breaches of fiduciary duty and unjust enrichment relating to the same allegations investigated by the SLC. On April 4, 2018, the plaintiff filed a motion to nonsuit, which the court granted without prejudice on April 13, 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Division of Enforcement of the SEC is conducting an investigation which the Company believes concerns certain issues raised by the foregoing and by the previously disclosed consolidated putative shareholder class action lawsuit, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intrexon Corporation Securities Litigation</font><font style="font-family:inherit;font-size:10pt;">, that was dismissed on November 1, 2017 and the previously disclosed shareholder derivative action captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basile v. Kirk et al.</font><font style="font-family:inherit;font-size:10pt;"> that was dismissed on January 25, 2018. The Company has met with the SEC staff and is voluntarily cooperating with their investigation. The Company's board of directors has authorized the SLC to monitor the Company's interaction with the SEC staff.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may become subject to other claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lines of Credit and Long Term Debt</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lines of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova has a </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> revolving line of credit with First National Bank of Omaha which matures on June 1, 2018. The line of credit bears interest at the greater of </font><font style="font-family:inherit;font-size:10pt;">2.95%</font><font style="font-family:inherit;font-size:10pt;"> above the London Interbank Offered Rate or </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> and the actual rate was </font><font style="font-family:inherit;font-size:10pt;">4.62%</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exemplar has a </font><font style="font-family:inherit;font-size:10pt;">$700</font><font style="font-family:inherit;font-size:10pt;"> revolving line of credit with American State Bank which matures on October 30, 2018. The line of credit bears interest at </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was an outstanding balance of </font><font style="font-family:inherit;font-size:10pt;">$321</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long Term Debt</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt consists of the following:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty-based financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,926</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,037</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt, less current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of </font><font style="font-family:inherit;font-size:10pt;">$4,775</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Trans Ova pays monthly installments of </font><font style="font-family:inherit;font-size:10pt;">$39</font><font style="font-family:inherit;font-size:10pt;">, which includes interest at </font><font style="font-family:inherit;font-size:10pt;">3.95%</font><font style="font-family:inherit;font-size:10pt;">. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency, a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was </font><font style="font-family:inherit;font-size:10pt;">$2,226</font><font style="font-family:inherit;font-size:10pt;">, which AquaBounty claimed over a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> year period. All amounts claimed by AquaBounty must be repaid in the form of a </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the date of the acquisition by Intrexon in March 2013, AquaBounty had claimed </font><font style="font-family:inherit;font-size:10pt;">$1,952</font><font style="font-family:inherit;font-size:10pt;"> of the available funds and this amount was recorded at its acquisition date fair value of </font><font style="font-family:inherit;font-size:10pt;">$1,107</font><font style="font-family:inherit;font-size:10pt;">. The Company accretes the difference of </font><font style="font-family:inherit;font-size:10pt;">$845</font><font style="font-family:inherit;font-size:10pt;"> between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Subsequent to the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long term debt of </font><font style="font-family:inherit;font-size:10pt;">$2,108</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future maturities of long term debt are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consists of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and licensing agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid product and service revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,138</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193,527</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">236,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Payments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the fair value of stock options and restricted stock units ("RSUs") issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,894</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Stock Option Plans</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April&#160;2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> new awards may be granted under the 2008 Plan. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">431,649</font><font style="font-family:inherit;font-size:10pt;"> stock options outstanding under the 2008 Plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">18,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares authorized for issuance under the 2013 Plan, of which </font><font style="font-family:inherit;font-size:10pt;">11,114,785</font><font style="font-family:inherit;font-size:10pt;"> stock options and </font><font style="font-family:inherit;font-size:10pt;">1,052,182</font><font style="font-family:inherit;font-size:10pt;"> RSUs were outstanding and </font><font style="font-family:inherit;font-size:10pt;">3,279,291</font><font style="font-family:inherit;font-size:10pt;"> shares were available for grant. In March 2018, Intrexon's board of directors approved, subject to shareholder approval at Intrexon's annual meeting in June 2018, an increase of </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to be reserved for issuance under the 2013 Plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity was as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,382,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.32</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,546,434</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.25</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable at March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,533,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.38</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, Intrexon granted </font><font style="font-family:inherit;font-size:10pt;">1,059,126</font><font style="font-family:inherit;font-size:10pt;"> RSUs with a weighted average grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$13.83</font><font style="font-family:inherit;font-size:10pt;"> per share, of which </font><font style="font-family:inherit;font-size:10pt;">1,052,182</font><font style="font-family:inherit;font-size:10pt;"> remain outstanding and unvested as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon currently uses authorized and unissued shares to satisfy share award exercises.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October&#160;2015, the compensation committee and the independent members of Intrexon's board of directors approved a compensation arrangement whereby the Company's Chief Executive Officer ("CEO") would receive a monthly salary. Previously, the CEO did not receive compensation for his services as an employee of the Company other than through his participation in the Company's Annual Executive Incentive Plan which became effective January 1, 2015. Pursuant to the compensation agreement, the CEO receives a base salary of </font><font style="font-family:inherit;font-size:10pt;">$200</font><font style="font-family:inherit;font-size:10pt;"> per month payable in fully vested shares of Intrexon common stock with such shares subject to a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") which was executed between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement became effective in November 2015, and had an initial term of </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. The independent members of Intrexon's board of directors, with the recommendation of the compensation committee of the board of directors, subsequently approved extensions of the RSU Agreement through March 31, 2019, all of which are on the same terms as the original RSU Agreement. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled </font><font style="font-family:inherit;font-size:10pt;">$486</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$471</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AquaBounty Stock Option Plans</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, AquaBounty's board of directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan").&#160;The&#160;AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and&#160;awards&#160;of restricted and direct stock purchases to directors, officers, employees, and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> new awards may be granted under the AquaBounty 2006 Plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">340,764</font><font style="font-family:inherit;font-size:10pt;"> options outstanding under both AquaBounty plans, of which </font><font style="font-family:inherit;font-size:10pt;">207,390</font><font style="font-family:inherit;font-size:10pt;"> were exercisable, at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.09</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted net loss per share:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historical net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,693,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,956,780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, have been excluded from the above computations of diluted weighted average shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> then ended as they would have been anti-dilutive:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,546,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,632,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,731,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,632,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Joint Ventures</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">S &amp; I Ophthalmic</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September&#160;2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S &amp; I Ophthalmic, LLC ("S &amp; I Ophthalmic"). The Sun LLC Agreement governed the affairs and the conduct of business of S &amp; I Ophthalmic. S &amp; I Ophthalmic leveraged experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> in October 2013 for a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in S &amp; I Ophthalmic. S &amp; I Ophthalmic was governed by a board of managers which had </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> members, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> each from the Company and Sun Pharmaceutical Subsidiary. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, both the Company and Sun Pharmaceutical Subsidiary agreed to dissolve S &amp; I Ophthalmic and terminate the related ECC agreement. In January 2018, the Company received </font><font style="font-family:inherit;font-size:10pt;">$2,598</font><font style="font-family:inherit;font-size:10pt;"> upon the dissolution of S &amp; I Ophthalmic which represented the Company's portion of S &amp; I Ophthalmic's remaining cash after all liabilities were settled.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">OvaXon</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development, and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of </font><font style="font-family:inherit;font-size:10pt;">$1,500</font><font style="font-family:inherit;font-size:10pt;"> in January 2014 for a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> members, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. Through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, both the Company and OvaScience have made subsequent capital contributions of </font><font style="font-family:inherit;font-size:10pt;">$4,350</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the Company and OvaScience agreed to terminate the ECC agreement with OvaScience. The Company and OvaScience are in discussions regarding dissolving the OvaXon joint venture and terminating the related ECC agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in OvaXon was </font><font style="font-family:inherit;font-size:10pt;">$146</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and is included in investments in affiliates in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Energy Partners</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> while retaining a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">. In addition, Intrexon has committed to make capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company's remaining commitment was </font><font style="font-family:inherit;font-size:10pt;">$6,011</font><font style="font-family:inherit;font-size:10pt;">. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> members. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> members of the Intrexon Energy Partners Board are designated by the Company and </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in Intrexon Energy Partners was </font><font style="font-family:inherit;font-size:10pt;">$(806)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(444)</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon Energy Partners II</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$18,000</font><font style="font-family:inherit;font-size:10pt;"> while retaining a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling </font><font style="font-family:inherit;font-size:10pt;">$18,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;">, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> members. </font><font style="font-family:inherit;font-size:10pt;">One</font><font style="font-family:inherit;font-size:10pt;"> member of the Intrexon Energy Partners II Board is designated by the Company and </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in Intrexon Energy Partners II was </font><font style="font-family:inherit;font-size:10pt;">$515</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$572</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EnviroFlight</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, both the Company and Darling have made subsequent capital contributions of </font><font style="font-family:inherit;font-size:10pt;">$8,250</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in New EnviroFlight was </font><font style="font-family:inherit;font-size:10pt;">$10,072</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7,092</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intrexon T1D Partners</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> while retaining a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">. Intrexon has committed to make capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company's remaining commitment was </font><font style="font-family:inherit;font-size:10pt;">$1,250</font><font style="font-family:inherit;font-size:10pt;">. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> members. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> members of the Intrexon T1D Partners Board are designated by the Company and </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investment in Intrexon T1D Partners was </font><font style="font-family:inherit;font-size:10pt;">$(67)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(943)</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Method Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized financial data as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, for the Company's equity method investments are shown in the following tables. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,598</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,610</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,343</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,190</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the Level 3 investments in preferred stock during the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend income from investments in preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized depreciation in the fair value of the investments in preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,190</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in Active Markets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The methods used to estimate the fair value of the Level 3 assets are discussed in Note </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between levels of the fair value hierarchy during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The Company's contingent consideration liabilities from previous acquisitions are measured on a recurring basis and were </font><font style="font-family:inherit;font-size:10pt;">$585</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes in the fair value of the Level 3 liabilities during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets, Net</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,459</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,748</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had </font><font style="font-family:inherit;font-size:10pt;">$13,823</font><font style="font-family:inherit;font-size:10pt;"> of accumulated impairment losses as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, developed technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,733</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, developed technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,383</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of in-process research and development includes certain in-process research and development technology acquired</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">been obtained for the in-process programs.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$4,926</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,618</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$35,100</font><font style="font-family:inherit;font-size:10pt;"> and recorded </font><font style="font-family:inherit;font-size:10pt;">$113</font><font style="font-family:inherit;font-size:10pt;"> of current domestic income tax expense. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$125</font><font style="font-family:inherit;font-size:10pt;"> of current foreign income tax benefit. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$11,800</font><font style="font-family:inherit;font-size:10pt;"> and recorded </font><font style="font-family:inherit;font-size:10pt;">$236</font><font style="font-family:inherit;font-size:10pt;"> of current domestic income tax expense. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$131</font><font style="font-family:inherit;font-size:10pt;"> of current foreign income tax benefit. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded deferred tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$4,074</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded deferred tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$638</font><font style="font-family:inherit;font-size:10pt;">. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling </font><font style="font-family:inherit;font-size:10pt;">$11,631</font><font style="font-family:inherit;font-size:10pt;">, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company has loss carryforwards for U.S. federal income tax purposes of approximately </font><font style="font-family:inherit;font-size:10pt;">$279,500</font><font style="font-family:inherit;font-size:10pt;"> available to offset future taxable income, and federal and state research and development tax credits of approximately </font><font style="font-family:inherit;font-size:10pt;">$7,800</font><font style="font-family:inherit;font-size:10pt;">, prior to consideration of annual limitations that may be imposed under Section&#160;382 of the Internal Revenue Code of 1986, as amended. These carryforwards will begin to expire in 2022. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company's direct foreign subsidiaries have foreign loss carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$160,700</font><font style="font-family:inherit;font-size:10pt;">, most of which do not expire.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Company recorded a net provisional income tax benefit upon enactment of the Tax Act. The Company has provisionally estimated its transition tax exposure to be </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries. The provisional amounts recorded are subject to further refinement within the measurement period prescribed by SAB 118. As a result, the recorded amounts are subject to change, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company utilized to provisionally compute the transition impact. No adjustments to these provisional amounts were recorded during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consists of the following:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies, embryos and other production materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Livestock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,271</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term Investments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For more information on the Company's method for determining the fair value of its assets, see Note 2 &#8211; "Fair Value of Financial Instruments" in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, all of the available-for-sale investments were due within one year based on their contractual maturities.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and there were </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mergers and Acquisitions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GenVec Acquisition</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of </font><font style="font-family:inherit;font-size:10pt;">684,240</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock and have the right to receive contingent consideration equal to&#160;</font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#160;of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within&#160;</font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#160;after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$17,582</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of&#160;</font><font style="font-family:inherit;font-size:10pt;">eleven years</font><font style="font-family:inherit;font-size:10pt;">. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related costs totaling </font><font style="font-family:inherit;font-size:10pt;">$238</font><font style="font-family:inherit;font-size:10pt;"> are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the&#160;</font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Condensed Pro Forma Financial Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GenVec's results of operations subsequent to the acquisition are included in the consolidated statement of operations. The following condensed pro forma financial information for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is presented as if the acquisition had been consummated on January&#160;1, 2016:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to the noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. Under the previous revenue guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to another collaborator, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (see Note 5 in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of these collaborations). Because the Company controls the performance obligation, ASC 606 requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under ASC 606, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$40,789</font><font style="font-family:inherit;font-size:10pt;"> of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company reduced deferred revenue by </font><font style="font-family:inherit;font-size:10pt;">$377</font><font style="font-family:inherit;font-size:10pt;"> as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC would have been recognized immediately under ASC 606. The milestone payment was received by the Company in form of ZIOPHARM's common stock and under previous guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. As a result of these changes under ASC 606, the Company recognized a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of </font><font style="font-family:inherit;font-size:10pt;">$40,412</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and licensing revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,988</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,505</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(930,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(891,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,831</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718) &#8211; Scope of Modification Accounting </font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-09")</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, the "Cash, cash equivalents, and restricted cash" beginning period balance increased by </font><font style="font-family:inherit;font-size:10pt;">$7,434</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying consolidated statement of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the beginning and ending period balances increased by </font><font style="font-family:inherit;font-size:10pt;">$6,987</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying consolidated statement of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> from what was previously reported in the Company's Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory </font><font style="font-family:inherit;font-size:10pt;">("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 230) - Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows</font><font style="font-family:inherit;font-size:10pt;">, and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </font><font style="font-family:inherit;font-size:10pt;">("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception </font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial&#160;conversion features (in Subtopic 470-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-Debt with Conversion and Other Options</font><font style="font-family:inherit;font-size:10pt;">), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Corporation ("Intrexon"), a Virginia corporation, including through its wholly owned subsidiaries Precigen, Inc. ("Precigen") and ActoBio Therapeutics, Inc. ("ActoBio"), uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trans Ova Genetics, L.C. ("Trans Ova"), and Progentus, L.C. ("Progentus"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in Iowa, Maryland, Missouri, New York, Oklahoma, and Texas.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, completed an underwritten public offering which resulted in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$10,616</font><font style="font-family:inherit;font-size:10pt;"> after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> of additional AquaBounty common stock, reducing its ownership stake from approximately </font><font style="font-family:inherit;font-size:10pt;">58%</font><font style="font-family:inherit;font-size:10pt;"> to approximately </font><font style="font-family:inherit;font-size:10pt;">53%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, Plant and Equipment, Net</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consist of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land and land improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,568</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Breeding stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,832</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction and other assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,331</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,320</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,087</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$3,456</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,782</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consist of the following:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land and land improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and building improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,568</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Breeding stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,832</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction and other assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,331</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,320</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,087</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Security and Affiliates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of </font><font style="font-family:inherit;font-size:10pt;">$800</font><font style="font-family:inherit;font-size:10pt;"> per month to be paid in the form of fully-vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">). The Services Agreement had a term of </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2019. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company issued </font><font style="font-family:inherit;font-size:10pt;">160,626</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">103,930</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, with values of </font><font style="font-family:inherit;font-size:10pt;">$2,041</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,039</font><font style="font-family:inherit;font-size:10pt;">, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement were </font><font style="font-family:inherit;font-size:10pt;">$14</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$66</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See also Note </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> regarding compensation arrangements between the Company and its CEO.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Facility, the Company may, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). Any issued Series A Preferred Stock is non-voting, accrues dividends of </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> per annum and, subject to limited exceptions, is senior to Intrexon's common stock with respect to the rights to the payment of dividends and on parity with the common stock with respect to the distribution of assets in the event of any liquidation, dissolution or winding up or change of control of Intrexon. Any issued Series A Preferred Stock is convertible into common stock only following receipt of shareholder approval by the Company, including a majority of the shares voted by those shareholders unaffiliated with Mr. Kirk (the "Shareholder Approval"), subject to any necessary regulatory approvals. Following receipt of the Shareholder Approval and receipt of any necessary regulatory approvals, any issued Series A Preferred Stock is convertible into Intrexon common stock based on a conversion price using the </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">-day volume-weighted average market price as of market closing on the fifth business day prior to the mailing of the proxy statement soliciting the Shareholder Approval, subject to adjustment for certain stock splits and similar events. The Company has agreed to take all reasonable steps necessary to seek Shareholder Approval on or before the date of its annual meeting of shareholders in 2019. Any issued Series A Preferred Stock is redeemable at the election of the Company at any time, or at the election of the Third Security Affiliate after December 31, 2020. The Preferred Stock Facility will expire on the earliest to occur of: (i) the date on which the Third Security Affiliate has purchased shares of Series A Preferred Stock in the aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, (ii) April 30, 2019, (iii) the date of the Shareholder Approval, and (iv) the mutual agreement of the parties. To date, the Company has not utilized the Preferred Stock Facility.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of </font><font style="font-family:inherit;font-size:10pt;">$21</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transactions with ECC Parties</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the value of the convertible note and warrants totaled </font><font style="font-family:inherit;font-size:10pt;">$494</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$575</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in other assets on the accompanying consolidated balance sheets. See Note </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of the Company's investments in Fibrocell.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Related Parties</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest.&#160;As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled </font><font style="font-family:inherit;font-size:10pt;">$603</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration and licensing revenues</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement, (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii)&#160;milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. The Company typically determines that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product and service revenues</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, have been excluded from the above computations of diluted weighted average shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> then ended as they would have been anti-dilutive:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,546,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,632,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,731,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,632,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the total consideration transferred was </font><font style="font-family:inherit;font-size:10pt;">$17,582</font><font style="font-family:inherit;font-size:10pt;">. The acquisition date fair value of each class of consideration transferred is presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt consists of the following:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty-based financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,926</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,037</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long term debt, less current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the computation of basic and diluted net loss per share:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historical net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,693,336</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,956,780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.33</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation costs included in the consolidated statements of operations are presented below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,894</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, developed technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,733</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents, developed technologies and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">218,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,383</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,558</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,720</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,459</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,748</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consists of the following:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies, embryos and other production materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,422</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Livestock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Feed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,013</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,271</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future maturities of long term debt are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and licensing revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,988</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,505</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(930,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(891,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,831</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity was as follows:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,382,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.32</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,546,434</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.25</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable at March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,533,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.38</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and results of operations and cash flows for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration and licensing revenues</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement, (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii)&#160;milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. The Company typically determines that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product and service revenues</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered. Payment terms are typically due within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Method Investments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;">) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators, using the fair value option. The fair value of the Company's investment in Oragenics was </font><font style="font-family:inherit;font-size:10pt;">$2,334</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,085</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included as equity securities in the accompanying consolidated balance sheets. The Company's ownership of Oragenics was </font><font style="font-family:inherit;font-size:10pt;">27.9%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">29.4%</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Unrealized depreciation in the fair value of these securities was </font><font style="font-family:inherit;font-size:10pt;">$751</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,341</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. See Note </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion regarding Oragenics.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized financial data as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, for the Company's equity method investments are shown in the following tables. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,598</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,610</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,343</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that certain of its collaborators and joint ventures as well as Harvest were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$191,731</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$185,261</font><font style="font-family:inherit;font-size:10pt;">, respectively, which represents the Company's maximum risk of loss related to the identified VIEs.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law and significantly revised U.S. corporate income tax law by, among other things, reducing the corporate income tax rate to 21% effective January 1, 2018, eliminating the corporate alternative minimum tax and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings from foreign subsidiaries. The U.S. Securities and Exchange Commission ("SEC") Staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed, including computations, in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company recognized provisional tax impacts related to revaluation of most of the Company's domestic deferred tax assets, the impact of revaluation of those deferred tax assets on the Company's valuation allowance and elimination of the corporate alternative minimum tax, and included those amounts in the consolidated financial statements for the year ended December 31, 2017. The actual impact of the Tax Act may differ from the Company's estimates due to, among other things, changes in interpretations and assumptions made, and guidance that may be issued as a result of the Tax Act.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Tax Act implemented a new minimum tax on global intangible low-taxed income ("GILTI"). A company can elect an accounting policy to account for GILTI in either of the following ways:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As a period charge in the future period in which the tax arises; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As part of deferred taxes related to the investment or subsidiary.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not made a policy decision regarding whether to record deferred taxes under the GILTI regime.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting is expected to be completed within the one-year measurement period as allowed by SAB 118 for items impacted or introduced by the Tax Act. No further adjustments to these provisional amounts occurred in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the amounts continue to be provisional.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$23,019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$21,837</font><font style="font-family:inherit;font-size:10pt;">, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling </font><font style="font-family:inherit;font-size:10pt;">$4,431</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,714</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. Under the previous revenue guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to another collaborator, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (see Note 5 in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of these collaborations). Because the Company controls the performance obligation, ASC 606 requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under ASC 606, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$40,789</font><font style="font-family:inherit;font-size:10pt;"> of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company reduced deferred revenue by </font><font style="font-family:inherit;font-size:10pt;">$377</font><font style="font-family:inherit;font-size:10pt;"> as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC would have been recognized immediately under ASC 606. The milestone payment was received by the Company in form of ZIOPHARM's common stock and under previous guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. As a result of these changes under ASC 606, the Company recognized a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of </font><font style="font-family:inherit;font-size:10pt;">$40,412</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and licensing revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Intrexon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,988</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances Without Adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Change Higher/(Lower)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,505</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(930,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(891,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,831</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718) &#8211; Scope of Modification Accounting </font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-09")</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, the "Cash, cash equivalents, and restricted cash" beginning period balance increased by </font><font style="font-family:inherit;font-size:10pt;">$7,434</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying consolidated statement of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the beginning and ending period balances increased by </font><font style="font-family:inherit;font-size:10pt;">$6,987</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying consolidated statement of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> from what was previously reported in the Company's Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory </font><font style="font-family:inherit;font-size:10pt;">("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 230) - Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows</font><font style="font-family:inherit;font-size:10pt;">, and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </font><font style="font-family:inherit;font-size:10pt;">("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception </font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial&#160;conversion features (in Subtopic 470-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-Debt with Conversion and Other Options</font><font style="font-family:inherit;font-size:10pt;">), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;"> ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders' Equity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Common Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, Intrexon closed a public offering of </font><font style="font-family:inherit;font-size:10pt;">6,900,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, including </font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were </font><font style="font-family:inherit;font-size:10pt;">$82,374</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts of </font><font style="font-family:inherit;font-size:10pt;">$3,688</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$188</font><font style="font-family:inherit;font-size:10pt;">, all of which were capitalized.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Components of Accumulated Other Comprehensive Loss</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss are as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, the Company commenced efforts to shift certain of the manufacturing and distribution operations of Oxitec's Brazilian subsidiary to a decentralized operation and as a result, the Company anticipates one-time charges of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2018. These charges are comprised primarily of the costs to vacate its existing leased premises, the write-down of certain fixed assets previously used in production, and severance costs.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S &amp; I Ophthalmic, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OvaXon, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harvest start-up entities (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,363</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, including the estimated remaining performance period as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Remaining Performance Period (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZIOPHARM Oncology, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oragenics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genopaver, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persea Bio, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ares Trading S.A.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon Energy Partners II, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrexon T1D Partners, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harvest start-up entities (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in ZIOPHARM Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM, a related party, with a per share stated value of </font><font style="font-family:inherit;font-size:10pt;">$1,200</font><font style="font-family:inherit;font-size:10pt;">, as consideration for amending their two previously existing ECC agreements. A summary of the terms of the Preferred Shares follows.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion. </font><font style="font-family:inherit;font-size:10pt;">The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the </font><font style="font-family:inherit;font-size:10pt;">twenty</font><font style="font-family:inherit;font-size:10pt;"> trading days ending on the Conversion Event Date or (ii) </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&amp;R Certificate of Designation").</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Rights.</font><font style="font-family:inherit;font-size:10pt;"> The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to </font><font style="font-family:inherit;font-size:10pt;">$12.00</font><font style="font-family:inherit;font-size:10pt;"> per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from </font><font style="font-family:inherit;font-size:10pt;">$12.00</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$24.00</font><font style="font-family:inherit;font-size:10pt;"> per Preferred Share per month.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting Rights</font><font style="font-family:inherit;font-size:10pt;">. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&amp;R Certificate of Designation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidation Rights. </font><font style="font-family:inherit;font-size:10pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&amp;R Certificate of Designation, including a change of control or the sale, lease transfer, or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the </font><font style="font-family:inherit;font-size:10pt;">twenty</font><font style="font-family:inherit;font-size:10pt;"> day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in ZIOPHARM preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in ZIOPHARM preferred stock is estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model are (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. A significant change in unobservable inputs discussed above could result in a significant impact on the fair value of the Company's investment in ZIOPHARM preferred stock. The fair value of the Company's investment in ZIOPHARM preferred stock, including additional Preferred Shares received as dividends, was </font><font style="font-family:inherit;font-size:10pt;">$165,703</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$160,832</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company received </font><font style="font-family:inherit;font-size:10pt;">3,624</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">3,216</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, of additional Preferred Shares and recognized </font><font style="font-family:inherit;font-size:10pt;">$4,871</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,923</font><font style="font-family:inherit;font-size:10pt;">, respectively, of dividend income in the accompanying consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in Fibrocell Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, Fibrocell Science, Inc. ("Fibrocell"), one of the Company's collaborators and a related party, sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid </font><font style="font-family:inherit;font-size:10pt;">$1,161</font><font style="font-family:inherit;font-size:10pt;"> in exchange for </font><font style="font-family:inherit;font-size:10pt;">1,161</font><font style="font-family:inherit;font-size:10pt;"> Convertible Preferred Shares and warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">498,843</font><font style="font-family:inherit;font-size:10pt;"> shares of Fibrocell common stock. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Company's investment in Fibrocell preferred stock totaled </font><font style="font-family:inherit;font-size:10pt;">$366</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$393</font><font style="font-family:inherit;font-size:10pt;">, respectively. See Note </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> for additional discussion of the warrants.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in Oragenics Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling&#160;</font><font style="font-family:inherit;font-size:10pt;">$3,385</font><font style="font-family:inherit;font-size:10pt;">&#160;for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrues an annual&#160;</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#160;dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increases to&#160;</font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">. Additionally, the Company and Oragenics amended certain future payment terms under its ECCs, as discussed in Note 5 of the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the most recent financial information available on Oragenics, the Company concluded that there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> value to its investment in Oragenics preferred stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in the Fair Value of Investments in Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in the Level 3 investments in preferred stock during the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend income from investments in preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized depreciation in the fair value of the investments in preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. EX-101.SCH 7 xon-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - Collaboration and Licensing Revenue link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Collaboration and Licensing Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2427405 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2427403 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2427404 - Disclosure - Commitments and Contingencies - Purchase Commitments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - Consolidated Statements of Cash Flows (Reconciliation of Cash) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2421404 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Investments in Joint Ventures link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Investments in Joint Ventures - EnviroFlight - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Investments in Joint Ventures - OvaXon - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Investments in Preferred Stock link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Investments in Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Investments in Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Lines of Credit and Long Term Debt link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Lines of Credit and Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Mergers and Acquisitions link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Mergers and Acquisitions - Condensed Pro forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Mergers and Acquisitions - GenVec - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Mergers and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2429403 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2428401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Share-Based Payments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Shareholders' Equity - Issuances of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2130100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2430401 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 xon-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 xon-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 xon-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Lines of Credit and Long Term Debt Debt Disclosure [Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Options Equity Option [Member] Restricted stock units Deferred Compensation, Share-based Payments [Member] Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2018 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four 2022 Long-term Debt, Maturities, Repayments of Principal in Year Five 2023 Long Term Debt, Maturities, Repayments Of Principal In Year Six Long Term Debt, Maturities, Repayments Of Principal In Year Six Thereafter Long Term Debt, Maturities, Repayments Of Principal After Year Six Long Term Debt, Maturities, Repayments Of Principal After Year Six Total Long Term Debt, Total, Excluding Royalty-based Financing Long Term Debt, Total, Excluding Royalty-based Financing Property, Plant and Equipment [Abstract] Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Subsequent Event [Table] Subsequent Event [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Other restructuring costs Other Restructuring Costs Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of products Cost Of Products [Member] Cost Of Products [Member] Cost of services Cost Of Services [Member] Cost Of Services [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation costs Allocated Share-based Compensation Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Equity Method Investments Equity Method Investments [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Inventory Disclosure [Abstract] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Inventory Inventory Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill Goodwill [Roll Forward] Beginning balance Goodwill Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Axis] Adjustments for Change in Accounting Principle [Domain] Adjustments for Change in Accounting Principle [Domain] Accounting Standards Update 2016-18 Accounting Standards Update 2016-18 [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Ares Trading S.A. Ares Trading S.A. [Member] Ares Trading S.A., a subsidiary of Merck Serono S.A. [Member] ZIOPHARM Oncology, Inc. Ziopharm [Member] ZIOPHARM Oncology, Inc. Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption Collaboration and licensing revenues Collaboration And Licensing Revenue Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss attributable to Intrexon Net Income (Loss) Attributable to Parent Current portion of deferred revenue Deferred Revenue, Current Long-term portion of deferred revenue Deferred Revenue, Noncurrent Accumulated deficit Retained Earnings (Accumulated Deficit) Cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Depreciation expense Depreciation Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Notes payable Notes Payable, Other Payables [Member] Royalty-based financing Royalty-based Financing [Member] Royalty-based Financing [Member] Other Other Long-Term Debt [Member] Other Long-Term Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long term debt Long-term Debt Less current portion Long-term Debt, Current Maturities Long term debt, net of current portion Long-term Debt, Excluding Current Maturities Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Cash Equivalents Short-term investments Short-term Investments Equity securities Other Marketable Securities, Current Receivables Receivables, Net, Current [Abstract] Trade, net Accounts Receivable, Net, Current Related parties, net Due from Related Parties, Current Other Accounts and Other Receivables, Net, Current Inventory Inventory, Gross Prepaid expenses and other Prepaid Expense and Other Assets, Current Total current assets Assets, Current Equity securities, noncurrent Other Marketable Securities, Noncurrent Investments in preferred stock Investments In Preferred Stock, Noncurrent Investments in preferred stock for which the entity has elected the fair value option, intended to be held longer than one year from the balance sheet date of the normal operating cycle, if longer. Property, plant and equipment, net Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Investments in affiliates Equity Method Investments Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Total Equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation and benefits Employee-related Liabilities, Current Other accrued liabilities Other Accrued Liabilities, Current Deferred revenue, including $28,684 and $29,155 from related parties as of March 31, 2018 and December 31, 2017, respectively Lines of credit Line of Credit, Current Current portion of long term debt Related party payables Due to Related Parties, Current Total current liabilities Liabilities, Current Deferred revenue, net of current portion, including $147,708 and $157,628 from related parties as of March 31, 2018 and December 31, 2017, respectively Deferred tax liabilities, net Deferred Tax Liabilities, Net, Noncurrent Other long term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 16) Commitments and Contingencies Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock, no par value, 200,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 129,239,376 and 122,087,040 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively Common Stock, Value, Outstanding Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Intrexon shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and total equity Liabilities and Equity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Collaboration and licensing agreements Collaboration and licensing agreements [Member] Upfront fees, milestone payments, and prepaid research fees received for collaboration and licensing agreements. Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Products and Services Revenues Products and Services Revenues [Member] Revenue from products and services sales. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Typical required notice period for voluntary termination of collaboration agreement Collaboration Agreement Termination Notice Period Notice period required for voluntary termination of collaboration. Typical payment terms Revenue, Performance Obligation, Description of Payment Terms Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Licensing and patent infringement suit Licensing And Patent Infringement Suit [Member] Licensing And Patent Infringement Suit [Member] Shareholder demand regarding allegations made by Seeking Alpha financial blog Shareholder Demand, Seeking Alpha Financial Blog Allegations [Member] Shareholder Demand related to allegations made in Seeking Alpha financial blog [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] XY, LLC XY, LLC [Member] XY, LLC [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Damages awarded to Trans Ova Litigation Settlement, Amount Awarded from Other Party Damages awarded against Trans Ova Litigation Settlement, Amount Awarded to Other Party Cumulative payments for royalties and licenses Payments for Royalties Royalty payments not yet deposited Royalty Payments Undeposited The amount of cash paid for royalties that have not been deposited as of the reporting date. Litigation settlement expense Litigation Settlement, Expense Claims dismissed Loss Contingency, Claims Dismissed, Number Total claims Loss Contingencies, Total Claims, Number Total number of claims. Claims pending resolution Loss Contingency, Pending Claims, Number Number of lawsuits Loss Contingency, New Claims Filed, Number Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Gain on foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to the noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Intrexon Comprehensive Income (Loss), Net of Tax, Attributable to Parent Investments, Debt and Equity Securities [Abstract] Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments Available-for-sale Securities [Table Text Block] Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Investors Investor [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] OvaXon, LLC Ova Xon [Member] OvaXon, LLC Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Investments In Affiliates Investments In Affiliates [Member] Investments In Affiliates [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Capital contributions Payments to Acquire Interest in Joint Venture Membership interest Equity Method Investment, Ownership Percentage Total number of seats on the joint venture's governing board Number of Seats on Governing Board Number of seats on the governing board. Total number of seats on the joint venture's governing board, internally selected Number of Seats on Governing Board, Internally Selected The number of seats on the governing board selected internally. Total number of seats on the joint venture's governing board, externally selected Number of Seats on Governing Board, Externally Selected The number of seats on the governing board, externally selected. Investment Collaboration and Licensing Revenue Collaborative Arrangement Disclosure [Text Block] Goodwill accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Amortization expense Amortization of Intangible Assets Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Supplies, embryos and other production materials Supplies, Embryos And Other Production Materials [Member] Supplies, Embryos And Other Production Materials [Member] Work in process Work In Process [Member] Work In Process [Member] Livestock Livestock [Member] Livestock [Member] Feed Feed [Member] Feed [Member] Inventory [Line Items] Inventory [Line Items] Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Line of Credit Revolving Credit Facility [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Trans Ova Genetics, LC Trans Ova Genetics Lc [Member] Trans Ova Genetics LC [Member] Exemplar Genetics, LLC Exemplar Genetics, LLC [Member] Exemplar Genetics, LLC [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] First National Bank of Omaha First National Bank of Omaha [Member] First National Bank of Omaha [Member] American State Bank American State Bank [Member] American State Bank [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Line of credit facility, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Line of credit facility, interest rate at period end Line of Credit Facility, Interest Rate at Period End Line of credit facility, outstanding balance Long-term Line of Credit Short-term Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Future Minimum Lease Payments Under Noncancelable Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Equity [Abstract] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summarized Financial Information for the Equity Method Investments Equity Method Investments [Table Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] 2018 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2019 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2021 Operating Leases, Future Minimum Payments, Due in Four Years 2022 Operating Leases, Future Minimum Payments, Due in Five Years 2023 Operating Leases, Future Minimum Payments, Due In Six Years Operating Leases, Future Minimum Payments, Due In Six Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] Foreign Tax Authority Foreign Tax Authority [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Taxable income (loss) Taxable Income Loss Taxable income (loss) Current income tax expense (benefit) Current Income Tax Expense (Benefit) Deferred income tax benefit Deferred Income Tax Expense (Benefit) Deferred tax liabilities Deferred Tax Liabilities, Net Operating loss carryforwards Operating Loss Carryforwards Federal and state research and development tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Provisional transition tax amount Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Transition Tax Amount Provisionally estimated transition tax exposure as a result of the Tax Cuts and Jobs Act of 2017. Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] U.S. government debt securities US Government Debt Securities [Member] Certificates of deposit Certificates of Deposit [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Aggregate Fair Value Available-for-sale Securities, Debt Securities S & I Ophthalmic, LLC S I Ophthalmic [Member] S & I Ophthalmic, LLC Return of investment upon dissolution of affiliate Proceeds from Equity Method Investment, Distribution, Return of Capital Schedule of Stock-Based Compensation Costs Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Total Intrexon Shareholders' Equity Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances (in shares) Common Stock, Shares, Outstanding Balances Cumulative effect of adoption of ASC 606 Cumulative Effect of New Accounting Principle in Period of Adoption1 Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption. Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Exercises of stock options and warrants (in shares) Stock Issued During Period, Shares, Stock Options and Warrants Exercised Number of new stock issued during the period as a result of exercises of stock options and warrants. Exercises of stock options and warrants Stock Issued During Period, Value, Stock Options and Warrants Exercised Value of stock issued as a result of the exercise of stock options and warrants. Shares issued as payment for services (in shares) Stock Issued During Period, Shares, Issued for Services Shares issued as payment for services Stock Issued During Period, Value, Issued for Services Shares issued in public offerings, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Shares and warrants issued in public offerings, net of issuance costs Stock Issued During Period, Value, New Issues Adjustments for noncontrolling interests Adjustments for noncontrolling interests Increase in noncontrolling interest balance because of current period activity, including business combinations and subsidiary equity issuances. Net loss Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Balances (in shares) Balances Maximum risk of loss related to the identified VIEs Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of financial liabilities measured at fair value on a recurring basis Liabilities, Fair Value Disclosure, Recurring Changes in fair value of Level 3 liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Mergers and Acquisitions [Abstract] Mergers and Acquisitions [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] GenVec, Inc. GenVec, Inc. [Member] GenVec, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of outstanding common stock acquired Business Acquisition, Percentage of Voting Interests Acquired Business combination, consideration paid, shares issued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Percent of collaboration payments Collaboration Arrangement, Percent Of Collaboration Payments Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party. Period subsequent to acquisition during which a portion of collaboration payments received will be paid to former stockholders of acquired entity Business Combination, Period Subsequent to Acquisition During Which A Portion of Collaboration Payments Received Will Be Paid to Former Stockholders of Acquired Entity The period subsequent to the acquisition during which a portion of collaboration payments received from previously existing collaborations will be paid to former stockholders of the acquired entity. Expected useful life of intangible asset Finite-Lived Intangible Asset, Useful Life Business combination, acquisition related costs Business Combination, Acquisition Related Costs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Business Combinations [Abstract] Common shares Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Warrants Business Combination, Consideration Transferred, Warrants Assumed Value of warrants assumed in a business acquisition. Contingent consideration Business Combination, Liabilities Arising from Contingencies, Amount Recognized1 The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity. Total consideration transferred Business Combination, Consideration Transferred Schedule of Long Term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Future Maturities of Long Term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Upfront and Milestone Payments Upfront And Milestone Payments [Member] Upfront and milestone payments received as collaboration for the entity's collaborations Intrexon Energy Partners, LLC Intrexon Energy Partners [Member] Intrexon Energy Partners, LLC Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Upfront Upfront [Member] Upfront consideration for collaboration Other Accrued Liabilities Other Accrued Liabilities [Member] Other Accrued Liabilities [Member] Collaborative arrangement consideration received, value Collaborative Arrangement Consideration Received Value Value of consideration received by the entity for collaboration Maximum additional capital contribution committed Joint Venture Additional Capital Contributions Committed Amount of additional capital contributions to the joint venture for which the entity is committed, maximum. Additional capital contributions committed, remaining commitment Joint Venture Additional Capital Contributions Committed, Remaining Commitment Remaining amount of additional capital contributions to the joint venture for which the entity is committed. Investment in Preferred Stock [Abstract] Investment in Preferred Stock [Abstract] Investments In Preferred Stock Investment In Preferred Stock [Text Block] The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to the company's investment in the preferred stock of another entity. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Intrexon Stock Option Plans Intrexon Stock Option Plan [Member] Stock option plans for Intrexon Corporation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Balances at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Balances at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Balances at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Balances at period end (in usd per share) Exercisable, weighted average exercise price, at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Balances, weighted average remaining contractual period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable at period end, weighted average remaining contractual period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Net Loss per Share Earnings Per Share [Text Block] Noncontrolling Interest [Table] Noncontrolling Interest [Table] AquaBounty Technologies, Inc. Aqua Bounty [Member] Aqua Bounty Technologies, Inc. Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Net proceeds from public financing Proceeds from Issuance of Common Stock Purchase of additional equity of majority-owned subsidiary Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent Parent ownership interest Noncontrolling Interest, Ownership Percentage by Parent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Short term investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Trade receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Other receivables Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Receivables Amount of other receivables acquired at the acquisition date. Prepaid expenses and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other noncurrent assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued compensation and benefits Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation And Benefits Amount of accrued compensation and benefits assumed at the acquisition date. Other accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Other long term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net EnviroFlight, LLC EnviroFlight, LLC [Member] EnviroFlight, LLC [Member] Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Foreign Countries Non-US [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of segments Number of Operating Segments Revenues Revenues Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Fair Value of Consideration Transferred Schedule of Business Acquisitions, by Acquisition [Table Text Block] Fair Value of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Condensed Pro forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Land and land improvements Land and Land Improvements Buildings and building improvements Buildings and Improvements, Gross Furniture and fixtures Furniture and Fixtures, Gross Equipment Machinery and Equipment, Gross Leasehold improvements Leasehold Improvements, Gross Breeding stock Breeding and Production Animals, Gross Amount before accumulated depreciation of animals maintained to create offspring or to produce goods to be sold for profit. Computer hardware and software Computer Hardware and Software Amount before accumulated depreciation and amortization of computer hardware and purchased software. Trees Trees Amount before accumulated depreciation of producing trees and trees in process. Construction and other assets in progress Construction in Progress, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Third Security, LLC Third Security [Member] Third Security, LLC Convertible Note and Warrants Convertible Note and Warrants [Member] Notes which are convertible into another security, usually common shares of the issuer with warrants attached. Other Assets Other Noncurrent Assets [Member] Affiliate of Third Security, LLC Affiliates Of Third Security [Member] Affiliates of Third Security, LLC Chief Executive Officer Chief Executive Officer [Member] Fibrocell Science, Inc. Fibrocell [Member] Fibrocell Science, Inc. Harvest Intrexon Enterprise Fund I, LP Harvest Intrexon Enterprise Fund I, LP [Member] Harvest Intrexon Enterprise Fund I, LP [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A preferred shares Series A Preferred Shares [Member] Series A redeemable preferred shares. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Ownership interest Related Party Ownership Interest The percentage of ownership of common stock or equity participation in a related party. Expense for services Professional and Contract Services Expense Initial term of services agreement Services Agreement Term Initial term of a services agreement. Value of convertible preferred shares authorized for issuance Convertible Preferred Stock, Amount Authorized The maximum value of preferred shares permitted to be issued. Convertible preferred shares, dividend rate Preferred Stock, Dividend Rate, Percentage Convertible preferred shares, conversion price, number of days used to calculate volume-weighted average market price Convertible Preferred Shares, Conversion Price, Consecutive Trading Days The consecutive days over which the volume-weighed average market price is calculated in order to determine the conversion price of convertible preferred shares. Sublease rental income Operating Leases, Income Statement, Sublease Revenue Fair value of financial assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Other nonoperating income Other Nonoperating Income (Expense) Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Oragenics, Inc. Oragenics [Member] Oragenics, Inc. Genopaver, LLC Genopaver, LLC [Member] Genopaver, LLC [Member] Intrexon Energy Partners, LLC Persea Bio, LLC Persea Bio, LLC [Member] Persea Bio, LLC Intrexon Energy Partners II, LLC Intrexon Energy Partners II, LLC [Member] Intrexon Energy Partners II, LLC [Member] Intrexon T1D Partners, LLC Intrexon T1D Partners, LLC [Member] Intrexon T1D Partners, LLC [Member] Harvest start-up entities Harvest Start-Up Entities, Aggregated [Member] Harvest Start-Up Entities, Aggregated [Member] Other Other Collaborations [Member] Aggregate of other collaborations not separately disclosed Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Average remaining performance period (in years) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Average Period Average period in which remaining performance obligations are expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Deferred revenue Deferred Revenue Outstanding contractual purchase commitments Long-term Purchase Commitment, Remaining Minimum Amount Committed Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services under long-term purchase commitments. Rent expense Operating Leases, Rent Expense Mergers and Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Schedule of Investments [Table] Schedule of Investments [Table] Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Other Contractual Payments Other Contractual Payments [Member] Other Contractual Payments [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Preferred stock Preferred Stock [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Collaborative arrangement consideration received, number of preferred shares (in shares) Collaborative Arrangement Consideration Received Preferred Shares Number of shares of preferred stock of a collaborator received by the entity as consideration. Preferred shares, stated value (in usd per share) Preferred Stock, Par or Stated Value Per Share Threshold consecutive trading days, conversion of shares Convertible Stock, Threshold Consecutive Trading Days Convertible Stock, Threshold Consecutive Trading Days Preferred shares, conversion calculation, divisor (in usd per share) Preferred Stock Conversion Rate Divisor Divisor of calculation used to convert preferred shares into common stock. Preferred shares, dividend rate (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount, Unconverted Shares The amount per share used to calculate dividend payments on preferred stock for unconverted shares after a conversion event. Dividend income, number of preferred shares received (in shares) Preferred Stock Dividends, Shares Noncash Dividend Income Noncash Dividend Income Amount of dividend income included in net income that results in no cash flow. Purchases of preferred stock and warrants Payments to Acquire Other Investments Convertible preferred shares issued (in shares) Convertible Preferred Shares, Shares Issued Total number of convertible preferred shares issued to shareholders. May be all or portion of the number of convertible preferred shares authorized. Number of common shares into which warrants are convertible (in shares) Warrants, Number Of Common Shares Into Which Warrants Can Be Converted The number of common shares into which warrants can be converted. Receivables converted to preferred stock Asset Conversion, Original Asset, Amount The amount of the original asset being converted in a noncash transaction. Preferred shares, initial dividend rate Preferred Stock, Initial Dividend Rate, Percentage The initial percentage rate used to calculate dividend payments on preferred stock applicable for an initial defined period. Preferred shares, subsequent dividend rate Preferred Stock, Subsequent Dividend Rate, Percentage The subsequent percentage rate used to calculate dividend payments on preferred stock applicable after the period for which the initial dividend rate has elapsed. Related Party Transactions Related Party Transactions Disclosure [Text Block] Computation of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding All Investors All Investors [Member] All Investors of Entity [Member] Income Statement [Abstract] Revenues Revenues [Abstract] Collaboration and licensing revenues, including $19,815 and $28,887 from related parties during the three months ended March 31, 2018 and 2017, respectively Product revenues Sales Revenue, Goods, Net Service revenues Sales Revenue, Services, Net Other revenues Other Revenue, Net Total revenues Operating Expenses Operating Expenses [Abstract] Cost of products Cost of Goods Sold Cost of services Cost of Services Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other Income, Net Nonoperating Income (Expense) [Abstract] Unrealized depreciation in fair value of equity securities and preferred stock, net Equity Securities and Preferred Stock, Unrealized Appreciation (Depreciation) The amounts of gains and losses from fair value changes of equity securities and preferred stock included in earnings. Interest expense Interest Expense Interest and dividend income Investment Income, Nonoperating Other income (expense), net Total other income, net Nonoperating Income (Expense) Equity in net loss of affiliates Income (Loss) from Equity Method Investments Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss Net loss attributable to the noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Intrexon Net loss attributable to Intrexon per share, basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted average shares outstanding, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Intrexon T1D Partners, LLC Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents, developed technologies and know-how Intellectual Property [Member] Customer relationships Customer Relationships [Member] Trademarks Trademarks [Member] In-process research and development In Process Research and Development [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Finite-Lived Intangible Assets, Net Schedule of Changes in Level 3 Investments Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Loss on disposal of long-lived assets Gain (Loss) on Disposition of Property Plant Equipment Unrealized depreciation on equity securities and preferred stock, net Noncash dividend income Amortization of premiums on investments Accretion (Amortization) of Discounts and Premiums, Investments Equity in net loss of affiliates Stock-based compensation expense Share-based Compensation Shares issued as payment for services Shares Issued During Period Value Issued For Services Expense Expense recognized for consideration of services paid in the form of stock. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. Provision for bad debts Provision for Doubtful Accounts Deferred income taxes Other noncash items Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables: Increase (Decrease) in Receivables [Abstract] Trade Increase (Decrease) in Accounts Receivable Related parties Increase (Decrease) in Due from Related Parties, Current Other Increase (Decrease) in Other Receivables Inventory Increase (Decrease) in Inventories Prepaid expenses and other Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Related party payables Increase (Decrease) in Due to Related Parties, Current Other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Maturities of investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Purchases of preferred stock and warrants Investments in affiliates Payments to Acquire Interest in Subsidiaries and Affiliates Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from repayment of notes receivable Proceeds from Collection of Notes Receivable Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from issuance of shares and warrants in public offerings, net of issuance costs Proceeds from Issuance of Common Stock and Warrants, Net The cash inflow from the additional capital contribution to the entity (in exchange for shares of common stock) and from issuance of rights to purchase common shares at a predetermined price (usually issued together with corporate debt), net of capitalized issuance costs. Acquisitions of noncontrolling interests Payments to Acquire Additional Interest in Subsidiaries Advances from lines of credit Proceeds from Lines of Credit Repayments of advances from lines of credit Repayments of Lines of Credit Proceeds from long term debt Proceeds from Issuance of Long-term Debt Payments of long term debt Repayments of Long-term Debt Payments of deferred consideration for acquisitions Payments Of Deferred Consideration Cash outflows representing payments for deferred consideration from a business combination. Proceeds from stock option and warrant exercises Proceeds from Stock Options and Warrants Exercised The cash inflow associated with the amount received (i) from exercise of stock options granted under share-based compensation arrangement and (ii) from holders exercising their stock warrants. Payment of stock issuance costs Payments of Stock Issuance Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Beginning of period End of period Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid Cash paid during the period for income taxes Income Taxes Paid Significant noncash financing and investing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock issued to acquire noncontrolling interest Stock Issued During Period, Value, Acquisition Of Noncontrolling Interests Value of stock issued to acquire noncontrolling interests during the period. Noncash dividend to shareholders Noncash Dividends To Shareholders Value of noncash dividend to shareholders Purchases of equipment included in accounts payable and other accrued liabilities Capital Expenditures Incurred but Not yet Paid Purchases of equipment financed through debt Liabilities Assumed Revenues Business Acquisition, Pro Forma Revenue Loss before income taxes Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest The pro forma income (loss) from continuing operations before income taxes and noncontrolling interest as if the business combination or combinations had been completed at the beginning of the period. Net loss Business Acquisition, Pro Forma Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The pro forma consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest, as if the business combination or combinations had been completed at the beginning of the period. Net loss attributable to the noncontrolling interests Business Acquisition, Pro Forma Net Income (Loss) Attributable to Noncontrolling Interest The pro forma net income (loss) attributable to noncontrolling interest as if the business combination or combinations had been completed at the beginning of the period. Net loss attributable to Intrexon Business Acquisition, Pro Forma Net Income (Loss) Related Parties, Aggregated Related Parties, Aggregated [Member] Related Parties, Aggregated [Member] Notes payable to banks Notes Payable to Banks [Member] Atlantic Canada Opportunities Agency Atlantic Canada Opportunities Agency [Member] Atlantic Canada Opportunities Agency [Member] Long term debt Debt instrument, periodic payment Debt Instrument, Periodic Payment Amount available under the grant for research and development Amount Available Under Financial Grant For Research And Development Amount available under research and development grant Claims period Government Award, Claim Period Length of period during which amounts can be claimed under research and development grant Royalty on products, percentage Rate Of Royalty Agreed To Be Paid Percentage of royalty on products commercialized under research and development grant Amount claimed Amount Claimed Under Financial Grant Amount claimed under research and development grant to date Long term debt, fair value at date of business combination Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Accreted difference between face value of amount drawn and acquisition date fair value Accreted Difference Between Face Value Of Amount Drawn And Acquisition Date Fair Value Accreted Difference Between Face Value Of Amount Drawn And Acquisition Date Fair Value Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Investments in Joint Ventures Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity securities Equity Securities [Member] Company's ownership percentage Unrealized depreciation in fair value of equity securities Unrealized Gain (Loss) on Investments Equity Method Investments Equity Method Investments [Member] Current assets Equity Method Investment, Summarized Financial Information, Current Assets Non-current assets Equity Method Investment, Summarized Financial Information, Noncurrent Assets Total assets Equity Method Investment, Summarized Financial Information, Assets Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Net assets Equity Method Investment Summarized Financial Information Assets Liabilities Net Equity Method Investment Summarized Financial Information Assets Liabilities Net Revenues Equity Method Investment, Summarized Financial Information, Revenue Operating expenses Other, net Net loss Equity Method Investment, Summarized Financial Information, Net Income (Loss) Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Underwriting discounts and commissions Expense Related to Distribution or Servicing and Underwriting Fees Capitalized offering expenses Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Other Other Financial Assets [Member] Other Financial Assets [Member] Assets Assets, Fair Value Disclosure [Abstract] Summarized Collaboration and Licensing Revenues Collaboration and Licensing Revenue [Table Text Block] Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. Summary of Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Summary of Deferred Revenue by Collaborator Deferred Revenue By Collaborator Disclosure Table Text Block [Table Text Block] Tabular disclosure of the amounts that comprise the deferred revenue by collaborator as of the balance sheet date. Income Taxes Income Tax Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Unrealized loss on investments Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Loss on foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Total accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Intrexon shareholders' equity Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Purchase of preferred stock Dividend income from investments in preferred stock Net unrealized depreciation in the fair value of the investments in preferred stock Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Ending balance Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] S & I Ophthalmic, LLC S I Opthalmic [Member] S & I Ophthalmic, LLC Intrexon Energy Partners II, LLC Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Restricted cash included in other assets Restricted Cash and Cash Equivalents, Noncurrent Cash, cash equivalents, and restricted cash Prepaid product and service revenues Prepaid Product And Service Revenues [Member] Prepaid Product And Service Revenues [Member] Other Deferred Revenue Other [Member] Other deferred revenue Deferred revenue Intrexon Stock Option Plan - 2008 Plan Intrexon Stock Option Plan 2008 Plan [Member] Intrexon Stock Option Plan - 2008 Equity Incentive Plan Intrexon Stock Option Plan - 2013 Plan Intrexon Stock Option Plan 2013 Plan [Member] Intrexon Stock Option Plan - 2013 Omnibus Incentive Plan AquaBounty Stock Option Plan - 2006 Plan Aqua Bounty 2006 Stock Option Plan [Member] AquaBounty Technologies, Inc. 2006 Equity Incentive Plan Aqua Bounty Stock Option Plans Aqua Bounty Stock Option Plans [Member] Aqua Bounty Technologies, Inc. Equity Incentive Plans Remaining shares available to grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Options outstanding (in shares) Number of shares authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized RSUs outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Additional shares to be authorized, approved by Board of Directors, pending shareholder approval Additional Shares To Be Authorized Pending Shareholder Approval Number of additional shares to be authorized for issuance under an established share-based compensation plan. Increase has been approved by the entity's board of directors but is still pending shareholder approval. RSUs granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted average grant date fair value of RSUs granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Monthly compensation, in the form of equity Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Monthly Expense Amount of monthly expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Lock-up period Lockup Period On Restricted Stock Unit Shares Period of time during which issued shares are subject to a lock-up on resale. Initial term of compensation arrangement Compensation Arrangement Initial Term Initial term of a compensation arrangement. Options exercisable (in shares) Weighted average exercise price of option (in usd per share) Historical net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding, basic and diluted (in shares) EX-101.PRE 11 xon-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2018
Apr. 30, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Trading Symbol XON  
Entity Registrant Name INTREXON CORP  
Entity Central Index Key 0001356090  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   129,294,079
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 119,930 $ 68,111
Restricted cash 6,987 6,987
Short-term investments 275 6,273
Equity securities 3,298 5,285
Receivables    
Trade, net 17,697 19,775
Related parties, net 10,585 17,913
Other 2,437 2,153
Inventory 20,271 20,493
Prepaid expenses and other 6,065 7,057
Total current assets 187,545 154,047
Equity securities, noncurrent 10,745 9,815
Investments in preferred stock 166,069 161,225
Property, plant and equipment, net 119,244 112,674
Intangible assets, net 231,883 232,877
Goodwill 154,748 153,289
Investments in affiliates 21,406 18,870
Other assets 4,026 4,054
Total assets 895,666 846,851
Current liabilities    
Accounts payable 7,842 8,701
Accrued compensation and benefits 11,356 6,474
Other accrued liabilities 18,041 21,080
Deferred revenue, including $28,684 and $29,155 from related parties as of March 31, 2018 and December 31, 2017, respectively 48,646 42,870
Lines of credit 321 233
Current portion of long term debt 501 502
Related party payables 147 313
Total current liabilities 86,854 80,173
Long term debt, net of current portion 7,425 7,535
Deferred revenue, net of current portion, including $147,708 and $157,628 from related parties as of March 31, 2018 and December 31, 2017, respectively 214,744 193,527
Deferred tax liabilities, net 11,631 15,620
Other long term liabilities 3,586 3,451
Total liabilities 324,240 300,306
Commitments and contingencies (Note 16)
Total equity    
Common stock, no par value, 200,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 129,239,376 and 122,087,040 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 0 0
Additional paid-in capital 1,492,916 1,397,005
Accumulated deficit (930,220) (847,820)
Accumulated other comprehensive loss (9,587) (15,554)
Total Intrexon shareholders' equity 553,109 533,631
Noncontrolling interests 18,317 12,914
Total equity 571,426 546,545
Total liabilities and total equity $ 895,666 $ 846,851
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Related Party Transaction [Line Items]    
Current portion of deferred revenue $ 48,646 $ 42,870
Long-term portion of deferred revenue $ 214,744 $ 193,527
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 129,239,376 122,087,040
Common stock, shares outstanding 129,239,376 122,087,040
Related Parties, Aggregated    
Related Party Transaction [Line Items]    
Current portion of deferred revenue $ 28,684 $ 29,155
Long-term portion of deferred revenue $ 147,708 $ 157,628
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues    
Collaboration and licensing revenues, including $19,815 and $28,887 from related parties during the three months ended March 31, 2018 and 2017, respectively $ 24,025 $ 33,065
Product revenues 7,152 8,130
Service revenues 12,247 12,031
Other revenues 419 521
Total revenues 43,843 53,747
Operating Expenses    
Cost of products 8,530 9,006
Cost of services 6,783 6,804
Research and development 37,267 34,180
Selling, general and administrative 39,737 35,138
Total operating expenses 92,317 85,128
Operating loss (48,474) (31,381)
Other Income, Net    
Unrealized depreciation in fair value of equity securities and preferred stock, net (1,096) (1,622)
Interest expense (99) (179)
Interest and dividend income 5,470 4,624
Other income (expense), net (659) 595
Total other income, net 3,616 3,418
Equity in net loss of affiliates (2,460) (4,947)
Loss before income taxes (47,318) (32,910)
Income tax benefit 4,086 533
Net loss (43,232) (32,377)
Net loss attributable to the noncontrolling interests 1,244 978
Net loss attributable to Intrexon $ (41,988) $ (31,399)
Net loss attributable to Intrexon per share, basic and diluted (in usd per share) $ (0.33) $ (0.26)
Weighted average shares outstanding, basic and diluted (in shares) 127,693,336 118,956,780
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Related Party Transaction [Line Items]    
Collaboration and licensing revenues $ 24,025 $ 33,065
Related Parties, Aggregated    
Related Party Transaction [Line Items]    
Collaboration and licensing revenues $ 19,815 $ 28,887
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Statement of Comprehensive Income [Abstract]    
Net loss $ (43,232) $ (32,377)
Other comprehensive income (loss):    
Unrealized gain (loss) on investments 2 (20)
Gain on foreign currency translation adjustments 5,906 3,252
Comprehensive loss (37,324) (29,145)
Comprehensive loss attributable to the noncontrolling interests 1,303 981
Comprehensive loss attributable to Intrexon $ (36,021) $ (28,164)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Shareholders' and Total Equity - 3 months ended Mar. 31, 2018 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total Intrexon Shareholders' Equity
Noncontrolling Interests
Balances (in shares) at Dec. 31, 2017 122,087,040 122,087,040          
Balances at Dec. 31, 2017 $ 546,545 $ 0 $ 1,397,005 $ (15,554) $ (847,820) $ 533,631 $ 12,914
Increase (Decrease) in Stockholders' Equity              
Cumulative effect of adoption of ASC 606 (40,412)   0 0 (40,412) (40,412) 0
Stock-based compensation expense 11,362   11,340     11,340 22
Exercises of stock options and warrants (in shares)   21,722          
Exercises of stock options and warrants 324   74     74 250
Shares issued as payment for services (in shares)   230,614          
Shares issued as payment for services 2,941   2,941     2,941 0
Shares issued in public offerings, net of issuance costs (in shares)   6,900,000          
Shares and warrants issued in public offerings, net of issuance costs 87,990   82,374     82,374 5,616
Adjustments for noncontrolling interests 0   (818)     (818) 818
Net loss (43,232)       (41,988) (41,988) (1,244)
Other comprehensive income (loss) $ 5,908     5,967   5,967 (59)
Balances (in shares) at Mar. 31, 2018 129,239,376 129,239,376          
Balances at Mar. 31, 2018 $ 571,426 $ 0 $ 1,492,916 $ (9,587) $ (930,220) $ 553,109 $ 18,317
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities    
Net loss $ (43,232) $ (32,377)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 8,382 7,400
Loss on disposal of long-lived assets 316 566
Unrealized depreciation on equity securities and preferred stock, net 1,096 1,622
Noncash dividend income (4,883) (3,926)
Amortization of premiums on investments 0 198
Equity in net loss of affiliates 2,460 4,947
Stock-based compensation expense 11,362 7,894
Shares issued as payment for services 2,941 2,915
Provision for bad debts 218 9
Deferred income taxes (4,074) (638)
Other noncash items 127 (146)
Receivables:    
Trade 1,856 1,931
Related parties 4,729 (4,994)
Other (215) 859
Inventory 231 2,058
Prepaid expenses and other 1,062 210
Other assets (47) (526)
Accounts payable (764) (990)
Accrued compensation and benefits 4,851 924
Other accrued liabilities (2,473) 69
Deferred revenue (13,800) (13,011)
Related party payables (165) 161
Other long term liabilities 134 156
Net cash used in operating activities (29,888) (24,689)
Cash flows from investing activities    
Maturities of investments 6,000 45,000
Purchases of preferred stock and warrants 0 (1,161)
Investments in affiliates (5,510) (4,579)
Return of investment upon dissolution of affiliate 2,598 0
Purchases of property, plant and equipment (10,774) (6,343)
Proceeds from sale of property, plant and equipment 230 137
Proceeds from repayment of notes receivable 0 1,500
Net cash provided by (used in) investing activities (7,456) 34,554
Cash flows from financing activities    
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs 87,990 0
Acquisitions of noncontrolling interests 0 (913)
Advances from lines of credit 1,239 1,678
Repayments of advances from lines of credit (1,151) (2,088)
Proceeds from long term debt 0 126
Payments of long term debt (140) (123)
Payments of deferred consideration for acquisitions 0 (1,991)
Proceeds from stock option and warrant exercises 324 175
Payment of stock issuance costs 0 (10)
Net cash provided by (used in) financing activities 88,262 (3,146)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 914 526
Net increase in cash, cash equivalents, and restricted cash 51,832 7,245
Cash, cash equivalents, and restricted cash    
Beginning of period 75,545 69,594
End of period 127,377 76,839
Supplemental disclosure of cash flow information    
Cash paid during the period for interest 82 70
Cash paid during the period for income taxes 20 0
Significant noncash financing and investing activities    
Stock issued to acquire noncontrolling interest 0 5,082
Noncash dividend to shareholders 0 22,385
Purchases of equipment included in accounts payable and other accrued liabilities 2,016 1,132
Purchases of equipment financed through debt $ 76 $ 0
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Statement of Cash Flows [Abstract]    
Cash and cash equivalents $ 119,930 $ 68,111
Restricted cash 6,987 6,987
Restricted cash included in other assets 460 447
Cash, cash equivalents, and restricted cash $ 127,377 $ 75,545
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
Organization
Intrexon Corporation ("Intrexon"), a Virginia corporation, including through its wholly owned subsidiaries Precigen, Inc. ("Precigen") and ActoBio Therapeutics, Inc. ("ActoBio"), uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date.
Trans Ova Genetics, L.C. ("Trans Ova"), and Progentus, L.C. ("Progentus"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in Iowa, Maryland, Missouri, New York, Oklahoma, and Texas.
Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil.
Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington.
ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively.
In January 2018, AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, completed an underwritten public offering which resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased $5,000 of additional AquaBounty common stock, reducing its ownership stake from approximately 58% to approximately 53%.
Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2018 and results of operations and cash flows for the interim periods ended March 31, 2018 and 2017. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2018, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Revenue Recognition
Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.
The Company's revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Collaboration and licensing revenues
The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.
The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.
At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.
The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.
Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. The Company typically determines that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.
Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.
As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.
From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
Product and service revenues
The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered. Payment terms are typically due within 30 days.
Equity Method Investments
The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 17) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.
The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators, using the fair value option. The fair value of the Company's investment in Oragenics was $2,334 and $3,085 as of March 31, 2018 and December 31, 2017, respectively, and is included as equity securities in the accompanying consolidated balance sheets. The Company's ownership of Oragenics was 27.9% and 29.4% as of March 31, 2018 and December 31, 2017, respectively. Unrealized depreciation in the fair value of these securities was $751 and $1,341 for the three months ended March 31, 2018 and 2017, respectively. See Note 7 for additional discussion regarding Oragenics.
Summarized financial data as of March 31, 2018 and December 31, 2017 and for the three months ended March 31, 2018 and 2017, for the Company's equity method investments are shown in the following tables.
 
March 31,
2018
 
December 31,
2017
Current assets
$
57,724

 
$
61,086

Non-current assets
15,553

 
13,598

Total assets
73,277

 
74,684

Current liabilities
7,946

 
6,213

Net assets
$
65,331

 
$
68,471


 
Three Months Ended 
 March 31,
 
2018
 
2017
Revenues
$
67

 
$
30

Operating expenses
8,610

 
13,343

Operating loss
(8,543
)
 
(13,313
)
Other, net
14

 
5

Net loss
$
(8,529
)
 
$
(13,308
)

Variable Interest Entities
As of March 31, 2018 and December 31, 2017, the Company determined that certain of its collaborators and joint ventures as well as Harvest were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of March 31, 2018 and December 31, 2017 were $191,731 and $185,261, respectively, which represents the Company's maximum risk of loss related to the identified VIEs.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law and significantly revised U.S. corporate income tax law by, among other things, reducing the corporate income tax rate to 21% effective January 1, 2018, eliminating the corporate alternative minimum tax and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings from foreign subsidiaries. The U.S. Securities and Exchange Commission ("SEC") Staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed, including computations, in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company recognized provisional tax impacts related to revaluation of most of the Company's domestic deferred tax assets, the impact of revaluation of those deferred tax assets on the Company's valuation allowance and elimination of the corporate alternative minimum tax, and included those amounts in the consolidated financial statements for the year ended December 31, 2017. The actual impact of the Tax Act may differ from the Company's estimates due to, among other things, changes in interpretations and assumptions made, and guidance that may be issued as a result of the Tax Act.
In addition, the Tax Act implemented a new minimum tax on global intangible low-taxed income ("GILTI"). A company can elect an accounting policy to account for GILTI in either of the following ways:
As a period charge in the future period in which the tax arises; or
As part of deferred taxes related to the investment or subsidiary.
The Company has not made a policy decision regarding whether to record deferred taxes under the GILTI regime.
The accounting is expected to be completed within the one-year measurement period as allowed by SAB 118 for items impacted or introduced by the Tax Act. No further adjustments to these provisional amounts occurred in the three months ended March 31, 2018 and the amounts continue to be provisional.
Segment Information
While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment. As of March 31, 2018 and December 31, 2017, the Company had $23,019 and $21,837, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $4,431 and $3,714 for the three months ended March 31, 2018 and 2017, respectively.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements
The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. Under the previous revenue guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to another collaborator, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (see Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 for additional discussion of these collaborations). Because the Company controls the performance obligation, ASC 606 requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under ASC 606, the Company recorded $40,789 of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company reduced deferred revenue by $377 as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC would have been recognized immediately under ASC 606. The milestone payment was received by the Company in form of ZIOPHARM's common stock and under previous guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. As a result of these changes under ASC 606, the Company recognized a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of $40,412.
In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the three months ended March 31, 2018 and consolidated balance sheet as of March 31, 2018 was as follows:
 
Three Months Ended March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Statement of Operations
 
 
 
 
 
Collaboration and licensing revenues
$
24,025

 
$
22,444

 
$
1,581

Net loss
(43,232
)
 
(44,813
)
 
1,581

Net loss attributable to Intrexon
(41,988
)
 
(43,569
)
 
1,581

 
March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Balance Sheet
 
 
 
 
 
Liabilities
 
 
 
 
 
Deferred revenue, current
$
48,646

 
$
42,320

 
$
6,326

Deferred revenue, net of current portion
214,744

 
182,239

 
32,505

Total Equity
 
 
 
 
 
Accumulated deficit
(930,220
)
 
(891,389
)
 
(38,831
)

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation-Stock Compensation (Topic 718) – Scope of Modification Accounting ("ASU 2017-09"). The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force) ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, the "Cash, cash equivalents, and restricted cash" beginning period balance increased by $7,434 for the three months ended March 31, 2018 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2018, and the beginning and ending period balances increased by $6,987 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2017 from what was previously reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2017.
In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions
3 Months Ended
Mar. 31, 2018
Mergers and Acquisitions [Abstract]  
Mergers and Acquisitions
Mergers and Acquisitions
GenVec Acquisition
In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired 100% of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of 684,240 shares of the Company's common stock and have the right to receive contingent consideration equal to 50% of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within three years after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements.
The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:
Common shares
$
15,616

Warrants
1,381

Contingent consideration
585

 
$
17,582


The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash and cash equivalents
$
2,054

Short term investments
542

Trade receivables
75

Other receivables
97

Prepaid expenses and other
227

Property and equipment
250

Intangible assets
14,000

Other noncurrent assets
58

Total assets acquired
17,303

Accounts payable
2,158

Accrued compensation and benefits
1,226

Other accrued expenses
856

Other long term liabilities
92

Deferred tax liabilities
239

Total liabilities assumed
4,571

Net assets acquired
12,732

Goodwill
4,850

Total consideration
$
17,582


The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of eleven years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology.
Acquisition-related costs totaling $238 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the three months ended March 31, 2017.
Condensed Pro Forma Financial Information
GenVec's results of operations subsequent to the acquisition are included in the consolidated statement of operations. The following condensed pro forma financial information for the three months ended March 31, 2017 is presented as if the acquisition had been consummated on January 1, 2016:
 
Three Months Ended 
 March 31,
 
2017
 
Pro forma
Revenues
$
53,861

Loss before income taxes
(36,765
)
Net loss
(36,232
)
Net loss attributable to the noncontrolling interests
978

Net loss attributable to Intrexon
(35,254
)
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures
3 Months Ended
Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]  
Investments in Joint Ventures
Investments in Joint Ventures
S & I Ophthalmic
In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governed the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leveraged experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic was governed by a board of managers which had four members, two each from the Company and Sun Pharmaceutical Subsidiary. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of $5,000.
In December 2017, both the Company and Sun Pharmaceutical Subsidiary agreed to dissolve S & I Ophthalmic and terminate the related ECC agreement. In January 2018, the Company received $2,598 upon the dissolution of S & I Ophthalmic which represented the Company's portion of S & I Ophthalmic's remaining cash after all liabilities were settled.
OvaXon
In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development, and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. Through March 31, 2018, both the Company and OvaScience have made subsequent capital contributions of $4,350.
In March 2018, the Company and OvaScience agreed to terminate the ECC agreement with OvaScience. The Company and OvaScience are in discussions regarding dissolving the OvaXon joint venture and terminating the related ECC agreement.
The Company's investment in OvaXon was $146 as of March 31, 2018 and December 31, 2017, and is included in investments in affiliates in the accompanying consolidated balance sheets.
Intrexon Energy Partners
In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of March 31, 2018, the Company's remaining commitment was $6,011. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.
The Company's investment in Intrexon Energy Partners was $(806) and $(444) as of March 31, 2018 and December 31, 2017, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
Intrexon Energy Partners II
In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.
The Company's investment in Intrexon Energy Partners II was $515 and $572 as of March 31, 2018 and December 31, 2017, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.
EnviroFlight
In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through March 31, 2018, both the Company and Darling have made subsequent capital contributions of $8,250.
The Company's investment in New EnviroFlight was $10,072 and $7,092 as of March 31, 2018 and December 31, 2017, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets.
Intrexon T1D Partners
In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Intrexon has committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of March 31, 2018, the Company's remaining commitment was $1,250. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has five members. Two members of the Intrexon T1D Partners Board are designated by the Company and three members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board.
The Company's investment in Intrexon T1D Partners was $(67) and $(943) as of March 31, 2018 and December 31, 2017, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration and Licensing Revenue
Collaboration and Licensing Revenue
The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.
The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained under ASC 606. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement.
See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.
The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Amounts for periods subsequent to January 1, 2018 reflect revenue recognition under ASC 606.
The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2018 and 2017.
 
Three Months Ended 
 March 31,
 
2018
 
2017
ZIOPHARM Oncology, Inc.
$
6,879

 
$
10,985

Oragenics, Inc.
342

 
569

Fibrocell Science, Inc.
835

 
1,739

Genopaver, LLC
1,288

 
1,680

S & I Ophthalmic, LLC

 
303

OvaXon, LLC

 
824

Intrexon Energy Partners, LLC
1,252

 
5,086

Persea Bio, LLC
252

 
289

Ares Trading S.A.
3,368

 
3,315

Intrexon Energy Partners II, LLC
615

 
1,149

Intrexon T1D Partners, LLC
1,468

 
1,132

Harvest start-up entities (1)
3,354

 
3,363

Other
4,372

 
2,631

Total
$
24,025

 
$
33,065

(1)
For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
Other than the termination of the OvaScience ECC in March 2018 (Note 4), there have been no significant changes to arrangements with our collaborators and licensees in the three months ended March 31, 2018. See Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 for additional details of the Company's existing collaboration and licensing agreements.
Deferred Revenue
Deferred revenue primarily consists of consideration received for the Company's collaborations and licensing agreements and prepayments for product and service revenues. Deferred revenue consists of the following:
 
March 31,
2018
 
December 31,
2017
Collaboration and licensing agreements
$
258,174

 
$
231,583

Prepaid product and service revenues
5,138

 
4,681

Other
78

 
133

Total
$
263,390

 
$
236,397

Current portion of deferred revenue
$
48,646

 
$
42,870

Long-term portion of deferred revenue
214,744

 
193,527

Total
$
263,390

 
$
236,397


The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of March 31, 2018 and December 31, 2017, including the estimated remaining performance period as of March 31, 2018.
 
Average Remaining Performance Period (Years)
 
March 31,
2018
 
December 31,
2017
ZIOPHARM Oncology, Inc.
5.8
 
$
86,365

 
$
90,496

Oragenics, Inc.
6.2
 
6,456

 
6,719

Fibrocell Science, Inc.
6.6
 
16,002

 
16,607

Genopaver, LLC
6.0
 
1,635

 
1,704

Intrexon Energy Partners, LLC
6.0
 
15,000

 
15,625

Persea Bio, LLC
6.8
 
3,375

 
3,500

Ares Trading S.A.
6.1
 
78,384

 
40,789

Intrexon Energy Partners II, LLC
6.7
 
13,333

 
13,833

Intrexon T1D Partners, LLC
7.0
 
8,334

 
8,435

Harvest start-up entities (1)
7.1
 
17,918

 
18,400

Other
3.7
 
10,494

 
14,423

Total
 
 
$
257,296

 
$
230,531

(1)
As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Short-term Investments
3 Months Ended
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]  
Short-term Investments
Short-term Investments
The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2018:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
Certificates of deposit
$
275

 
$

 
$

 
$
275

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2017:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
6,000

 
$

 
$
(2
)
 
$
5,998

Certificates of deposit
275

 

 

 
275

Total
$
6,275

 
$

 
$
(2
)
 
$
6,273


For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
As of March 31, 2018, all of the available-for-sale investments were due within one year based on their contractual maturities.
Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and there were none as of March 31, 2018.
As of March 31, 2018 and December 31, 2017, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Preferred Stock
3 Months Ended
Mar. 31, 2018
Investment in Preferred Stock [Abstract]  
Investments In Preferred Stock
Investments in Preferred Stock
Investment in ZIOPHARM Preferred Stock
In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM, a related party, with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements. A summary of the terms of the Preferred Shares follows.
Conversion. The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the twenty trading days ending on the Conversion Event Date or (ii) $1.00. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation").
Dividend Rights. The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from $12.00 to $24.00 per Preferred Share per month.
Voting Rights. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation.
Liquidation Rights. In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer, or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the twenty day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.
The investment in ZIOPHARM preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in ZIOPHARM preferred stock is estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model are (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. A significant change in unobservable inputs discussed above could result in a significant impact on the fair value of the Company's investment in ZIOPHARM preferred stock. The fair value of the Company's investment in ZIOPHARM preferred stock, including additional Preferred Shares received as dividends, was $165,703 and $160,832 as of March 31, 2018 and December 31, 2017, respectively. During the three months ended March 31, 2018 and 2017, the Company received 3,624 shares and 3,216 shares, respectively, of additional Preferred Shares and recognized $4,871 and $3,923, respectively, of dividend income in the accompanying consolidated statements of operations.
Investment in Fibrocell Preferred Stock
In March 2017, Fibrocell Science, Inc. ("Fibrocell"), one of the Company's collaborators and a related party, sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 498,843 shares of Fibrocell common stock. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of March 31, 2018 and December 31, 2017, the fair value of the Company's investment in Fibrocell preferred stock totaled $366 and $393, respectively. See Note 17 for additional discussion of the warrants.
Investment in Oragenics Preferred Stock
In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrues an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increases to 20%. Additionally, the Company and Oragenics amended certain future payment terms under its ECCs, as discussed in Note 5 of the Company's Annual Report on Form 10-K for the year ended December 31, 2017. As of March 31, 2018 and December 31, 2017, based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock.
Changes in the Fair Value of Investments in Preferred Stock
The following table summarizes the changes in the Level 3 investments in preferred stock during the three months ended March 31, 2018.
 
Three Months Ended 
 March 31, 2018
Beginning balance
$
161,225

Dividend income from investments in preferred stock
4,883

Net unrealized depreciation in the fair value of the investments in preferred stock
(39
)
Ending balance
$
166,069

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at March 31, 2018:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
March 31,
2018
Assets
 
 
 
 
 
 
 
Equity securities
9,622

 
4,421

 

 
14,043

Preferred stock

 

 
166,069

 
166,069

Other

 
769

 

 
769

Total
$
9,622

 
$
5,190

 
$
166,069

 
$
180,881

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2017:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2017
Assets
 
 
 
 
 
 
 
U.S. government debt securities
$

 
$
5,998

 
$

 
$
5,998

Equity securities
10,537

 
4,563

 

 
15,100

Preferred stock

 

 
161,225

 
161,225

Other

 
850

 

 
850

Total
$
10,537

 
$
11,411

 
$
161,225

 
$
183,173


The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The methods used to estimate the fair value of the Level 3 assets are discussed in Note 7.
There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2018.
The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The Company's contingent consideration liabilities from previous acquisitions are measured on a recurring basis and were $585 at March 31, 2018 and December 31, 2017. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the three months ended March 31, 2018.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory
3 Months Ended
Mar. 31, 2018
Inventory Disclosure [Abstract]  
Inventory
Inventory
Inventory consists of the following:
 
March 31,
2018
 
December 31,
2017
Supplies, embryos and other production materials
$
3,386

 
$
2,673

Work in process
4,422

 
4,767

Livestock
10,991

 
11,040

Feed
1,472

 
2,013

Total inventory
$
20,271

 
$
20,493

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property, Plant and Equipment, Net
3 Months Ended
Mar. 31, 2018
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net
Property, plant and equipment consist of the following:
 
March 31,
2018
 
December 31,
2017
Land and land improvements
$
11,815

 
$
11,767

Buildings and building improvements
18,160

 
18,183

Furniture and fixtures
2,516

 
2,515

Equipment
69,568

 
65,863

Leasehold improvements
27,811

 
25,277

Breeding stock
4,204

 
3,832

Computer hardware and software
10,442

 
10,128

Trees
7,996

 
6,642

Construction and other assets in progress
15,819

 
14,113

 
168,331

 
158,320

Less: Accumulated depreciation and amortization
(49,087
)
 
(45,646
)
Property, plant and equipment, net
$
119,244

 
$
112,674


Depreciation expense was $3,456 and $2,782 for the three months ended March 31, 2018 and 2017, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net
3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net
Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for the three months ended March 31, 2018 are as follows:
Balance at December 31, 2017
$
153,289

Foreign currency translation adjustments
1,459

Balance at March 31, 2018
$
154,748


The Company had $13,823 of accumulated impairment losses as of March 31, 2018 and December 31, 2017.
Intangible assets consist of the following as of March 31, 2018:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
266,579

 
$
(48,586
)
 
$
217,993

Customer relationships
10,700

 
(6,733
)
 
3,967

Trademarks
6,800

 
(2,760
)
 
4,040

In-process research and development
5,883

 

 
5,883

Total
$
289,962

 
$
(58,079
)
 
$
231,883


Intangible assets consist of the following as of December 31, 2017:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
263,615

 
$
(44,954
)
 
$
218,661

Customer relationships
10,700

 
(6,383
)
 
4,317

Trademarks
6,800

 
(2,567
)
 
4,233

In-process research and development
5,666

 

 
5,666

Total
$
286,781

 
$
(53,904
)
 
$
232,877


The balance of in-process research and development includes certain in-process research and development technology acquired
in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have
been obtained for the in-process programs.
Amortization expense was $4,926 and $4,618 for the three months ended March 31, 2018 and 2017, respectively.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Lines of Credit and Long Term Debt
Lines of Credit and Long Term Debt
Lines of Credit
Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha which matures on June 1, 2018. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and the actual rate was 4.62% as of March 31, 2018. As of March 31, 2018, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of March 31, 2018.
Exemplar has a $700 revolving line of credit with American State Bank which matures on October 30, 2018. The line of credit bears interest at 5.25% per annum. As of March 31, 2018, there was an outstanding balance of $321.
Long Term Debt
Long term debt consists of the following:
 
March 31,
2018
 
December 31,
2017
Notes payable
$
4,896

 
$
5,010

Royalty-based financing
2,108

 
2,132

Other
922

 
895

Long term debt
7,926

 
8,037

Less current portion
501

 
502

Long term debt, less current portion
$
7,425

 
$
7,535


Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $4,775 as of March 31, 2018. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.
AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency, a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,226, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the date of the acquisition by Intrexon in March 2013, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Subsequent to the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long term debt of $2,108 as of March 31, 2018.
Future maturities of long term debt are as follows:
2018
$
398

2019
411

2020
382

2021
830

2022
373

2023
386

Thereafter
3,038

Total
$
5,818


The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
3 Months Ended
Mar. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three months ended March 31, 2018, the Company had U.S. taxable loss of approximately $35,100 and recorded $113 of current domestic income tax expense. For the three months ended March 31, 2018, the Company recognized $125 of current foreign income tax benefit. For the three months ended March 31, 2017, the Company had U.S. taxable income of approximately $11,800 and recorded $236 of current domestic income tax expense. For the three months ended March 31, 2017, the Company recognized $131 of current foreign income tax benefit. For the three months ended March 31, 2018, the Company recorded deferred tax benefit of $4,074. For the three months ended March 31, 2017, the Company recorded deferred tax benefit of $638. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $11,631, are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
As of March 31, 2018, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $279,500 available to offset future taxable income, and federal and state research and development tax credits of approximately $7,800, prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. These carryforwards will begin to expire in 2022. As of March 31, 2018, the Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $160,700, most of which do not expire.
In 2017, the Company recorded a net provisional income tax benefit upon enactment of the Tax Act. The Company has provisionally estimated its transition tax exposure to be zero, as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries. The provisional amounts recorded are subject to further refinement within the measurement period prescribed by SAB 118. As a result, the recorded amounts are subject to change, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company utilized to provisionally compute the transition impact. No adjustments to these provisional amounts were recorded during the three months ended March 31, 2018.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Shareholders' Equity
Shareholders' Equity
Issuances of Common Stock
In January 2018, Intrexon closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374, after deducting underwriting discounts of $3,688 and offering expenses of $188, all of which were capitalized.
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss are as follows:
 
March 31,
2018
 
December 31,
2017
Unrealized loss on investments
$

 
$
(2
)
Loss on foreign currency translation adjustments
(9,587
)
 
(15,552
)
Total accumulated other comprehensive loss
$
(9,587
)
 
$
(15,554
)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Payments
Share-Based Payments
The Company records the fair value of stock options and restricted stock units ("RSUs") issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Cost of products
$
25

 
$
26

Cost of services
77

 
78

Research and development
3,258

 
2,193

Selling, general and administrative
8,002

 
5,597

Total
$
11,362

 
$
7,894


Intrexon Stock Option Plans
In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of March 31, 2018, there were 431,649 stock options outstanding under the 2008 Plan.
Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of March 31, 2018, there were 18,000,000 shares authorized for issuance under the 2013 Plan, of which 11,114,785 stock options and 1,052,182 RSUs were outstanding and 3,279,291 shares were available for grant. In March 2018, Intrexon's board of directors approved, subject to shareholder approval at Intrexon's annual meeting in June 2018, an increase of 2,000,000 shares of common stock to be reserved for issuance under the 2013 Plan.
Stock option activity was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2017
11,382,747

 
$
28.99

 
7.32
Granted
656,339

 
14.84

 
 
Exercised
(21,722
)
 
(3.40
)
 
 
Forfeited
(186,811
)
 
(26.37
)
 
 
Expired
(284,119
)
 
(27.67
)
 
 
Balances at March 31, 2018
11,546,434

 
28.31

 
7.25
Exercisable at March 31, 2018
6,533,996

 
29.29

 
6.38

During the three months ended March 31, 2018, Intrexon granted 1,059,126 RSUs with a weighted average grant date fair value of $13.83 per share, of which 1,052,182 remain outstanding and unvested as of March 31, 2018.
Intrexon currently uses authorized and unissued shares to satisfy share award exercises.
In October 2015, the compensation committee and the independent members of Intrexon's board of directors approved a compensation arrangement whereby the Company's Chief Executive Officer ("CEO") would receive a monthly salary. Previously, the CEO did not receive compensation for his services as an employee of the Company other than through his participation in the Company's Annual Executive Incentive Plan which became effective January 1, 2015. Pursuant to the compensation agreement, the CEO receives a base salary of $200 per month payable in fully vested shares of Intrexon common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") which was executed between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement became effective in November 2015, and had an initial term of twelve months. The independent members of Intrexon's board of directors, with the recommendation of the compensation committee of the board of directors, subsequently approved extensions of the RSU Agreement through March 31, 2019, all of which are on the same terms as the original RSU Agreement. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled $486 and $471 for the three months ended March 31, 2018 and 2017, respectively.
AquaBounty Stock Option Plans
In March 2016, AquaBounty's board of directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan"). The AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, no new awards may be granted under the AquaBounty 2006 Plan.
As of March 31, 2018, there were 340,764 options outstanding under both AquaBounty plans, of which 207,390 were exercisable, at a weighted average exercise price of $7.09 per share.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Operating Leases
The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At March 31, 2018, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2018
$
6,096

2019
9,441

2020
9,506

2021
8,601

2022
7,595

2023
6,558

Thereafter
23,923

Total
$
71,720


Rent expense, including other facility expenses, was $3,259 and $2,301 for the three months ended March 31, 2018 and 2017, respectively.
Purchase Commitments
As of March 31, 2018, the Company had outstanding contractual purchase commitments of $15,098, which primarily relate to amounts that will be paid in 2018, 2019, and 2020 upon delivery of commercial non-browning apple trees.
Contingencies
In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breached a 2004 licensing agreement and infringed on patents that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. In Colorado District Court, the matter proceeded to a jury trial in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with a compulsory license to XY's technology, subject to an ongoing royalty obligation. Both parties appealed the court's order, which appeal is pending before the Court of Appeals for the Federal Circuit. Since the inception of the 2004 agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the April 2016 court order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the court's April 2016 order, aggregate royalty and license payments were $3,170, of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded expense of $4,228 representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of March 31, 2018, this amount is included in restricted cash on the accompanying consolidated balance sheet. In December 2016, Trans Ova elected to void the outstanding checks discussed above, and these amounts have been reclassified to other accrued liabilities on the accompanying consolidated balance sheets as of March 31, 2018 and December 31, 2017. Depending on the outcome of an appeal decision, the damages awarded to either party could decrease, increase, or be eliminated. The appeal decision may also remand to the Colorado District Court all, or a portion, of the issues being appealed. In December 2016, XY filed a complaint for patent infringement and trade secret misappropriation against Trans Ova in the District Court of Waco, Texas. Since the claims in this 2016 complaint directly relate to the 2012 licensing dispute and patent issues, Trans Ova filed and was granted a motion for change of venue to Colorado District Court. Trans Ova also filed a motion to dismiss, from which the Court recently dismissed nine of the twelve counts of the complaint. Presently, three counts for patent infringement remain pending. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation, to modify the court-ordered license to XY's technologies, or to recover monetary damages stemming from Trans Ova's counterclaims for antitrust violations by XY and its parent company, Inguran.
In June and July 2016, two shareholders made separate demands under Virginia law demanding that the Company file suit against certain of its current officers and directors for alleged breaches of fiduciary duty and other claims. The demands were based upon and asserted the allegations contained in a report published in April 2016 on the Seeking Alpha financial blog. In July 2016, the Company's board of directors authorized its Special Litigation Committee ("SLC"), consisting of independent directors, to investigate the claims and allegations made in the two shareholder demands and to decide on behalf of the Company whether the claims and allegations should be pursued. In February 2017, the SLC completed its review and evaluation and unanimously determined that there was no basis for any of the allegations, that the Company's officers and directors did not breach their fiduciary duties or any other applicable law, and that prosecution of the asserted claims was not in the best interest of Intrexon or its shareholders.
Following the SLC's determination, in March 2017, a derivative complaint captioned Luger v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, alleging causes of action for breaches of fiduciary duty and unjust enrichment relating to the same allegations investigated by the SLC. On April 4, 2018, the plaintiff filed a motion to nonsuit, which the court granted without prejudice on April 13, 2018.
The Division of Enforcement of the SEC is conducting an investigation which the Company believes concerns certain issues raised by the foregoing and by the previously disclosed consolidated putative shareholder class action lawsuit, captioned Intrexon Corporation Securities Litigation, that was dismissed on November 1, 2017 and the previously disclosed shareholder derivative action captioned Basile v. Kirk et al. that was dismissed on January 25, 2018. The Company has met with the SEC staff and is voluntarily cooperating with their investigation. The Company's board of directors has authorized the SLC to monitor the Company's interaction with the SEC staff.
The Company may become subject to other claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2018 and December 31, 2017, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Related Party Transactions
Related Party Transactions
Third Security and Affiliates
The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15). The Services Agreement had a term of one year, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2019. For the three months ended March 31, 2018 and 2017, the Company issued 160,626 shares and 103,930 shares, respectively, with values of $2,041 and $2,039, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement were $14 and $66 for the three months ended March 31, 2018 and 2017, respectively.
See also Note 15 regarding compensation arrangements between the Company and its CEO.
In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Facility, the Company may, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). Any issued Series A Preferred Stock is non-voting, accrues dividends of 8% per annum and, subject to limited exceptions, is senior to Intrexon's common stock with respect to the rights to the payment of dividends and on parity with the common stock with respect to the distribution of assets in the event of any liquidation, dissolution or winding up or change of control of Intrexon. Any issued Series A Preferred Stock is convertible into common stock only following receipt of shareholder approval by the Company, including a majority of the shares voted by those shareholders unaffiliated with Mr. Kirk (the "Shareholder Approval"), subject to any necessary regulatory approvals. Following receipt of the Shareholder Approval and receipt of any necessary regulatory approvals, any issued Series A Preferred Stock is convertible into Intrexon common stock based on a conversion price using the 20-day volume-weighted average market price as of market closing on the fifth business day prior to the mailing of the proxy statement soliciting the Shareholder Approval, subject to adjustment for certain stock splits and similar events. The Company has agreed to take all reasonable steps necessary to seek Shareholder Approval on or before the date of its annual meeting of shareholders in 2019. Any issued Series A Preferred Stock is redeemable at the election of the Company at any time, or at the election of the Third Security Affiliate after December 31, 2020. The Preferred Stock Facility will expire on the earliest to occur of: (i) the date on which the Third Security Affiliate has purchased shares of Series A Preferred Stock in the aggregate amount of $100,000, (ii) April 30, 2019, (iii) the date of the Shareholder Approval, and (iv) the mutual agreement of the parties. To date, the Company has not utilized the Preferred Stock Facility.
The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $21 and $11 for the three months ended March 31, 2018 and 2017, respectively.
Transactions with ECC Parties
In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties.
The Company holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. As of March 31, 2018 and December 31, 2017, the value of the convertible note and warrants totaled $494 and $575, respectively, and is included in other assets on the accompanying consolidated balance sheets. See Note 7 for additional discussion of the Company's investments in Fibrocell.
Other Related Parties
In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $603 for the three months ended March 31, 2017. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss per Share
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Net Loss per Share
Net Loss per Share
The following table presents the computation of basic and diluted net loss per share:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Historical net loss per share:
 
 
 
Numerator:
 
 
 
Net loss attributable to Intrexon
$
(41,988
)
 
$
(31,399
)
Denominator:
 
 
 
Weighted average shares outstanding, basic and diluted
127,693,336

 
118,956,780

Net loss attributable to Intrexon per share, basic and diluted
$
(0.33
)
 
$
(0.26
)

The following potentially dilutive securities as of March 31, 2018 and 2017, have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive:
 
March 31,
 
2018
 
2017
Options
11,546,434

 
12,632,507

Restricted stock units
1,052,182

 

Warrants
133,264

 

Total
12,731,880

 
12,632,507

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
3 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
In May 2018, the Company commenced efforts to shift certain of the manufacturing and distribution operations of Oxitec's Brazilian subsidiary to a decentralized operation and as a result, the Company anticipates one-time charges of up to approximately $6,000 in the second quarter of 2018. These charges are comprised primarily of the costs to vacate its existing leased premises, the write-down of certain fixed assets previously used in production, and severance costs.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2018 and results of operations and cash flows for the interim periods ended March 31, 2018 and 2017. The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2018, or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Consolidation
The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Revenue Recognition
Revenue Recognition
Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and distinct performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.
The Company's revenue recognition accounting policies for periods prior to January 1, 2018 can be found in the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Collaboration and licensing revenues
The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.
The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services, and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.
At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts, milestone payments upon the achievement of certain development, regulatory and commercial activities, and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.
The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.
Milestone payments are evaluated at the inception of the agreement to determine whether the milestones are considered probable of being achieved. The Company typically determines that the milestones are not probable at inception of the agreement due to the uncertainty of when and if the milestone will be achieved.
Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.
As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.
From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.
Product and service revenues
The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when the customer takes ownership of the promised product or when the promised service is rendered.
Equity Method Investments
Equity Method Investments
The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 17) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.
Income Taxes
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Segment Information
Segment Information
While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. Under the previous revenue guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to another collaborator, ZIOPHARM Oncology, Inc. ("ZIOPHARM"), as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (see Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 for additional discussion of these collaborations). Because the Company controls the performance obligation, ASC 606 requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under ASC 606, the Company recorded $40,789 of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company reduced deferred revenue by $377 as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC would have been recognized immediately under ASC 606. The milestone payment was received by the Company in form of ZIOPHARM's common stock and under previous guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. As a result of these changes under ASC 606, the Company recognized a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of $40,412.
In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the three months ended March 31, 2018 and consolidated balance sheet as of March 31, 2018 was as follows:
 
Three Months Ended March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Statement of Operations
 
 
 
 
 
Collaboration and licensing revenues
$
24,025

 
$
22,444

 
$
1,581

Net loss
(43,232
)
 
(44,813
)
 
1,581

Net loss attributable to Intrexon
(41,988
)
 
(43,569
)
 
1,581

 
March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Balance Sheet
 
 
 
 
 
Liabilities
 
 
 
 
 
Deferred revenue, current
$
48,646

 
$
42,320

 
$
6,326

Deferred revenue, net of current portion
214,744

 
182,239

 
32,505

Total Equity
 
 
 
 
 
Accumulated deficit
(930,220
)
 
(891,389
)
 
(38,831
)

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation-Stock Compensation (Topic 718) – Scope of Modification Accounting ("ASU 2017-09"). The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force) ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, the "Cash, cash equivalents, and restricted cash" beginning period balance increased by $7,434 for the three months ended March 31, 2018 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2018, and the beginning and ending period balances increased by $6,987 in the accompanying consolidated statement of cash flows for the three months ended March 31, 2017 from what was previously reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2017.
In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Summarized Financial Information for the Equity Method Investments
Summarized financial data as of March 31, 2018 and December 31, 2017 and for the three months ended March 31, 2018 and 2017, for the Company's equity method investments are shown in the following tables.
 
March 31,
2018
 
December 31,
2017
Current assets
$
57,724

 
$
61,086

Non-current assets
15,553

 
13,598

Total assets
73,277

 
74,684

Current liabilities
7,946

 
6,213

Net assets
$
65,331

 
$
68,471


 
Three Months Ended 
 March 31,
 
2018
 
2017
Revenues
$
67

 
$
30

Operating expenses
8,610

 
13,343

Operating loss
(8,543
)
 
(13,313
)
Other, net
14

 
5

Net loss
$
(8,529
)
 
$
(13,308
)
Accounting Standards Update 2014-09  
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the three months ended March 31, 2018 and consolidated balance sheet as of March 31, 2018 was as follows:
 
Three Months Ended March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Statement of Operations
 
 
 
 
 
Collaboration and licensing revenues
$
24,025

 
$
22,444

 
$
1,581

Net loss
(43,232
)
 
(44,813
)
 
1,581

Net loss attributable to Intrexon
(41,988
)
 
(43,569
)
 
1,581

 
March 31, 2018
 
As Reported
 
Balances Without Adoption of ASC 606
 
Effect of Change Higher/(Lower)
Consolidated Balance Sheet
 
 
 
 
 
Liabilities
 
 
 
 
 
Deferred revenue, current
$
48,646

 
$
42,320

 
$
6,326

Deferred revenue, net of current portion
214,744

 
182,239

 
32,505

Total Equity
 
 
 
 
 
Accumulated deficit
(930,220
)
 
(891,389
)
 
(38,831
)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions (Tables)
3 Months Ended
Mar. 31, 2018
Business Acquisition [Line Items]  
Condensed Pro forma Financial Information
The following condensed pro forma financial information for the three months ended March 31, 2017 is presented as if the acquisition had been consummated on January 1, 2016:
 
Three Months Ended 
 March 31,
 
2017
 
Pro forma
Revenues
$
53,861

Loss before income taxes
(36,765
)
Net loss
(36,232
)
Net loss attributable to the noncontrolling interests
978

Net loss attributable to Intrexon
(35,254
)
GenVec, Inc.  
Business Acquisition [Line Items]  
Fair Value of Consideration Transferred
The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:
Common shares
$
15,616

Warrants
1,381

Contingent consideration
585

 
$
17,582

Fair Value of Assets Acquired and Liabilities Assumed
The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:
Cash and cash equivalents
$
2,054

Short term investments
542

Trade receivables
75

Other receivables
97

Prepaid expenses and other
227

Property and equipment
250

Intangible assets
14,000

Other noncurrent assets
58

Total assets acquired
17,303

Accounts payable
2,158

Accrued compensation and benefits
1,226

Other accrued expenses
856

Other long term liabilities
92

Deferred tax liabilities
239

Total liabilities assumed
4,571

Net assets acquired
12,732

Goodwill
4,850

Total consideration
$
17,582

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue (Tables)
3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenues
The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2018 and 2017.
 
Three Months Ended 
 March 31,
 
2018
 
2017
ZIOPHARM Oncology, Inc.
$
6,879

 
$
10,985

Oragenics, Inc.
342

 
569

Fibrocell Science, Inc.
835

 
1,739

Genopaver, LLC
1,288

 
1,680

S & I Ophthalmic, LLC

 
303

OvaXon, LLC

 
824

Intrexon Energy Partners, LLC
1,252

 
5,086

Persea Bio, LLC
252

 
289

Ares Trading S.A.
3,368

 
3,315

Intrexon Energy Partners II, LLC
615

 
1,149

Intrexon T1D Partners, LLC
1,468

 
1,132

Harvest start-up entities (1)
3,354

 
3,363

Other
4,372

 
2,631

Total
$
24,025

 
$
33,065

(1)
For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
Summary of Deferred Revenue
Deferred revenue consists of the following:
 
March 31,
2018
 
December 31,
2017
Collaboration and licensing agreements
$
258,174

 
$
231,583

Prepaid product and service revenues
5,138

 
4,681

Other
78

 
133

Total
$
263,390

 
$
236,397

Current portion of deferred revenue
$
48,646

 
$
42,870

Long-term portion of deferred revenue
214,744

 
193,527

Total
$
263,390

 
$
236,397

Summary of Deferred Revenue by Collaborator
The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of March 31, 2018 and December 31, 2017, including the estimated remaining performance period as of March 31, 2018.
 
Average Remaining Performance Period (Years)
 
March 31,
2018
 
December 31,
2017
ZIOPHARM Oncology, Inc.
5.8
 
$
86,365

 
$
90,496

Oragenics, Inc.
6.2
 
6,456

 
6,719

Fibrocell Science, Inc.
6.6
 
16,002

 
16,607

Genopaver, LLC
6.0
 
1,635

 
1,704

Intrexon Energy Partners, LLC
6.0
 
15,000

 
15,625

Persea Bio, LLC
6.8
 
3,375

 
3,500

Ares Trading S.A.
6.1
 
78,384

 
40,789

Intrexon Energy Partners II, LLC
6.7
 
13,333

 
13,833

Intrexon T1D Partners, LLC
7.0
 
8,334

 
8,435

Harvest start-up entities (1)
7.1
 
17,918

 
18,400

Other
3.7
 
10,494

 
14,423

Total
 
 
$
257,296

 
$
230,531

(1)
As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Short-term Investments (Tables)
3 Months Ended
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]  
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments
The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2018:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
Certificates of deposit
$
275

 
$

 
$

 
$
275

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2017:
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate
Fair Value
U.S. government debt securities
$
6,000

 
$

 
$
(2
)
 
$
5,998

Certificates of deposit
275

 

 

 
275

Total
$
6,275

 
$

 
$
(2
)
 
$
6,273

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Preferred Stock (Tables)
3 Months Ended
Mar. 31, 2018
Investment in Preferred Stock [Abstract]  
Schedule of Changes in Level 3 Investments
The following table summarizes the changes in the Level 3 investments in preferred stock during the three months ended March 31, 2018.
 
Three Months Ended 
 March 31, 2018
Beginning balance
$
161,225

Dividend income from investments in preferred stock
4,883

Net unrealized depreciation in the fair value of the investments in preferred stock
(39
)
Ending balance
$
166,069

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at March 31, 2018:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
March 31,
2018
Assets
 
 
 
 
 
 
 
Equity securities
9,622

 
4,421

 

 
14,043

Preferred stock

 

 
166,069

 
166,069

Other

 
769

 

 
769

Total
$
9,622

 
$
5,190

 
$
166,069

 
$
180,881

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2017:
 
Quoted Prices in Active Markets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
December 31,
2017
Assets
 
 
 
 
 
 
 
U.S. government debt securities
$

 
$
5,998

 
$

 
$
5,998

Equity securities
10,537

 
4,563

 

 
15,100

Preferred stock

 

 
161,225

 
161,225

Other

 
850

 

 
850

Total
$
10,537

 
$
11,411

 
$
161,225

 
$
183,173

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory (Tables)
3 Months Ended
Mar. 31, 2018
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventory consists of the following:
 
March 31,
2018
 
December 31,
2017
Supplies, embryos and other production materials
$
3,386

 
$
2,673

Work in process
4,422

 
4,767

Livestock
10,991

 
11,040

Feed
1,472

 
2,013

Total inventory
$
20,271

 
$
20,493

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property, Plant and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2018
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
March 31,
2018
 
December 31,
2017
Land and land improvements
$
11,815

 
$
11,767

Buildings and building improvements
18,160

 
18,183

Furniture and fixtures
2,516

 
2,515

Equipment
69,568

 
65,863

Leasehold improvements
27,811

 
25,277

Breeding stock
4,204

 
3,832

Computer hardware and software
10,442

 
10,128

Trees
7,996

 
6,642

Construction and other assets in progress
15,819

 
14,113

 
168,331

 
158,320

Less: Accumulated depreciation and amortization
(49,087
)
 
(45,646
)
Property, plant and equipment, net
$
119,244

 
$
112,674

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net (Tables)
3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for the three months ended March 31, 2018 are as follows:
Balance at December 31, 2017
$
153,289

Foreign currency translation adjustments
1,459

Balance at March 31, 2018
$
154,748

Schedule of Intangible Assets
Intangible assets consist of the following as of March 31, 2018:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
266,579

 
$
(48,586
)
 
$
217,993

Customer relationships
10,700

 
(6,733
)
 
3,967

Trademarks
6,800

 
(2,760
)
 
4,040

In-process research and development
5,883

 

 
5,883

Total
$
289,962

 
$
(58,079
)
 
$
231,883


Intangible assets consist of the following as of December 31, 2017:
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
263,615

 
$
(44,954
)
 
$
218,661

Customer relationships
10,700

 
(6,383
)
 
4,317

Trademarks
6,800

 
(2,567
)
 
4,233

In-process research and development
5,666

 

 
5,666

Total
$
286,781

 
$
(53,904
)
 
$
232,877

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of Long Term Debt Instruments
Long term debt consists of the following:
 
March 31,
2018
 
December 31,
2017
Notes payable
$
4,896

 
$
5,010

Royalty-based financing
2,108

 
2,132

Other
922

 
895

Long term debt
7,926

 
8,037

Less current portion
501

 
502

Long term debt, less current portion
$
7,425

 
$
7,535

Schedule of Future Maturities of Long Term Debt
Future maturities of long term debt are as follows:
2018
$
398

2019
411

2020
382

2021
830

2022
373

2023
386

Thereafter
3,038

Total
$
5,818

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity (Tables)
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss are as follows:
 
March 31,
2018
 
December 31,
2017
Unrealized loss on investments
$

 
$
(2
)
Loss on foreign currency translation adjustments
(9,587
)
 
(15,552
)
Total accumulated other comprehensive loss
$
(9,587
)
 
$
(15,554
)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments (Tables)
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock-Based Compensation Costs
Stock-based compensation costs included in the consolidated statements of operations are presented below:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Cost of products
$
25

 
$
26

Cost of services
77

 
78

Research and development
3,258

 
2,193

Selling, general and administrative
8,002

 
5,597

Total
$
11,362

 
$
7,894

Schedule of Stock Option Activity
Stock option activity was as follows:
 
Number of Shares
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2017
11,382,747

 
$
28.99

 
7.32
Granted
656,339

 
14.84

 
 
Exercised
(21,722
)
 
(3.40
)
 
 
Forfeited
(186,811
)
 
(26.37
)
 
 
Expired
(284,119
)
 
(27.67
)
 
 
Balances at March 31, 2018
11,546,434

 
28.31

 
7.25
Exercisable at March 31, 2018
6,533,996

 
29.29

 
6.38

XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Future Minimum Lease Payments Under Noncancelable Operating Leases
At March 31, 2018, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
2018
$
6,096

2019
9,441

2020
9,506

2021
8,601

2022
7,595

2023
6,558

Thereafter
23,923

Total
$
71,720

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss per Share (Tables)
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share
The following table presents the computation of basic and diluted net loss per share:
 
Three Months Ended 
 March 31,
 
2018
 
2017
Historical net loss per share:
 
 
 
Numerator:
 
 
 
Net loss attributable to Intrexon
$
(41,988
)
 
$
(31,399
)
Denominator:
 
 
 
Weighted average shares outstanding, basic and diluted
127,693,336

 
118,956,780

Net loss attributable to Intrexon per share, basic and diluted
$
(0.33
)
 
$
(0.26
)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share
The following potentially dilutive securities as of March 31, 2018 and 2017, have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive:
 
March 31,
 
2018
 
2017
Options
11,546,434

 
12,632,507

Restricted stock units
1,052,182

 

Warrants
133,264

 

Total
12,731,880

 
12,632,507

XML 55 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization (Details) - USD ($)
$ in Thousands
1 Months Ended
Jan. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Noncontrolling Interest [Line Items]      
Net proceeds from public financing $ 82,374    
AquaBounty Technologies, Inc.      
Noncontrolling Interest [Line Items]      
Net proceeds from public financing 10,616    
Purchase of additional equity of majority-owned subsidiary $ 5,000    
Parent ownership interest   53.00% 58.00%
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Revenue Recognition - Additional Information (Details)
3 Months Ended
Mar. 31, 2018
Products and Services Revenues  
Disaggregation of Revenue [Line Items]  
Typical payment terms 30 days
Collaboration and licensing agreements  
Disaggregation of Revenue [Line Items]  
Typical required notice period for voluntary termination of collaboration agreement 90 days
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis $ 180,881   $ 183,173
Oragenics, Inc.      
Schedule of Equity Method Investments [Line Items]      
Company's ownership percentage 27.90%   29.40%
Equity securities      
Schedule of Equity Method Investments [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis $ 14,043   $ 15,100
Equity securities | Oragenics, Inc.      
Schedule of Equity Method Investments [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis 2,334   $ 3,085
Unrealized depreciation in fair value of equity securities $ (751) $ (1,341)  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]      
Operating expenses $ 92,317 $ 85,128  
Operating loss (48,474) (31,381)  
Other, net 3,616 3,418  
Equity Method Investments      
Schedule of Equity Method Investments [Line Items]      
Current assets 57,724   $ 61,086
Non-current assets 15,553   13,598
Total assets 73,277   74,684
Current liabilities 7,946   6,213
Net assets 65,331   $ 68,471
Revenues 67 30  
Operating expenses 8,610 13,343  
Operating loss (8,543) (13,313)  
Other, net 14 5  
Net loss $ (8,529) $ (13,308)  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Maximum risk of loss related to the identified VIEs $ 191,731 $ 185,261
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Segment Information - Additional Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
segment
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Segment Reporting Information [Line Items]      
Number of segments | segment 1    
Property, plant and equipment, net $ 119,244   $ 112,674
Revenues 43,843 $ 53,747  
Foreign Countries      
Segment Reporting Information [Line Items]      
Property, plant and equipment, net 23,019   $ 21,837
Revenues $ 4,431 $ 3,714  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jan. 01, 2018
Dec. 31, 2017
Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Collaboration and licensing revenues $ 24,025 $ 33,065      
Net loss (43,232) (32,377)      
Net loss attributable to Intrexon (41,988) (31,399)      
Current portion of deferred revenue 48,646     $ 42,870  
Long-term portion of deferred revenue 214,744     193,527  
Accumulated deficit (930,220)     (847,820)  
Cash, cash equivalents, and restricted cash 127,377 76,839   75,545 $ 69,594
Accounting Standards Update 2014-09          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative Effect of New Accounting Principle in Period of Adoption     $ 40,412    
Ares Trading S.A.          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Collaboration and licensing revenues 3,368 3,315      
Ares Trading S.A. | Accounting Standards Update 2014-09          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative Effect of New Accounting Principle in Period of Adoption     40,789    
ZIOPHARM Oncology, Inc.          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Collaboration and licensing revenues 6,879 10,985      
ZIOPHARM Oncology, Inc. | Accounting Standards Update 2014-09          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative Effect of New Accounting Principle in Period of Adoption     $ (377)    
Calculated under Revenue Guidance in Effect before Topic 606          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Collaboration and licensing revenues 22,444        
Net loss (44,813)        
Net loss attributable to Intrexon (43,569)        
Current portion of deferred revenue 42,320        
Long-term portion of deferred revenue 182,239        
Accumulated deficit (891,389)        
Difference between Revenue Guidance in Effect before and after Topic 606          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Collaboration and licensing revenues 1,581        
Net loss 1,581        
Net loss attributable to Intrexon 1,581        
Current portion of deferred revenue 6,326        
Long-term portion of deferred revenue 32,505        
Accumulated deficit $ (38,831)        
Accounting Standards Update 2016-18          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cash, cash equivalents, and restricted cash   $ 6,987   $ 7,434 $ 6,987
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions - GenVec - Additional Information (Details) - GenVec, Inc. - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Business Acquisition [Line Items]    
Percentage of outstanding common stock acquired 100.00%  
Business combination, consideration paid, shares issued 684,240  
Percent of collaboration payments 50.00%  
Period subsequent to acquisition during which a portion of collaboration payments received will be paid to former stockholders of acquired entity 3 years  
Expected useful life of intangible asset 11 years  
Selling, general and administrative    
Business Acquisition [Line Items]    
Business combination, acquisition related costs   $ 238
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) - GenVec, Inc.
$ in Thousands
1 Months Ended
Jun. 30, 2017
USD ($)
Business Acquisition [Line Items]  
Common shares $ 15,616
Warrants 1,381
Contingent consideration 585
Total consideration transferred $ 17,582
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Jun. 30, 2017
Business Acquisition [Line Items]      
Goodwill $ 154,748 $ 153,289  
GenVec, Inc.      
Business Acquisition [Line Items]      
Cash and cash equivalents     $ 2,054
Short term investments     542
Trade receivables     75
Other receivables     97
Prepaid expenses and other     227
Property and equipment     250
Intangible assets     14,000
Other noncurrent assets     58
Total assets acquired     17,303
Accounts payable     2,158
Accrued compensation and benefits     1,226
Other accrued expenses     856
Other long term liabilities     92
Deferred tax liabilities     239
Total liabilities assumed     4,571
Net assets acquired     12,732
Goodwill     4,850
Total consideration     $ 17,582
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mergers and Acquisitions - Condensed Pro forma Financial Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2017
USD ($)
Business Combinations [Abstract]  
Revenues $ 53,861
Loss before income taxes (36,765)
Net loss (36,232)
Net loss attributable to the noncontrolling interests 978
Net loss attributable to Intrexon $ (35,254)
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2018
USD ($)
Oct. 31, 2013
USD ($)
Mar. 31, 2018
USD ($)
board_seat
Mar. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Schedule of Equity Method Investments [Line Items]          
Return of investment upon dissolution of affiliate     $ 2,598 $ 0  
S & I Ophthalmic, LLC          
Schedule of Equity Method Investments [Line Items]          
Capital contributions   $ 5,000     $ 5,000
Membership interest   50.00%      
Total number of seats on the joint venture's governing board | board_seat     4    
Total number of seats on the joint venture's governing board, internally selected | board_seat     2    
Total number of seats on the joint venture's governing board, externally selected | board_seat     2    
Return of investment upon dissolution of affiliate $ 2,598        
S & I Ophthalmic, LLC | Investors          
Schedule of Equity Method Investments [Line Items]          
Capital contributions   $ 5,000     $ 5,000
Membership interest   50.00%      
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - OvaXon - Additional Information (Details)
$ in Thousands
1 Months Ended 50 Months Ended
Jan. 31, 2014
USD ($)
Mar. 31, 2018
USD ($)
board_seat
Dec. 31, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]      
Investment   $ 21,406 $ 18,870
OvaXon, LLC      
Schedule of Equity Method Investments [Line Items]      
Capital contributions $ 1,500 $ 4,350  
Membership interest 50.00%    
Total number of seats on the joint venture's governing board | board_seat   4  
Total number of seats on the joint venture's governing board, internally selected | board_seat   2  
Total number of seats on the joint venture's governing board, externally selected | board_seat   2  
OvaXon, LLC | Investments In Affiliates      
Schedule of Equity Method Investments [Line Items]      
Investment   $ 146 $ 146
Investors | OvaXon, LLC      
Schedule of Equity Method Investments [Line Items]      
Capital contributions $ 1,500 $ 4,350  
Membership interest 50.00%    
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)
1 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2018
USD ($)
board_seat
Dec. 31, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]      
Investment   $ 21,406,000 $ 18,870,000
Intrexon Energy Partners, LLC      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Maximum additional capital contribution committed $ 25,000,000    
Additional capital contributions committed, remaining commitment   $ 6,011,000  
Total number of seats on the joint venture's governing board | board_seat   5  
Total number of seats on the joint venture's governing board, internally selected | board_seat   2  
Total number of seats on the joint venture's governing board, externally selected | board_seat   3  
Intrexon Energy Partners, LLC | Other Accrued Liabilities      
Schedule of Equity Method Investments [Line Items]      
Investment   $ (806,000) $ (444,000)
Intrexon Energy Partners, LLC | Investors      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Capital contributions $ 25,000,000    
Maximum additional capital contribution committed 25,000,000    
Upfront and Milestone Payments | Intrexon Energy Partners, LLC | Upfront      
Schedule of Equity Method Investments [Line Items]      
Collaborative arrangement consideration received, value $ 25,000,000    
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)
1 Months Ended
Dec. 31, 2015
USD ($)
Mar. 31, 2018
USD ($)
board_seat
Dec. 31, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]      
Investment   $ 21,406,000 $ 18,870,000
Intrexon Energy Partners II, LLC      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Maximum additional capital contribution committed $ 10,000,000    
Total number of seats on the joint venture's governing board | board_seat   5  
Total number of seats on the joint venture's governing board, internally selected | board_seat   1  
Total number of seats on the joint venture's governing board, externally selected | board_seat   4  
Intrexon Energy Partners II, LLC | Investments In Affiliates      
Schedule of Equity Method Investments [Line Items]      
Investment   $ 515,000 $ 572,000
Intrexon Energy Partners II, LLC | Investors      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Capital contributions $ 18,000,000    
Maximum additional capital contribution committed 10,000,000    
Intrexon Energy Partners II, LLC | All Investors      
Schedule of Equity Method Investments [Line Items]      
Capital contributions 4,000,000    
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments | Upfront      
Schedule of Equity Method Investments [Line Items]      
Collaborative arrangement consideration received, value $ 18,000,000    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($)
$ in Thousands
25 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]    
Investment $ 21,406 $ 18,870
EnviroFlight, LLC    
Schedule of Equity Method Investments [Line Items]    
Capital contributions 8,250  
EnviroFlight, LLC | Investments In Affiliates    
Schedule of Equity Method Investments [Line Items]    
Investment 10,072 $ 7,092
EnviroFlight, LLC | Investors    
Schedule of Equity Method Investments [Line Items]    
Capital contributions $ 8,250  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)
1 Months Ended
Mar. 31, 2016
USD ($)
Mar. 31, 2018
USD ($)
board_seat
Dec. 31, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]      
Investment   $ 21,406,000 $ 18,870,000
Intrexon T1D Partners, LLC      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Maximum additional capital contribution committed $ 5,000,000    
Additional capital contributions committed, remaining commitment   $ 1,250,000  
Total number of seats on the joint venture's governing board | board_seat   5  
Total number of seats on the joint venture's governing board, internally selected | board_seat   2  
Total number of seats on the joint venture's governing board, externally selected | board_seat   3  
Intrexon T1D Partners, LLC | Investors      
Schedule of Equity Method Investments [Line Items]      
Membership interest 50.00%    
Capital contributions $ 10,000,000    
Maximum additional capital contribution committed 5,000,000    
Intrexon T1D Partners, LLC | Upfront | Upfront and Milestone Payments      
Schedule of Equity Method Investments [Line Items]      
Collaborative arrangement consideration received, value $ 10,000,000    
Intrexon T1D Partners, LLC | Other Accrued Liabilities      
Schedule of Equity Method Investments [Line Items]      
Investment   $ (67,000) $ (943,000)
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues $ 24,025 $ 33,065
ZIOPHARM Oncology, Inc.    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 6,879 10,985
Oragenics, Inc.    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 342 569
Fibrocell Science, Inc.    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 835 1,739
Genopaver, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 1,288 1,680
S & I Ophthalmic, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 0 303
OvaXon, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 0 824
Intrexon Energy Partners, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 1,252 5,086
Persea Bio, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 252 289
Ares Trading S.A.    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 3,368 3,315
Intrexon Energy Partners II, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 615 1,149
Intrexon T1D Partners, LLC    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues 1,468 1,132
Harvest start-up entities    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues [1] 3,354 3,363
Other    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaboration and licensing revenues $ 4,372 $ 2,631
[1] For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]    
Current portion of deferred revenue $ 48,646 $ 42,870
Long-term portion of deferred revenue 214,744 193,527
Deferred revenue 263,390 236,397
Collaboration and licensing agreements    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 258,174 231,583
Prepaid product and service revenues    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 5,138 4,681
Other    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue $ 78 $ 133
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]    
Deferred revenue $ 263,390 $ 236,397
ZIOPHARM Oncology, Inc.    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 5 years 9 months 18 days  
Oragenics, Inc.    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years 2 months 12 days  
Fibrocell Science, Inc.    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years 7 months 6 days  
Genopaver, LLC    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years  
Intrexon Energy Partners, LLC    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years  
Persea Bio, LLC    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years 9 months 18 days  
Ares Trading S.A.    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years 1 month 6 days  
Intrexon Energy Partners II, LLC    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 6 years 8 months 12 days  
Intrexon T1D Partners, LLC    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 7 years  
Harvest start-up entities    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) [1] 7 years 1 month 6 days  
Other    
Deferred Revenue Arrangement [Line Items]    
Average remaining performance period (in years) 3 years 8 months 12 days  
Upfront and Milestone Payments    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue $ 257,296 230,531
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 86,365 90,496
Upfront and Milestone Payments | Oragenics, Inc.    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 6,456 6,719
Upfront and Milestone Payments | Fibrocell Science, Inc.    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 16,002 16,607
Upfront and Milestone Payments | Genopaver, LLC    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 1,635 1,704
Upfront and Milestone Payments | Intrexon Energy Partners, LLC    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 15,000 15,625
Upfront and Milestone Payments | Persea Bio, LLC    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 3,375 3,500
Upfront and Milestone Payments | Ares Trading S.A.    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 78,384 40,789
Upfront and Milestone Payments | Intrexon Energy Partners II, LLC    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 13,333 13,833
Upfront and Milestone Payments | Intrexon T1D Partners, LLC    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue 8,334 8,435
Upfront and Milestone Payments | Harvest start-up entities    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue [1] 17,918 18,400
Upfront and Milestone Payments | Other    
Deferred Revenue Arrangement [Line Items]    
Deferred revenue $ 10,494 $ 14,423
[1] As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost   $ 6,275
Gross Unrealized Gains   0
Gross Unrealized Losses $ 0 (2)
Aggregate Fair Value   6,273
U.S. government debt securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost   6,000
Gross Unrealized Gains   0
Gross Unrealized Losses   (2)
Aggregate Fair Value   5,998
Certificates of deposit    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 275 275
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Aggregate Fair Value $ 275 $ 275
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Preferred Stock - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Nov. 30, 2017
Mar. 31, 2017
Jun. 30, 2016
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Schedule of Investments [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis       $ 180,881   $ 183,173
Noncash Dividend Income       4,883 $ 3,926  
Purchases of preferred stock and warrants       0 $ 1,161  
Preferred stock            
Schedule of Investments [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis       $ 166,069   161,225
Fibrocell Science, Inc.            
Schedule of Investments [Line Items]            
Convertible preferred shares issued (in shares)   1,161     1,161  
Number of common shares into which warrants are convertible (in shares)   498,843        
Convertible preferred shares, dividend rate       4.00%    
ZIOPHARM Oncology, Inc.            
Schedule of Investments [Line Items]            
Preferred shares, stated value (in usd per share)     $ 1,200      
Threshold consecutive trading days, conversion of shares       20 days    
Preferred shares, dividend rate (in usd per share)       $ 12.00    
Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share)       24.00    
ZIOPHARM Oncology, Inc. | Minimum            
Schedule of Investments [Line Items]            
Preferred shares, conversion calculation, divisor (in usd per share)       $ 1.00    
Other Contractual Payments | Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.            
Schedule of Investments [Line Items]            
Collaborative arrangement consideration received, number of preferred shares (in shares)     100,000      
Oragenics, Inc. | Preferred stock            
Schedule of Investments [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis       $ 0   0
Receivables converted to preferred stock $ 3,385          
Preferred shares, initial dividend rate       12.00%    
Preferred shares, subsequent dividend rate       20.00%    
ZIOPHARM Oncology, Inc.            
Schedule of Investments [Line Items]            
Dividend income, number of preferred shares received (in shares)       3,624 3,216  
Noncash Dividend Income       $ 4,871 $ 3,923  
ZIOPHARM Oncology, Inc. | Preferred stock            
Schedule of Investments [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis       165,703   160,832
Fibrocell Science, Inc.            
Schedule of Investments [Line Items]            
Purchases of preferred stock and warrants   $ 1,161        
Fibrocell Science, Inc. | Preferred stock            
Schedule of Investments [Line Items]            
Fair value of financial assets measured at fair value on a recurring basis       $ 366   $ 393
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Purchase of preferred stock $ 0 $ 1,161
Dividend income from investments in preferred stock 4,883 $ 3,926
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 161,225  
Dividend income from investments in preferred stock 4,883  
Net unrealized depreciation in the fair value of the investments in preferred stock (39)  
Ending balance $ 166,069  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Assets    
Fair value of financial assets measured at fair value on a recurring basis $ 180,881 $ 183,173
U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis   5,998
Equity securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 14,043 15,100
Preferred stock    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 166,069 161,225
Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 769 850
Quoted Prices in Active Markets (Level 1)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 9,622 10,537
Quoted Prices in Active Markets (Level 1) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis   0
Quoted Prices in Active Markets (Level 1) | Equity securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 9,622 10,537
Quoted Prices in Active Markets (Level 1) | Preferred stock    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Quoted Prices in Active Markets (Level 1) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Other Observable Inputs (Level 2)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 5,190 11,411
Significant Other Observable Inputs (Level 2) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis   5,998
Significant Other Observable Inputs (Level 2) | Equity securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 4,421 4,563
Significant Other Observable Inputs (Level 2) | Preferred stock    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 769 850
Significant Unobservable Inputs (Level 3)    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 166,069 161,225
Significant Unobservable Inputs (Level 3) | U.S. government debt securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis   0
Significant Unobservable Inputs (Level 3) | Equity securities    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 0 0
Significant Unobservable Inputs (Level 3) | Preferred stock    
Assets    
Fair value of financial assets measured at fair value on a recurring basis 166,069 161,225
Significant Unobservable Inputs (Level 3) | Other    
Assets    
Fair value of financial assets measured at fair value on a recurring basis $ 0 $ 0
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Additional Information (Details) - Significant Unobservable Inputs (Level 3) - USD ($)
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of financial liabilities measured at fair value on a recurring basis $ 585,000 $ 585,000
Changes in fair value of Level 3 liabilities $ 0  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Inventory [Line Items]    
Inventory $ 20,271 $ 20,493
Supplies, embryos and other production materials    
Inventory [Line Items]    
Inventory 3,386 2,673
Work in process    
Inventory [Line Items]    
Inventory 4,422 4,767
Livestock    
Inventory [Line Items]    
Inventory 10,991 11,040
Feed    
Inventory [Line Items]    
Inventory $ 1,472 $ 2,013
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Abstract]    
Land and land improvements $ 11,815 $ 11,767
Buildings and building improvements 18,160 18,183
Furniture and fixtures 2,516 2,515
Equipment 69,568 65,863
Leasehold improvements 27,811 25,277
Breeding stock 4,204 3,832
Computer hardware and software 10,442 10,128
Trees 7,996 6,642
Construction and other assets in progress 15,819 14,113
Property, plant and equipment, gross 168,331 158,320
Less: Accumulated depreciation and amortization (49,087) (45,646)
Property, plant and equipment, net $ 119,244 $ 112,674
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property, Plant and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 3,456 $ 2,782
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
Goodwill  
Beginning balance $ 153,289
Foreign currency translation adjustments 1,459
Ending balance $ 154,748
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill accumulated impairment losses $ (13,823)   $ (13,823)
Amortization expense $ 4,926 $ 4,618  
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 289,962 $ 286,781
Accumulated Amortization (58,079) (53,904)
Net 231,883 232,877
Patents, developed technologies and know-how    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 266,579 263,615
Accumulated Amortization (48,586) (44,954)
Net 217,993 218,661
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 10,700 10,700
Accumulated Amortization (6,733) (6,383)
Net 3,967 4,317
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 6,800 6,800
Accumulated Amortization (2,760) (2,567)
Net 4,040 4,233
In-process research and development    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 5,883 5,666
Accumulated Amortization 0 0
Net $ 5,883 $ 5,666
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit
3 Months Ended
Mar. 31, 2018
USD ($)
Trans Ova Genetics, LC | First National Bank of Omaha  
Line of Credit Facility [Line Items]  
Line of credit facility, maximum borrowing capacity $ 5,000,000
Line of credit facility, interest rate at period end 4.62%
Line of credit facility, outstanding balance $ 0
Trans Ova Genetics, LC | First National Bank of Omaha | Minimum  
Line of Credit Facility [Line Items]  
Debt instrument, interest rate, stated percentage 3.00%
Trans Ova Genetics, LC | First National Bank of Omaha | London Interbank Offered Rate (LIBOR)  
Line of Credit Facility [Line Items]  
Line of credit facility, basis spread on variable rate 2.95%
Exemplar Genetics, LLC | American State Bank  
Line of Credit Facility [Line Items]  
Line of credit facility, maximum borrowing capacity $ 700,000
Debt instrument, interest rate, stated percentage 5.25%
Line of credit facility, outstanding balance $ 321,000
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Long term debt $ 7,926 $ 8,037
Less current portion 501 502
Long term debt, net of current portion 7,425 7,535
Notes payable    
Debt Instrument [Line Items]    
Long term debt 4,896 5,010
Royalty-based financing    
Debt Instrument [Line Items]    
Long term debt 2,108 2,132
Other    
Debt Instrument [Line Items]    
Long term debt $ 922 $ 895
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2013
Debt Instrument [Line Items]      
Long term debt $ 7,926 $ 8,037  
Notes payable to banks | Trans Ova Genetics, LC | American State Bank      
Debt Instrument [Line Items]      
Long term debt 4,775    
Debt instrument, periodic payment $ 39    
Debt instrument, interest rate, stated percentage 3.95%    
Royalty-based financing      
Debt Instrument [Line Items]      
Long term debt $ 2,108 $ 2,132  
Royalty-based financing | AquaBounty Technologies, Inc. | Atlantic Canada Opportunities Agency      
Debt Instrument [Line Items]      
Long term debt 2,108    
Amount available under the grant for research and development $ 2,226    
Claims period 5 years    
Royalty on products, percentage 10.00%    
Amount claimed     $ 1,952
Long term debt, fair value at date of business combination     1,107
Accreted difference between face value of amount drawn and acquisition date fair value     $ 845
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1
Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details)
$ in Thousands
Mar. 31, 2018
USD ($)
Debt Disclosure [Abstract]  
2018 $ 398
2019 411
2020 382
2021 830
2022 373
2023 386
Thereafter 3,038
Total $ 5,818
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Operating Loss Carryforwards [Line Items]      
Deferred income tax benefit $ (4,074,000) $ (638,000)  
Deferred tax liabilities 11,631,000    
Provisional transition tax amount     $ 0
Domestic Tax Authority      
Operating Loss Carryforwards [Line Items]      
Taxable income (loss) (35,100,000) 11,800,000  
Current income tax expense (benefit) 113,000 236,000  
Operating loss carryforwards 279,500,000    
Federal and state research and development tax credits 7,800,000    
Foreign Tax Authority      
Operating Loss Carryforwards [Line Items]      
Current income tax expense (benefit) (125,000) $ (131,000)  
Operating loss carryforwards $ 160,700,000    
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Issuances of Common Stock (Details)
$ in Thousands
1 Months Ended
Jan. 31, 2018
USD ($)
shares
Class of Stock [Line Items]  
Shares issued in public offerings, net of issuance costs (in shares) | shares 6,900,000
Net proceeds from public financing $ 82,374
Underwriting discounts and commissions 3,688
Capitalized offering expenses $ 188
Affiliate of Third Security, LLC  
Class of Stock [Line Items]  
Shares issued in public offerings, net of issuance costs (in shares) | shares 1,000,000
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1
Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Intrexon shareholders' equity $ 553,109 $ 533,631
Unrealized loss on investments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Intrexon shareholders' equity 0 (2)
Loss on foreign currency translation adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Intrexon shareholders' equity (9,587) (15,552)
Total accumulated other comprehensive loss    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Intrexon shareholders' equity $ (9,587) $ (15,554)
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation costs $ 11,362 $ 7,894
Cost of products    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation costs 25 26
Cost of services    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation costs 77 78
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation costs 3,258 2,193
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation costs $ 8,002 $ 5,597
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2018
Nov. 30, 2015
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Apr. 30, 2016
Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares issued as payment for services     $ 2,941 $ 2,915      
Chief Executive Officer              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Monthly compensation, in the form of equity   $ 200          
Lock-up period   3 years          
Initial term of compensation arrangement   12 months          
Chief Executive Officer | Selling, general and administrative              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares issued as payment for services     $ 486 $ 471      
Intrexon Stock Option Plan - 2008 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Remaining shares available to grant (in shares)             0
Options outstanding (in shares) 431,649   431,649        
Intrexon Stock Option Plan - 2013 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Remaining shares available to grant (in shares) 3,279,291   3,279,291        
Options outstanding (in shares) 11,114,785   11,114,785        
Number of shares authorized for issuance (in shares) 18,000,000   18,000,000        
RSUs outstanding (in shares) 1,052,182   1,052,182        
Additional shares to be authorized, approved by Board of Directors, pending shareholder approval 2,000,000            
RSUs granted (in shares)     1,059,126        
Weighted average grant date fair value of RSUs granted (in usd per share)     $ 13.83        
Intrexon Stock Option Plans              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options outstanding (in shares) 11,546,434   11,546,434   11,382,747    
Options exercisable (in shares) 6,533,996   6,533,996        
Weighted average exercise price of option (in usd per share) $ 28.31   $ 28.31   $ 28.99    
AquaBounty Stock Option Plan - 2006 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Remaining shares available to grant (in shares)           0  
Aqua Bounty Stock Option Plans              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options outstanding (in shares) 340,764   340,764        
Options exercisable (in shares) 207,390   207,390        
Weighted average exercise price of option (in usd per share) $ 7.09   $ 7.09        
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Number of Shares    
Balances at beginning of period (in shares) 11,382,747  
Granted (in shares) 656,339  
Exercised (in shares) (21,722)  
Forfeited (in shares) (186,811)  
Expired (in shares) (284,119)  
Balances at end of period (in shares) 11,546,434 11,382,747
Exercisable at end of period (in shares) 6,533,996  
Weighted Average Exercise Price    
Balances at beginning of period (in usd per share) $ 28.99  
Granted (in usd per share) 14.84  
Exercised (in usd per share) (3.40)  
Forfeited (in usd per share) (26.37)  
Expired (in usd per share) (27.67)  
Balances at period end (in usd per share) 28.31 $ 28.99
Exercisable, weighted average exercise price, at end of period (in usd per share) $ 29.29  
Weighted Average Remaining Contractual Term (Years)    
Balances, weighted average remaining contractual period 7 years 3 months 7 years 3 months 24 days
Exercisable at period end, weighted average remaining contractual period 6 years 4 months 18 days  
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details)
$ in Thousands
Mar. 31, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2018 $ 6,096
2019 9,441
2020 9,506
2021 8,601
2022 7,595
2023 6,558
Thereafter 23,923
Total $ 71,720
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Operating Leases - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]    
Rent expense $ 3,259 $ 2,301
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Purchase Commitments - Additional Information (Details)
$ in Thousands
Mar. 31, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Outstanding contractual purchase commitments $ 15,098
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Contingencies - Additional Information (Details)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended 50 Months Ended
Apr. 30, 2016
USD ($)
Jul. 31, 2016
claim
Mar. 31, 2018
claim
Dec. 31, 2016
USD ($)
Apr. 30, 2016
USD ($)
Licensing and patent infringement suit          
Loss Contingencies [Line Items]          
Damages awarded to Trans Ova $ 528        
Cumulative payments for royalties and licenses         $ 3,170
Royalty payments not yet deposited 2,759       $ 2,759
Litigation settlement expense       $ 4,228  
Licensing and patent infringement suit | XY, LLC          
Loss Contingencies [Line Items]          
Damages awarded against Trans Ova $ 6,066        
Claims dismissed | claim     9    
Total claims | claim     12    
Claims pending resolution | claim     3    
Shareholder demand regarding allegations made by Seeking Alpha financial blog          
Loss Contingencies [Line Items]          
Number of lawsuits | claim   2      
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details) - USD ($)
1 Months Ended 3 Months Ended
Oct. 31, 2017
Nov. 30, 2015
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Related Party Transaction [Line Items]          
Shares issued as payment for services     $ 2,941,000    
Fair value of financial assets measured at fair value on a recurring basis     180,881,000   $ 183,173,000
Other nonoperating income     (659,000) $ 595,000  
Series A preferred shares          
Related Party Transaction [Line Items]          
Convertible preferred shares, conversion price, number of days used to calculate volume-weighted average market price 20 days        
Affiliate of Third Security, LLC | Series A preferred shares          
Related Party Transaction [Line Items]          
Value of convertible preferred shares authorized for issuance $ 100,000,000        
Convertible preferred shares, dividend rate 8.00%        
Third Security, LLC          
Related Party Transaction [Line Items]          
Expense for services     $ 14,000 $ 66,000  
Initial term of services agreement   1 year      
Shares issued as payment for services (in shares)     160,626 103,930  
Shares issued as payment for services     $ 2,041,000 $ 2,039,000  
Sublease rental income     21,000 11,000  
Third Security, LLC | Common Stock          
Related Party Transaction [Line Items]          
Expense for services   $ 800,000      
Harvest Intrexon Enterprise Fund I, LP          
Related Party Transaction [Line Items]          
Other nonoperating income       $ 603,000  
Convertible Note and Warrants | Other Assets | Fibrocell Science, Inc.          
Related Party Transaction [Line Items]          
Fair value of financial assets measured at fair value on a recurring basis     $ 494,000   $ 575,000
Third Security, LLC | Chief Executive Officer          
Related Party Transaction [Line Items]          
Ownership interest     100.00%    
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Numerator:    
Net loss attributable to Intrexon $ (41,988) $ (31,399)
Denominator:    
Weighted average shares outstanding, basic and diluted (in shares) 127,693,336 118,956,780
Net loss attributable to Intrexon per share, basic and diluted (in usd per share) $ (0.33) $ (0.26)
XML 102 R91.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 12,731,880 12,632,507
Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 11,546,434 12,632,507
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 1,052,182 0
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 133,264 0
XML 103 R92.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events - Additional Information (Details)
$ in Thousands
3 Months Ended
Jun. 30, 2018
USD ($)
Scenario, Forecast | Subsequent Event  
Subsequent Event [Line Items]  
Other restructuring costs $ 6,000
EXCEL 104 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 105 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 106 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 108 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 310 371 1 true 112 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.dna.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.dna.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.dna.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1002001 - Statement - Consolidated Statements of Operations (Parenthetical) Sheet http://www.dna.com/role/ConsolidatedStatementsOfOperationsParenthetical Consolidated Statements of Operations (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.dna.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements of Shareholders' and Total Equity Sheet http://www.dna.com/role/ConsolidatedStatementsOfShareholdersAndTotalEquity Consolidated Statements of Shareholders' and Total Equity Statements 7 false false R8.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.dna.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 1005001 - Statement - Consolidated Statements of Cash Flows (Reconciliation of Cash) Sheet http://www.dna.com/role/ConsolidatedStatementsOfCashFlowsReconciliationOfCash Consolidated Statements of Cash Flows (Reconciliation of Cash) Statements 9 false false R10.htm 2101100 - Disclosure - Organization Sheet http://www.dna.com/role/Organization Organization Notes 10 false false R11.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 2111100 - Disclosure - Mergers and Acquisitions Sheet http://www.dna.com/role/MergersAndAcquisitions Mergers and Acquisitions Notes 12 false false R13.htm 2112100 - Disclosure - Investments in Joint Ventures Sheet http://www.dna.com/role/InvestmentsInJointVentures Investments in Joint Ventures Notes 13 false false R14.htm 2114100 - Disclosure - Collaboration and Licensing Revenue Sheet http://www.dna.com/role/CollaborationAndLicensingRevenue Collaboration and Licensing Revenue Notes 14 false false R15.htm 2115100 - Disclosure - Short-term Investments Sheet http://www.dna.com/role/ShortTermInvestments Short-term Investments Notes 15 false false R16.htm 2116100 - Disclosure - Investments in Preferred Stock Sheet http://www.dna.com/role/InvestmentsInPreferredStock Investments in Preferred Stock Notes 16 false false R17.htm 2117100 - Disclosure - Fair Value Measurements Sheet http://www.dna.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 2119100 - Disclosure - Inventory Sheet http://www.dna.com/role/Inventory Inventory Notes 18 false false R19.htm 2120100 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net Notes 19 false false R20.htm 2121100 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 20 false false R21.htm 2122100 - Disclosure - Lines of Credit and Long Term Debt Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebt Lines of Credit and Long Term Debt Notes 21 false false R22.htm 2123100 - Disclosure - Income Taxes Sheet http://www.dna.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2124100 - Disclosure - Shareholders' Equity Sheet http://www.dna.com/role/ShareholdersEquity Shareholders' Equity Notes 23 false false R24.htm 2126100 - Disclosure - Share-Based Payments Sheet http://www.dna.com/role/ShareBasedPayments Share-Based Payments Notes 24 false false R25.htm 2127100 - Disclosure - Commitments and Contingencies Sheet http://www.dna.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 25 false false R26.htm 2128100 - Disclosure - Related Party Transactions Sheet http://www.dna.com/role/RelatedPartyTransactions Related Party Transactions Notes 26 false false R27.htm 2129100 - Disclosure - Net Loss per Share Sheet http://www.dna.com/role/NetLossPerShare Net Loss per Share Notes 27 false false R28.htm 2130100 - Disclosure - Subsequent Events Sheet http://www.dna.com/role/SubsequentEvents Subsequent Events Notes 28 false false R29.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 29 false false R30.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.dna.com/role/SummaryOfSignificantAccountingPolicies 30 false false R31.htm 2311301 - Disclosure - Mergers and Acquisitions (Tables) Sheet http://www.dna.com/role/MergersAndAcquisitionsTables Mergers and Acquisitions (Tables) Tables http://www.dna.com/role/MergersAndAcquisitions 31 false false R32.htm 2314301 - Disclosure - Collaboration and Licensing Revenue (Tables) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueTables Collaboration and Licensing Revenue (Tables) Tables http://www.dna.com/role/CollaborationAndLicensingRevenue 32 false false R33.htm 2315301 - Disclosure - Short-term Investments (Tables) Sheet http://www.dna.com/role/ShortTermInvestmentsTables Short-term Investments (Tables) Tables http://www.dna.com/role/ShortTermInvestments 33 false false R34.htm 2316301 - Disclosure - Investments in Preferred Stock (Tables) Sheet http://www.dna.com/role/InvestmentsInPreferredStockTables Investments in Preferred Stock (Tables) Tables http://www.dna.com/role/InvestmentsInPreferredStock 34 false false R35.htm 2317301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.dna.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.dna.com/role/FairValueMeasurements 35 false false R36.htm 2319301 - Disclosure - Inventory (Tables) Sheet http://www.dna.com/role/InventoryTables Inventory (Tables) Tables http://www.dna.com/role/Inventory 36 false false R37.htm 2320301 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.dna.com/role/PropertyPlantAndEquipmentNet 37 false false R38.htm 2321301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://www.dna.com/role/GoodwillAndIntangibleAssetsNet 38 false false R39.htm 2322301 - Disclosure - Lines of Credit and Long Term Debt (Tables) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtTables Lines of Credit and Long Term Debt (Tables) Tables http://www.dna.com/role/LinesOfCreditAndLongTermDebt 39 false false R40.htm 2324301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.dna.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.dna.com/role/ShareholdersEquity 40 false false R41.htm 2326301 - Disclosure - Share-Based Payments (Tables) Sheet http://www.dna.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.dna.com/role/ShareBasedPayments 41 false false R42.htm 2327301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.dna.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.dna.com/role/CommitmentsAndContingencies 42 false false R43.htm 2329301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.dna.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.dna.com/role/NetLossPerShare 43 false false R44.htm 2401401 - Disclosure - Organization (Details) Sheet http://www.dna.com/role/OrganizationDetails Organization (Details) Details http://www.dna.com/role/Organization 44 false false R45.htm 2402403 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionAdditionalInformationDetails Summary of Significant Accounting Policies - Revenue Recognition - Additional Information (Details) Details 45 false false R46.htm 2402404 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesEquityMethodInvestmentsAdditionalInformationDetails Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) Details 46 false false R47.htm 2402405 - Disclosure - Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesSummarizedUnauditedFinancialInformationForEquityMethodInvestmentsDetails Summary of Significant Accounting Policies - Summarized Unaudited Financial Information for the Equity Method Investments (Details) Details 47 false false R48.htm 2402406 - Disclosure - Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesVariableInterestEntitiesAdditionalInformationDetails Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) Details 48 false false R49.htm 2402407 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetails Summary of Significant Accounting Policies - Segment Information - Additional Information (Details) Details 49 false false R50.htm 2402408 - Disclosure - Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details) Sheet http://www.dna.com/role/SummaryOfSignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details) Details 50 false false R51.htm 2411402 - Disclosure - Mergers and Acquisitions - GenVec - Additional Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsGenvecAdditionalInformationDetails Mergers and Acquisitions - GenVec - Additional Information (Details) Details 51 false false R52.htm 2411403 - Disclosure - Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsGenvecFairValueOfConsiderationTransferredDetails Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) Details 52 false false R53.htm 2411404 - Disclosure - Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsGenvecFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 53 false false R54.htm 2411405 - Disclosure - Mergers and Acquisitions - Condensed Pro forma Financial Information (Details) Sheet http://www.dna.com/role/MergersAndAcquisitionsCondensedProFormaFinancialInformationDetails Mergers and Acquisitions - Condensed Pro forma Financial Information (Details) Details 54 false false R55.htm 2412401 - Disclosure - Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesSIOphthalmicAdditionalInformationDetails Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details) Details 55 false false R56.htm 2412402 - Disclosure - Investments in Joint Ventures - OvaXon - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesOvaxonAdditionalInformationDetails Investments in Joint Ventures - OvaXon - Additional Information (Details) Details 56 false false R57.htm 2412403 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) Details 57 false false R58.htm 2412404 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonEnergyPartnersIiAdditionalInformationDetails Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) Details 58 false false R59.htm 2412405 - Disclosure - Investments in Joint Ventures - EnviroFlight - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesEnviroflightAdditionalInformationDetails Investments in Joint Ventures - EnviroFlight - Additional Information (Details) Details 59 false false R60.htm 2412406 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInJointVenturesIntrexonT1DPartnersAdditionalInformationDetails Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) Details 60 false false R61.htm 2414402 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummarizedCollaborationAndLicensingRevenuesDetails Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) Details 61 false false R62.htm 2414403 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummaryOfDeferredRevenueDetails Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) Details 62 false false R63.htm 2414404 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) Sheet http://www.dna.com/role/CollaborationAndLicensingRevenueSummaryOfDeferredRevenueByCollaboratorDetails Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) Details 63 false false R64.htm 2415402 - Disclosure - Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) Sheet http://www.dna.com/role/ShortTermInvestmentsSummaryOfAmortizedCostGrossUnrealizedGainsAndLossesAndFairValueOfShortTermInvestmentsDetails Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) Details 64 false false R65.htm 2416402 - Disclosure - Investments in Preferred Stock - Additional Information (Details) Sheet http://www.dna.com/role/InvestmentsInPreferredStockAdditionalInformationDetails Investments in Preferred Stock - Additional Information (Details) Details 65 false false R66.htm 2416403 - Disclosure - Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) Sheet http://www.dna.com/role/InvestmentsInPreferredStockScheduleOfChangesInLevel3InvestmentsDetails Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) Details 66 false false R67.htm 2417402 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.dna.com/role/FairValueMeasurementsSummaryOfPlacementInFairValueHierarchyOfFinancialAssetsThatAreMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Details 67 false false R68.htm 2417403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 68 false false R69.htm 2419402 - Disclosure - Inventory (Details) Sheet http://www.dna.com/role/InventoryDetails Inventory (Details) Details http://www.dna.com/role/InventoryTables 69 false false R70.htm 2420402 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) Details 70 false false R71.htm 2420403 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details) Sheet http://www.dna.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetails Property, Plant and Equipment, Net - Additional Information (Details) Details 71 false false R72.htm 2421402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 72 false false R73.htm 2421403 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetAdditionalInformationDetails Goodwill and Intangible Assets, Net - Additional Information (Details) Details 73 false false R74.htm 2421404 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) Sheet http://www.dna.com/role/GoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsDetails Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) Details 74 false false R75.htm 2422402 - Disclosure - Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLinesOfCreditAdditionalInformationDetails Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) Details 75 false false R76.htm 2422403 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtScheduleOfLongTermDebtInstrumentsDetails Lines of Credit and Long Term Debt - Schedule of Long Term Debt Instruments (Details) Details 76 false false R77.htm 2422404 - Disclosure - Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtLongTermDebtAdditionalInformationDetails Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) Details 77 false false R78.htm 2422405 - Disclosure - Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Sheet http://www.dna.com/role/LinesOfCreditAndLongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) Details 78 false false R79.htm 2423401 - Disclosure - Income Taxes (Details) Sheet http://www.dna.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.dna.com/role/IncomeTaxes 79 false false R80.htm 2424402 - Disclosure - Shareholders' Equity - Issuances of Common Stock (Details) Sheet http://www.dna.com/role/ShareholdersEquityIssuancesOfCommonStockDetails Shareholders' Equity - Issuances of Common Stock (Details) Details 80 false false R81.htm 2424403 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.dna.com/role/ShareholdersEquityComponentsOfAccumulatedOtherComprehensiveLossDetails Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) Details 81 false false R82.htm 2426402 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsScheduleOfStockBasedCompensationCostsDetails Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) Details 82 false false R83.htm 2426403 - Disclosure - Share-Based Payments - Additional Information (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails Share-Based Payments - Additional Information (Details) Details 83 false false R84.htm 2426404 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details) Sheet http://www.dna.com/role/ShareBasedPaymentsScheduleOfStockOptionActivityDetails Share-Based Payments - Schedule of Stock Option Activity (Details) Details 84 false false R85.htm 2427402 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) Details 85 false false R86.htm 2427403 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails Commitments and Contingencies - Operating Leases - Additional Information (Details) Details 86 false false R87.htm 2427404 - Disclosure - Commitments and Contingencies - Purchase Commitments - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesPurchaseCommitmentsAdditionalInformationDetails Commitments and Contingencies - Purchase Commitments - Additional Information (Details) Details 87 false false R88.htm 2427405 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details) Sheet http://www.dna.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetails Commitments and Contingencies - Contingencies - Additional Information (Details) Details 88 false false R89.htm 2428401 - Disclosure - Related Party Transactions (Details) Sheet http://www.dna.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.dna.com/role/RelatedPartyTransactions 89 false false R90.htm 2429402 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.dna.com/role/NetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 90 false false R91.htm 2429403 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) Sheet http://www.dna.com/role/NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) Details 91 false false R92.htm 2430401 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.dna.com/role/SubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 92 false false All Reports Book All Reports xon-20180331.xml xon-20180331.xsd xon-20180331_cal.xml xon-20180331_def.xml xon-20180331_lab.xml xon-20180331_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 110 0001356090-18-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356090-18-000006-xbrl.zip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

JM0C#$C/#$D#!E-+X_9AC2K4N8:C7A*Z<27\L>G(KEL:? MUVALK(&72+X8W_=[5J'%Y?=-OWEPV1[V;FPQX MKMK#ZX,"CW6;Z%,RF_$(/L-CV "V! -7'L8&2*7;5>DYEJ%@V'-5V R^F2H0 M4A1*<]!040);M(XR.BZ1:Q4+B\B$J*6F@'UYB#WT_?!>@RCV;-CD%._MK^S> MA;XP[$KCD48VBH0=#-,_VWFG,W M^_OY8 4X<2L#,TF>Q&'V@>D=HS^YEUX\A:>!,FG_#Q=HS>=*?)?]8RTC9SGO M8M>IO"?(8*572+X_._>M,E/J-__WZ:8C&]N?I$MZX>NMU_WY4UK\\_J84>^D M-8EKGSU.JZ=!&S4L]O8@OR^#+S4;K M(ZRY

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end

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